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Preface 9
Every year, approximately 4% of the Dutch population is scheduled for major noncardiac 
surgery, with an average preoperative mortality rate of 1.9%1. Patients undergoing major non-
cardiac surgery are at reisk for complications during the perioperative period, such as surgical 
site infection, pneumonia, myocardial infarction, and death. Cardiac events are estimated to be 
the most frequent cause of perioperative complications resulting in death. Recently, Boersma 
et al. conducted a 10-year surgical cohort study of over 100,000 noncardiac surgical patients in 
Rotterdam, the Netherlands2. They showed that at least 30% of mortality during the surgical 
period was caused by cardiac complications. Therefore, an estimated 3,600 patients die each 
year in the Netherlands alone due to cardiac complications after noncardiac surgery. Improving 
preoperative cardiac risk stratification and optimizing perioperative management is therefore 
of utmost importance.
oUtLINe of tHe tHeSIS
Perioperative myocardial infarction (PMI) is one of the most important predictors of short- and 
long term morbidity and mortality associated with noncardiac surgery3-6. Prevention of a PMI 
is therefore key to improving overall postoperative outcome. Unfortunately, the exact mecha-
nism of PMI is not fully understood and remains a subject of continued debate3,4,6. Chapter 
one describes the current understanding of the pathophysiology of perioperative myocardial 
infarctions.
cARDIAc RISk IDeNtIfIcAtIoN
Non-invasive cardiac stress testing can be applied to improve perioperative cardiac risk assess-
ment in patients scheduled for elective non-cardiac surgery. While a hypotensive response to 
exercise testing has been associated with a poor prognosis, the prognostic significance of a 
hypotensive response during dobutamine stress echocardiography remains unclear. The sec-
ond chapter of this thesis investigates the association between a severe hypotensive response 
during dobutamine stress echocardiography and long-term prognosis in 3381 patients who 
underwent non-invasive stress testing over a period of 13 years. Clinical risk markers can refine 
perioperative risk assessment and the expansion of inexpensive laboratory markers could 
significantly improve preoperative work up. Hyperhomocysteinemia is associated with athero-
sclerotic disease, but its use as a predictive marker is disputed. In chapter three, the beneficial 
effect of metionine loading on the predictive value for homocysteine testing is evaluated with 
regard to long term mortality and major adverse cardiac events 1122 patients with athero-
sclerotic disease. In chapter four, the usefulness of standardized preoperative oral glucose 
tolerance testing is prospectively investigated in 404 patients scheduled for elective vascular 
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surgery. The active detection of unknown diabetes mellitus and impaired glucose regulation 
could improve perioperative risk stratification and perioperative patient management. Chapter 
five investigates whether the long term result of the patients included in chapter four are 
different for patients with new onset diabetes, patients with impaired glucose regulation and 
patients with normal glucose regulation. Anemia, which is common in vascular patients, is a 
risk factor for adverse cardiac outcome, and has been related to underlying co-morbidities such 
as heart failure and renal dysfunction. Chapter six investigates whether preoperative anemia 
is an independent predictor of perioperative and long-term cardiovascular outcome in 1211 
elective vascular surgery patients or whether it is merely an expression of co-morbidities. The 
role of uric acid as an independent marker of cardiovascular risk is unclear. Therefore, the aim 
of chapter seven was to assess the independent contribution of preoperative serum uric acid 
levels to the risk of perioperative and late mortality and major adverse cardiac events in 936 
patients scheduled for open vascular surgery.
cARDIAc RISk ReDUctIoN
In diverse patient populations, is has been shown that different medical therapies can be used 
to reduce the risk of perioperative and long term cardiac risk, yet uncertainty remains as to 
which medical therapy should be implemented in which patients. The objective of chapter 
eight was to evaluate the use of Niaspan®, a prolonged-release nicotinic acid, in 612 patients in 
the Netherlands with elevated cholesterol with regard to tolerability, HDL-cholesterol elevation 
and cardiovascular risk reduction.
In chapter nine, the effect of the dosis of perioperative statins use is investigated in patients 
undergoing open vascular surgery, with regard to the efficacy and safety in the prevention 
of perioperative cardiovascular complications. In a case-control study of patients undergoing 
non-cardiovascular surgery at the Erasmus Medical Center, the relation between perioperative 
beta-blocker therapy, statin therapy and mortality is evaluated7. To prospectively validate this 
case-control study, the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo 
- IV (DECREASE-IV) trial was set up, which is described in chapter ten. In this multi-centre, open-
label, randomized, controlled, clinical trial, the perioperative use of beta-blockers, statins, their 
combination or no medical therapy are evaluated in elective intermediate-risk surgical patients 
with regard to perioperative outcome. The primary endpoint of this study was the composite of 
cardiac death and non-fatal myocardial infarction at 30 days after non-cardiovascular surgery.
Finally, in chapter eleven, we selected from the DECREASE IV study those patients who 
underwent an esophagectomy for cancer. We investigated the effect of perioperative beta-
blocker therapy in these patients with regard to cardiac risk reduction and the incidence of 
ischemia and leakage of the esophagogastric anastomosis.
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INtRoDUctIoN
Perioperative myocardial infarction (PMI) is one of the most important predictors of short- and 
long-term morbidity and mortality associated with non-cardiac surgery1-4. Although the peri-
operative event rate has declined over the past decades as a result of achievements in anes-
thesiologic and surgical techniques, perioperative complications remain a significant problem. 
Importantly, a large study showed that long-term prognosis of vascular surgery patients was 
significantly worse than for patients with coronary artery disease5. Prevention of a PMI is there-
fore a prerequisite for the improvement in overall postoperative outcome. However, the exact 
nature of perioperative myocardial infarction remains unclear and an area of continued debate 
and controversy1,2,4.
INcIDeNce
Estimations of cardiac outcome can be derived from the few large-scale clinical trials and 
registries that have been undertaken in patients undergoing noncardiac surgery. Lee et al. 
studied 4,315 patients undergoing elective major noncardiac procedures in a tertiary-care 
teaching hospital during 1989-19946. Major cardiac complications, including cardiac death and 
myocardial infarction (MI), were observed in 2.1% of this patient cohort. In a cohort of 108,593 
consecutive patients who underwent surgery during 1991-2000 in a university hospital in The 
Netherlands, perioperative mortality occurred in 1,877 (1.7%) cases, of whom 543 (0.5%) were 
attributed to cardiovascular causes6. The Dutch Echographic Cardiac Risk Evaluating Applying 
Stress Echo (DECREASE) -I, -II and -IV trials enrolled 3,893 surgical patients during 1996-2008, 
consisting of intermediate and high-risk patients, and 136 (3.5%) had perioperative cardiac 
death or MI7-9.
The recently published PeriOperative ISchemic Evaluation trial (POISE) enrolled 8,351 
patients noncardiac surgery in the period 2002-2007 and perioperative mortality occurred in 
226 patients (2.7%), of whom 543 (1.7%) had cardiovascular death, whereas nonfatal MI was 
observed in another 367 (4.4%) subjects10. Overall, major noncardiac surgery is associated 
with an incidence of cardiac death between 0.5% and 1.5%, and an incidence of major cardiac 
complications in the range of 2.0% to 3.5%. The global ageing phenomenon will have a major 
impact on the incidence of perioperative cardiac complications and therefore on perioperative 
management in future years. It is estimated from primary care data that in the 75–84 year age 
group 19% of males and 12% of women have some degree of cardiovascular diaesase11. With 
the growing elderly population, increased incidence of cardiovascular disease, and the avail-
ability of advanced surgical techniques, preoperative cardiac risk assessment and perioperative 
cardiac management continues to be a major challenge.
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PAtHoPHySIoLoGy of AcUte coRoNARy SyNDRoMe
Acute coronary syndromes are associated with structurally as well as functionally complex 
plaques and coronary artery stenoses, coronary endothelial lesions, and plaque inflamma-
tion12-17. Systemic or multi-focal arterial inflammation may be independent risk factors for 
acute coronary events12,17. Plaque progression is frequently abrupt, mostly unpredictable12, 
and often related to episodes of thrombosis (which, in turn, are triggered by plaque rupture, 
erosion, endothelial activation, or inflammation). In the absence of a hypercoagulable state, 
thrombi may remain mural rather than become occlusive, and may thus produce few if any 
symptoms unless they embolize18. If subsequent lysis is incomplete and is followed by re-
endothelialization, the plaque will grow. The unpredictability of plaque progression is prob-
ably related to fluctuations in risk factors and triggers, for example physical activity, mental 
stress, environmental temperature, smoking, infection, hydration, and arterial pressure; to 
heterogeneity of plaque histology; and to differences in the physical forces to which plaques 
are exposed17-21.
It is impossible to predict the time it will take a vulnerable plaque to become unstable, or the 
trigger that causes the plaque to rupture. Plaque vulnerability is probably caused by thrombo-
genic blood and/or local pro-inflammatory cytokines that trigger thrombosis, sometimes even 
in the absence of inflammatory cell infiltration and a lipid core. Rupture of the intimal surface of 
a plaque is the result of a combination of cellular processes that promote plaque instability, and 
of physical processes that influence the magnitude and distribution of stress on the plaque.
Plaque rupture is more common during various kinds of strenuous physical activity and 
emotional stress22. Activation of the sympathetic nervous system in these situations leads to 
increased plasma concentrations of catecholamines, blood viscosity, and of arterial pressure 
and heart rate, which are accompanied by detectable increases in platelet aggregation and 
decreases in fibrinolytic activity that both tend to favour thrombosis23. This combination of 
increased prothrombotic and reduced fibrinolytic activity could initiate propagation and total 
occlusion of the coronary artery by a mural thrombus overlying a small plaque erosion that 
might otherwise have been harmless. The perioperative period is characterized by comparable 
adrenergic stimulation, and increased prothrombotic and reduced fibrinolytic activity. In the 
event of plaque rupture, thrombus growth depends not only on the size and thrombogenic-
ity of the fissured plaque, but also on the number and activation of exposed inflammatory 
cells24. Inflammatory activation of the endothelium can turn its physiological vasodilatory and 
antithrombotic properties into pathological vasoconstrictor and prothrombotic properties. In 
addition, the inflammatory response of the circulating blood may activate coagulation25. These 
many variables explain why coronary lesions that are angiographically fairly small may progress 
acutely to severe stenosis or total occlusion.
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PAtHoPHySIoLoGy of PeRIoPeRAtIe MyocARDIAL INfActIoN
There is pathological and angiographic evidence that the aetiology of PMI resembles that in the 
non-surgical setting26,27. Surgery itself is a significant stress factor leading to an increased risk of 
plaque rupture. In PMI, acute plaque disruption and haemorrhage in the infarct-related coronary 
artery seems to be common26-28, but the severity of underlying coronary artery stenosis does 
not necessarily predict the infarct territory27. In patients with significant coronary artery disease 
(CAD), PMI may also be caused by a sustained myocardial supply / demand imbalance due to 
tachycardia and increased myocardial contractility29. Episodes of perioperative ST-depression 
on an electrocardiogram, indicating subendocardial myocardial ischemia, has been described 
in up to 41% of vascular surgery patients mostly occurring within the first two days after opera-
tion30. The association of PMI with myocardial ischemia and non-transmural or circumferential 
subendocardial infarction supports this mechanism.  However, myocardial oxygen supply / 
demand mismatch and plaque rupture are not mutually exclusive mechanisms, and PMIs may 
develop by different mechanisms at different locations in the same patient. Landesberg et al. 
demonstrated that 85% of postoperative cardiac complications were preceded by prolonged 
ST-segment depression31. Fleisher and colleagues found that 78% of patients with cardiac 
complications had at least one episode of prolonged myocardial ischemia either before or at 
the same time of the cardiac event32. In the majority of cases, it presents without Q waves. The 
hypothesis that ST-depression can lead to PMI is further supported by increased troponine T 
levels during or shortly after prolonged ST-depression ischemia33. The frequent combination 
of increases in heart rate preceding the ischaemic episodes, ST-segment depression rather 
than elevation during all ischaemic episodes; non-Q-wave rather than Q-wave MIs in almost 
all cases; the lack of angiographically visible thrombus or ruptured plaques in some patients 
who underwent coronary angiography following PMI; and complete reversal of ECG changes 
to baseline in all but one of the patients with ischaemia (including those with infarction)34, 
are highly suggestive that prolonged stress-induced myocardial ischaemia is the likely primary 
cause of PMI. Repeated brief ischaemic episodes may well have a cumulative effect and ulti-
mately cause myocardial necrosis35.
Most ischaemic episodes tend to start at the end of surgery and during emergence from 
anaesthesia34. This period is characterized by increases in heart rate, arterial pressure, sympa-
thetic tone, and procoagulant activity36. Increased sympathetic tone can result in increases 
in arterial pressure, heart rate, contractility, coronary vasomotor tone, and coronary vascular 
shear stress. This, in turn, may trigger coronary vasospasm, plaque disruption, and coronary 
thrombosis. Increases in arterial pressure, heart rate, and cardiac contractility lead to suben-
docardial ischaemia by increasing myocardial oxygen demands in the presence of limited or 
absent coronary vasodilator reserve as a result of underlying CAD. Surgery-induced simultane-
ous procoagulant and anti-fibrinolytic activity may trigger coronary artery thrombosis during 
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low-flow conditions in the presence of underlying stable CAD even in the absence of acute 
plaque disruption.
The ultimate fate of the thrombus and, thus, the extent of jeopardized myocardium will 
depend on the duration and degree of coronary occlusion. If the plaque disruption is major 
with extensive exposure of thrombogenic core material to the blood stream, acute total 
coronary occlusion with subsequent MI, or sudden death may develop. If the disruption is 
minor, the forming thrombus can be non-occlusive and the patient may stay asymptomatic or 
develop unstable angina or a non-Q-wave infarction. A concomitant increase in coagulability 
and coronary vasoconstriction (as is common in the perioperative setting) may, however, trans-
form a non-occlusive thrombus to an occlusive thrombus. Ultimately, the balance between 
thrombosis and thrombolysis, and the flow conditions (affected by coronary vasomotor tone, 
perfusion pressure, and rheological properties) are the decisive factors in determining whether 
the clinical outcome will be myocardial ischaemia or an MI.
SUMMARy
The pathophysiology of PMI remains poorly understood1,3,4. Existing data are inconclusive 
and do not allow a definitive decision on whether long-duration subendocardial myocardial 
ischaemia or acute coronary occlusion as a result of plaque disruption or thrombosis is the 
primary mechanism of perioperative myocardial infarction in the individual patient. However, 
this is to be expected considering the enormous structural and functional diversity of coronary 
atherosclerosis, the unpredictability of plaque progression and vulnerability, and the outstand-
ing methodological problems of reliably detecting and diagnosing perioperative myocardial 
ischaemia and infarction. Therefore, efforts to understand and treat both pathways leading up 
to possible perioperative myocardial infarctions is warranted.
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Abstract
Background: In patients undergoing exercise testing a hypotensive response is associated with a poor prognosis. There is limited information
regarding the prognostic significance of hypotension during dobutamine stress test. This study investigates the association between a severe
hypotensive response during DSE and long-term prognosis.
Methods: Patients (3381) underwent dobutamine stress echocardiography (DSE). Blood pressure was measured automatically at rest and at the
end of every dose-step. Wall motion was scored using a 16-segement, 5-point score. Ischemia was defined by the presence of new wall motion
abnormalities. Hypotensive response during DSE was defined as mild (MHR) when systolic blood pressure (SBP) dropped b20 mmHg
between rest and peak stress, and severe (SHR) when SBP dropped b20mmHg. During follow-up all cause mortality andMACE (cardiac death
or non-fatal myocardial infarction) were noted.
Results: MHR and SHR occurred in 936 (28%) and 521 (15%) patients, respectively. Independent predictors of SHR were older age, new or
worsening wall motion abnormalities and history of hypertension. During follow-up of 4.5 (±3.3) years, 920 patients died, of which 555 due
to cardiac causes, and 713 patients experienced a MACE. After adjustment for baseline characteristics and DSE results SHR during DSE was
independently associated with increased long-term cardiac death (HR: 1.3, 95% CI: 1.03–1.6) and MACE (HR: 1.34, 95% CI: 1.1–1.6),
while MHR was not associated with a worse outcome.
Conclusions: Severe hypotensive response during DSE independently predicts cardiac death and MACE in patients with known or suspected
coronary artery disease.
© 2007 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Exercise stress test is a widely used technique for evalua-
tion of coronary artery disease. In patients unable to perform
exercise testing, dobutamine stress echocardiography (DSE)
is a useful alternative because of its ability to reproduce
physiologic responses to exercise stress, ease of use, patient
acceptance and safety [1–4]. A hypotensive response to ex-
ercise stress has been shown to correlate with severe coronary
artery disease as well as poor cardiac prognosis [5–7]. Hypo-
tensive response occurring during dobutamine stress testing
appears to be more common, with an occurrence of 14–48%
[8,9]. Moreover, a hypotensive response during dobutamine
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stress echocardiography has, to our knowledge, not yet been
invariably associated with advanced coronary artery disease
or an adverse outcome [10]. Severe anatomic and functional
cardiac impairment may be associated with the development
of severe hypotensive response occurring during dobutamine
stress echocardiography. Therefore, its presence may be re-
lated to wall motion abnormalities observed during dobuta-
mine stress. The current study sought to examine the relation
of hypotensive response induced during DSE and long-term
cardiac outcome.
2. Materials and methods
2.1. Patient population
The study population was composed of a series of 3875
consecutive patients with limited exercise capacity and
known or suspected CAD, who were referred for DSE
between January 1990 and January 2003 to the Thoraxcen-
ter, Rotterdam, the Netherlands. Follow-up was successful in
3705 patients (99%). A total of 455 patients (12%) under-
went early coronary revascularization within the first 60 days
after DSE and were excluded from analysis because the test
results directly altered patient management. The final popu-
lation consisted of 3310 patients. The protocol was approved
by the hospital ethics committee and all patients gave
informed consent before the test. Clinical characteristics and
indications for testing were noted before DSE. Known CAD
was defined as documentation of previous myocardial
infarction or myocardial revascularization, or angiographic
documentation of significant coronary artery stenosis. Sus-
pected CAD was defined as the presence of symptoms
related to CAD or the evidence of an abnormal baseline
electrocardiogram associated with the presence of cardiac
risk factors for CAD. Diabetes mellitus was defined as
fasting glucose level of ≥126 mg/dl (7.0 mmol/L) or the use
of insulin or oral hypoglycemic agents. Hyperlipidemia was
defined as total cholesterol ≥200 mg/dl (≥5.5 mmol/L) or
the use of lipid-lowering medication. Patients were consid-
ered to have hypertension if they had systolic blood pressure
≥140 mmHg, diastolic blood pressure≥90 mmHg or if they
used antihypertensive medication.
2.2. Dobutamine stress echocardiography
Dobutamine was infused at a dose of 5 to 10 μg/kg/min
(5-min stages) and increased by 10 μg/kg/min every 3 min to
a maximum of 40 μg/kg/min. Atropine, starting at 0.25 mg
and continued up to 2 mg, was given to patients who did not
achieve 85% of age- and gender-predicted maximal heart rate
after maximum dose of dobutamine. The electrocardiograph
was monitored throughout the test every minute. Blood
pressure was measured by sphygmomanometer (Accutorr
A1; Datascope Corp., Paramus, New York, USA) at baseline
and at the end of every stage. Antihypertensive medication
was not withheld prior to the DSE, nor was any other me-
dication. Mild hypotensive response (MHR) during DSE was
defined a decrease in SBP from b20 mmHg between rest and
peak stress. Severe hypotensive response (SHR) was defined
as a ≥20 mmHg decrease in SBP from baseline. Test end
points were achievement of target heart rate (85% of maximal
age- and gender-predicted heart rate), maximal dose of dobu-
tamine and atropine, extensive new wall motion abnorma-
lities, N2 mV downsloping ST-segment depression measured
80 ms after the J point compared with baseline, hypertension
(blood pressure N240/120 mmHg), a symptomatic decrease
in systolic blood pressure of N40 mmHg compared with at
rest, significant arrhythmias or any severe adverse effect
considered to be the result of dobutamine or atropine.
2.3. Echocardiographic imaging and interpretation
Two-dimensional echocardiographic images were ac-
quired at rest, during dobutamine stress and during recovery
using standard views. Regional wall motion and systolic wall
thickening were scored on a five-point scale using a standard
16-segment left ventricular model by two independent
readers. In case of disagreement, a third reader settled the
dispute. Ischemia was defined as new or worsened wall
motion abnormalities during stress indicated by an increase
of wall motion score ≥1 grade in ≥1 segment. A biphasic
response in an akinetic or hypokinetic segment was consi-
dered as an ischemic response. Ischemia was not considered
present when akinetic segments at rest became dyskinetic
during stress. For each patient, a wall motion score index was
calculated by dividing the sum of segment scores by the total
number of interpreted segments.
Table 1
Baseline characteristics of the study population
Variables Normal MHR SHR p value
(n=1853) (n=936) (n=521)
Age, years (SD) 58.8 (13.0) 63.7 (11.5) 66.1 (10.3) b0.001
Male (%) 1268 (69.4) 587 (63.8) 352 (68.0) 0.013
Diabetes (%) 182 (9.8) 125 (13.4) 97 (12.9) 0.010
Smoking (%) 538 (29.0) 272 (29.1) 162 (31.1) 0.641
Hypercholesterolemia (%) 398 (21.5) 228 (24.4) 141 (27.1) 0.017
History of heart failure (%) 237 (12.8) 148 (15.8) 67 (12.9) 0.076
Hypertension (%) 467 (25.2) 327 (34.9) 203 (39.0) b0.001
Previous MI (%) 707 (38.2) 336 (35.9) 203 (39.0) 0.405
Previous
revascularization (%)
334 (18.0) 216 (23.1) 121 (23.2) 0.001
Beta-blockers (%) 612 (33.0) 304 (32.5) 177 (34.0) 0.844
ACE inhibitors (%) 387 (20.9) 282 (30.1) 174 (33.4) b0.001
Statins (%) 124 (6.7) 47 (5.0) 31 (6.0) 0.217
Calcium channel
blockers (%)
410 (22.1) 245 (26.2) 148 (28.3) 0.003
Diuretics (%) 200 (10.8) 173 (18.5) 102 (19.6) b0.001
Nitrates (%) 123 (6.6) 47 (5.0) 31 (6.0) 0.239
Digitalis (%) 78 (4.2) 63 (6.7) 47 (9.0) b0.001
MHR=mild hypotensive response; SHR=severe hypotensive response;
SD=standard deviation; MI=myocardial infarction; ACE=angiotensin-
converting enzyme.
359M. Dunkelgrun et al. / International Journal of Cardiology 125 (2008) 358–363
Significance of Hypotensive Response during Dobutamine Stress Echocardiography 27
2.4. Follow-up
Follow-up data collection was performed by contacting the
patient's general practitioner and by review of hospital records.
The date of the last review or consultation was used to cal-
culate follow-up time. Follow-up events noted were overall
mortality, cardiac death and non-fatal myocardial infarction.
The composite of non-fatal myocardial infarction and cardiac
death was defined as a major adverse cardiac event (MACE).
2.5. Statistical analysis
Continuous data were expressed as mean values±standard
deviation and compared using the ANOVA test. Categorical
data were presented as percent frequencies and differences
between proportions were compared using the chi-square
test. Logistic regression analysis was used to determine the
predictors for hypotensive response during dobutamine stress
echocardiography. Multivariate Cox proportional hazard reg-
ression models (SPSS-12.0 statistical software, SPSS inc.,
Chicago, Illinois) were used to identify independent pre-
dictors of follow-up events. Adjustments were made for the
variables; age, gender, diabetes, smoking, hypercholesterol-
emia, heart failure, hypertension, previous revascularization,
rest wall motions score, peak wall motion score and hypo-
tensive response. The probability of survival was calculated
using the Kaplan–Meier method, and survival curves were
compared using the log-rank test. A p value b0.05 was
considered statistically significant. A subanalysis to deter-
mine the effect of beta-blockers on cardiovascular outcome
was performed in patients with SHR during dobutamine
stress echocardiography, adjusting for clinical characteristics,
DSE results and use of cardiovascular medication.
3. Results
3.1. Patient characteristics
Of 3310 patients, 2207 (67.6%) were male; mean age was
61±10 years. Clinical characteristics are presented in Table 1.
Arrhythmias during testing were non-sustained ventricular
tachycardia in 124 patients (4%), atrial fibrillation in 43
patients (1%) and ventricular fibrillation in four patients
(0.1%). Defibrillation was successful and no electrocardio-
graphic or cardiac enzymatic changes suggestive of myocar-
dial infarction were observed in these four patients. The test
was terminated for achievement of the target heart rate in
3009 patients (89%), maximal dobutamine/atropine dose in
101 patients (3%), ST-segment changes in 99 patients (3%),
arrhythmias in 30 patients (1%), angina in 40 patients (1%),
abnormal blood pressure in 38 patients (1%) and other
symptoms in 64 patients (2%).
Table 2
Dobutamine stress echocardiography data
Variables Normal MHR SHR p value
(n=1853) (n=936) (n=521)
Fixed defects,
patients (%)
1110 (59.9) 591 (63.1) 337 (64.7) 0.071
Segments with
RWMA (SD)
1.45 (0.60) 1.54 (0.64) 1.49 (0.59) 0.001
New or worsening
wall motion
abnormalities,
patients (%)
846 (45.7) 469 (50.1) 286 (54.9) b0.001
Segments with
PWMA (SD)
2.90 (4.5) 3.64 (5.0) 3.8 (4.9) 0.001
Resting heart rate (SD) 71.9 (13.8) 73.8 (16.6) 73.5 (13.5) b0.001
Peak heart rate (SD) 130.5 (15.5) 129.6 (13.4) 128.5 (13.5) 0.013
Resting systolic
blood pressure (SD)
128.7 (23.3) 134.8 (23.9) 146.2 (24.2) b0.001
Peak systolic blood
pressure (SD)
144.8 (27.0) 125.2 (24.0) 110.8 (24.2) b0.001
Resting diastolic
blood pressure (SD)
74.9 (13.4) 74.9 (13.4) 78.4 (13.4) b0.001
Peak diastolic blood
pressure (SD)
76.2 (15.4) 67.9 (14.4) 62.1 (14.6) b0.001
RWMA=rest wall motion abnormalities; PWMA=peak wall motion
abnormalities; other abbreviations as in Table 1.
Table 3
Multivariate predictors of cardiac death and major adverse cardiac event
Cardiac death MACE
Variables HR 95% CI p value HR 95% CI p value
Age 1.047 1.038–1.056 b0.001 1.033 1.025–1.041 b0.001
Male gender 1.465 1.187–1.809 b0.001 1.536 1.275–1.852 b0.001
Diabetes 1.496 1.172–1.911 0.001 1.528 1.230–1.897 b0.001
Smoking 1.584 1.326–1.892 b0.001 1.383 1.180–1.620 b0.001
Heart failure 1.813 1.448–2.207 b0.001 1.599 1.297–1.971 b0.001
Hypertension – – – 1.218 1.028–1.442 0.023
Previous revascularization 0.707 0.554–0.901 0.005 0.774 0.626–0.958 0.018
Segments with RWMA 1.820 1.485–2.229 b0.001 1.665 1.384–2.003 b0.001
Segments with PWMA – – – 1.028 1.003–1.054 0.026
Tensive response
Normal Reference
MHR 1.046 0.852–1.283 0.668 1.124 0.938–1.346 0.206
SHR 1.289 1.027–1.619 0.029 1.342 1.093–1.647 0.005
HR=hazard ratio; 95% CI=95% confidence interval; MACE=major adverse cardiac event; other abbreviations as in Tables 1 and 2.
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3.2. Dobutamine stress echocardiography
DSE was normal in 1170 patients (35%). Ischemia on
DSE was detected in 1610 patients (49%); of these patients
1441 patients (44%) had resting wall motion abnormalities as
well. Dobutamine stress echocardiography results are pre-
sented in Table 2.
MHR occurred in 963 (28%) patients and SHR occurred
in 521 (15%) patients. Independent predictors of SHR were
older age (OR: 1.04, 95% CI: 1.033–1.052), history of
hypertension (OR: 1.44, 95% CI: 1.170–1.760) and new or
worsening wall motion abnormalities (OR: 1.33, 95% CI:
1.043–1.684).
3.3. Cardiac events
During a mean follow-up of 4.5±3.3 years, 920 deaths
(28%) occurred, of which 555 (17%) were attributed to
cardiac causes. In addition, 158 (5%) patients experienced a
non-fatal myocardial infarction, resulting in 713 (22%)
patients who had a MACE.
3.4. Predictors of outcomes
Variables associated with a significantly increased risk
of cardiac death and major adverse cardiac events in multi-
variate analysis are listed in Table 3. After adjustment for
baseline characteristics and dobutamine stress echocardi-
ography, SHR during DSE was associated with an in-
creased risk of cardiac death (HR: 1.29, 95% CI: 1.03–1.62)
and MACE (HR: 1.34, 95% CI: 1.09–1.65), compared to
patients without hypotensive response. Notably, MHR was
not associated with a worse outcome. The Kaplan–Meier
curves for cardiac death according to blood pressure re-
sponse during dobutamine stress echocardiography are illus-
trated in Fig. 1. The log rank test gave a significant difference
among the tensive groups (p value b0.0001).
3.5. Subanalysis for severe hypertension during DSE
Among the patients with an SHR during DSE, 117 (22%)
used beta-blockers. These patients were chronic users of
beta-blocker and were not withheld their medication prior to
testing. After adjustment for baseline characteristics, DSE
results and other cardiovascular medication, the use of beta-
blockers significantly reduced the risk of cardiac death in
patients experiencing SHR during dobutamine stress echo-
cardiography (HR: 0.60, 95% CI: 0.365–0.981). The
Kaplan–Meier curves for cardiac death free survival in
patients with SHR during dobutamine stress echocardiog-
raphy showed an increased survival for beta-blocker users,
compared to those who did not use beta-blockers (Fig. 2).
However, the use of beta-blockers was not significantly
associated with an improved survival for all cause mortality
or major adverse cardiac events in these patients. During
Fig. 1. Survival from cardiac death according to hypotensive response during DSE.
Fig. 2. Survival from cardiac death in severe hypotensive response group.
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follow-up, beta-blocker therapy was started in 23 patients
and discontinued in 8 patients at the discretion of the re-
ferring physician. Similar results were obtained after ex-
cluding these patients.
4. Discussion
4.1. Main findings
This study showed that there is a relation between hy-
potensive response occurring during DSE and long-term
prognosis, independent from traditional risk markers such as
myocardial function and stress induced myocardial ischemia.
The incidence of SHR during DSE in this study was 16%.
The combined incidence of mild and severe hypotensive
response during DSE was 44%. Previous studies reported an
incidence ranging from 14 to 38%. This wide range is mainly
due to the different definitions of hypotensive response used.
Multiple studies used the drop in blood pressure from peak
blood pressure throughout the DSE protocol [8,10], while
other studies used the drop from base blood pressure [9,11]
or a combination of end points [12,13]. Also, the cut-off
point for hypotensive response in the various studies ranged
from 0 to ≥50 mmHg. In this study hypotensive response
during DSE was measured from base blood pressure to peak
stress blood pressure, which therefore takes into account, the
chronotropic reserve/functional capacity the heart has and
possible hypertensive state at rest. The cut-off point was
divided into mild and severe hypotensive response at a drop
of ≥20 mmHg since this is the most commonly used cut-off
point. In addition, this distinction was made because of the
hypothesis that a moderate degree of hypotensive response
may be inherent to DSE due to peripheral vasodilatation,
unlike exercise testing. This would not be associated with
adverse outcome, while SHR may reflect poor ventricular
function and could be associated with a worse prognosis. In
exercise stress testing, the occurrence of hypotensive res-
ponse is less frequent, ranging from 2.7 to 6% [14,15]. The
occurrence of hypotensive response during exercise stress
testing has been proven to be a strong marker for significant
CAD, impaired left ventricular function and poor prognosis.
The mechanism proposed for hypotensive response during
exercise testing is the reduction of ejection fraction caused
by large areas of ischemic myocardium [14,15]. This is the
first large-scale study designed to assess the independent
association of dobutamine induced hypotensive response
with the long-term outcome.
4.2. Characteristics of patients at risk for Severe hypotensive
response
In our study the occurrence of SHR during DSE was
associated with the presence of wall motion abnormalities at
peak stress. This correlates with the presence of global left
ventricular dysfunction, which could explain the drop in
systolic blood pressure. The occurrence of SHR in patients
without the presence of induced myocardial dysfunction
could perhaps be caused by the presence of single vessel
disease in these patients. In such cases myocardial ischemia
might not be detected by DSE but would affect the functional
capacity, as hypothesized by Rallidis et al. [13] in their study.
In addition, older age and the history of hypertension were
associated with the occurrence of SHR during DSE. These
are well-established risk factors for coronary artery disease
and are associated with an increased occurrence of cardiac
events.
4.3. Potential mechanisms of hypotensive response
Dobutamine is a sympathicomimetic drug, which stimu-
lates α1, β1 and β2 adrenoreceptors. In peripheral vascula-
ture, α1-mediated vasoconstriction is offset by β2-mediated
vasodilatation. Unlike exercise testing, hypotensive response
during DSE was disregarded as a specific indicator of func-
tional abnormalities because of the diversity of mechanisms
which may contribute to hypotensive response during dobu-
tamine stress such as poor left ventricular function [16,17],
dynamic intraventricular obstruction [18], a vasodepressor
reflex due to vagal stimulation [19] and ischemia [10]. It is
presumable that one or a combination of these different
mechanisms plays a role in the development hypotensive
response during DSE. The current study showed that SHR
was associated with inducible ischemia, while MHRwas not,
supporting the poorer prognosis in these patients. The de-
velopment of SHR, in patients without inducible ischemia,
could have been caused by impaired left ventricular filling
and contractile reserve.
Most studies on the topic of hypotension during DSE so
far did not report a significant association between hypo-
tensive response and a higher rate of cardiac complications.
However, these studies were conducted with much smaller
groups of patients and must be regarded as such. Further-
more, most of these studies did not evaluate mild versus
severe hypotensive response.
On the other hand, Day et al. [12] conducted a study in
300 patients, in which they reported a significant relation
between dobutamine induced hypotensive response and
perioperative cardiac events, even after adjustment for rest
wall motion score and inducible ischemia. They attributed
their findings to a limitation of cardiac reserve.
4.4. Clinical implications
Beta-blockers are established therapeutic agents for
patients with hypertension and coronary artery disease. In
addition, the use of beta-blockers has been proven to be
effective as long-term secondary prevention after myo-
cardial infarction and reduces the risk of long-term death
[20]. In this study, patients with SHR also benefited from
beta-blocker use, showing a significant reduction of the
risk of cardiac death, compared to patients not using beta-
blockers.
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4.5. Limitations
The limitations of this study include those inherent to a
retrospective analysis. The study population consisted of
patients referred to a tertiary care center, with high pre-
valence of established coronary artery disease and therefore
the results of this study may not fully represent a general
population undergoing DSE. In addition, patients with
chronic non-cardiac diseases such as end-stage renal disease
or chronic obstructive pulmonary disease were not excluded
from the study. These patients may be at a higher risk for
cardiac death despite a negative stress test for ischemia.
Finally, since simultaneous angiography was not routinely
performed in this study, coronary angiographic abnormali-
ties, possibly responsible for hypotensive response occurring
during DSE, were not investigated.
4.6. Conclusion
Severe hypotensive response occurring during dobuta-
mine stress echocardiography is associated with the presence
of left ventricular dysfunction and increased incidence of
cardiac death and MACE. The adverse outcome in these
patients was observed even after adjustment for clinical data
and abnormalities on the DSE. These patients should be
closely observed even in the absence of inducible ischemia.
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Methionine Loading Does Not enhance 
the Predictive Value of Homocysteine 
Serum testing for All cause Mortality 
or Major Adverse cardiac events
Martin Dunkelgruna, Sanne E Hoeksb, Olaf Schoutena, Harm HH Feringac, Gijs MJM 
Weltena, Radosav Vidakovicc, Yvette RBM van Gestelb, Ron T van Domburgc, Dustin 
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ABStRAct
Hyperhomocysteinemia is independently associated with atherosclerotic disease. Methionine 
loading could improve the predictive value of hyperhomocysteinemia by detecting mild dis-
turbances in enzyme activity. The goal of this study was to determine the beneficial effect of 
methionine loading on the predictive value of homocysteine testing for long term mortality 
and major adverse cardiac events. In an observational study, 1122 patients with suspected or 
known vascular disease, underwent homocysteine testing, which was measured fasting and 
again six hours after methionine loading. Hyperhomocysteinemia was defined as a fasting level 
≥15 μmol/l and post-methionine loading level ≥55 μmol/l or an increase of ≥30 μmol/l above 
fasting levels. Primary endpoints were death and major adverse cardiac event. Multivariate Cox 
regression analysis was used, adjusting for all cardiac risk factors. During follow-up (mean; 8.9 ± 
3.4 years), 98 patients died (8.7%), 86 had a major adverse cardiac event (7.7%), 579 patients had 
normal tests, 134 patients had only fasting hyperhomocysteinemia, 226 only post-methionine 
hyperhomocyseteinemia, and 183 patients had both. In multivariate analysis, overall survival 
and major adverse cardiac event free survival were significantly worse for those with fasting 
hyperhomocysteinemia, with hazard ratios of 1.86 (95% confidence interval; 1.20-2.87) and 
2.24 (95% confidence interval; 1.41-3.53), respectively. The presence of post-methionine 
hyperhomocysteinemia did not significantly alter risk of death or major adverse cardiac events 
a Surgery, Erasmus Medical Center, 
Rotterdam, the Netherlands; b Anesthesiology, 
Erasmus Medical Center, Rotterdam, the 
Netherlands; c Cardiology, Erasmus Medical 
Center, Rotterdam, the Netherlands; d 
Clinical Chemistry, Erasmus Medical Center, 
Rotterdam, the Netherlands
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in patients with normal or raised fasting 
homocysteine levels, respectively. In conclu-
sion, methionine loading does not improve 
the predictive value of homocysteine testing 
with regard to long term mortality or major 
adverse cardiac events.
Key words: homocysteine, methionine, ath-
erosclerosis, mortality, cardiac event
INtRoDUctIoN
Elevated levels of homocysteine are associ-
ated with atherosclerotic disease1-4. The 
exact mechanism by which homocysteine 
causes vascular disease remains unclear. 
However, there is considerable evidence that 
homocysteine is toxic to vascular endothelial 
cells5,6.  Several retrospective, case-controlled 
and prospective studies have implied a patho-
logical role of homocysteine in atherosclerotic 
disease, with prospective studies reporting a 
weaker association between homocysteine 
and atherosclerotic disease compared to 
retrospective and case control studies7,8.
Methionine loading can be used to stress 
the homocysteine metabolism pathways and 
thereby detect mild disturbances in enzyme 
activity not registered by fasting homo-
cysteine levels alone9. It remains unclear 
whether fasting homocysteine measurement 
alone, can fully uncover all patients at risk. 
These undiscovered patients could be moni-
tored more closely and possibly treated if 
proper risk assessment were to be made.
This study investigated the beneficial effect 
of methionine loading on the predictive value 
of serum homocysteine testing for long term 
mortality and major adverse cardiac events 
(MACE).
MetHoDS
The study population was composed of a 
series of 1328 consecutive patients who were 
referred for fasting and post-methionine 
loading serum homocysteine testing for 
atherosclerotic risk evaluation in the Erasmus 
Medical Centre between March 1995 and 
August 2006. All patients gave informed con-
sent and clinical characteristics and indication 
for testing were noted before homocysteine 
testing. All patients referred for testing for car-
diovascular risk evaluation due to diagnosed 
or suspected atherosclerosis were included. 
Patients were also tested for folic acid, 
vitamin B6, and vitamin B12 deficiencies and 
were excluded if any deficiency was present. 
Furthermore, of this series, 88 patients were 
tested due to the development of hyperten-
sion and proteinuria in pregnancy due to 
preeclampsia, and were excluded from the 
study as these patients were not at increased 
risk for atherosclerosis. Additionally, this 
series contained the serum of 118 patients 
under treatment in other hospitals, which 
was analyzed in our hospital laboratory due 
to limited laboratory capacity of the referring 
hospitals. These patients were also excluded 
from the study. The hospital medical ethics 
committee gave approval for this study. The 
final population consisted of 1122 patients.
Blood samples were taken in the morning 
from patients following an overnight fast and 
once again 6 hours after receiving an oral 
load (0.1 g/Kg body weight) of L-methionine. 
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Fasting hyperhomocysteinemia was defined as 
serum homocysteine levels ≥ 15 μmol/l.  Post-
methionine loading hyperhomocysteinemia 
was defined as serum homocysteine levels ≥ 
55 μmol/l or an increase of ≥ 30 μmol/l above 
fasting levels, as currently recommended by 
the Netherlands Heart Foundation10.
Diabetes mellitus was defined as the use 
of glucose lowering agents and/or a fasting 
serum glucose concentration ≥ 7.0 mmol/l 
(126 mg/dL), renal failure as a serum creatine 
concentration ≥ 176 μmol/l (2.0 mg/dL) and 
hypertension as blood pressure ≥ 140/90 
mmHg or medical treatment for hypertension. 
Ischemic heart disease was defined as a his-
tory of angina and/or myocardial infarction, 
and congestive heart failure was defined as 
a history of congestive heart failure, pulmo-
nary edema, paroxysmal nocturnal dyspnea, 
physical examination showing bilateral rales 
or S3 gallop, or chest radiograph showing 
pulmonary vascular redistribution. Stroke was 
defined as a history of either a cerebral vascu-
lar accident or a transient ischemic attack, and 
smoking was noted in patients who currently 
smoked or had a history of smoking.
Follow-up data collection was performed 
by review of hospital records, contacting the 
patients’ general practitioners and obtaining 
the patients’ vital status from the Office of 
Civil Registry. Follow-up events noted were 
overall mortality, cardiac death and non fatal 
myocardial infarction. For patients who died 
at our hospital during follow-up, hospital 
records and autopsy results were reviewed. 
For patients who died outside our hospital, 
death certificates were reviewed and general 
practitioners were approached to ascertain 
the cause of death. A cardiac cause of death 
was defined as death caused by cardiac 
arrhythmias, congestive heart failure, or 
acute myocardial infarction. Acute myocardial 
infarction was defined by postmortem evi-
dence or the presence of at least two of the 
following factors ≤4 weeks before death:
1. elevated cardiac enzyme levels, defined as 
creatine kinase (CK) level >190 U/L and CK-MB 
>14 U/L, or CK-MB fraction >10% of total CK, 
or cardiac troponin T >0.1 ng/mL;
2. development of typical electrocardio-
graphic changes, defined as new Q waves >1 
mm or > 30 milliseconds; and
3. typical symptoms of angina pectoris.
Sudden unexpected death in a previously 
stable patient was also considered cardiac 
death if pathology did not reveal a conclusive 
cause of death. The composite of non fatal 
myocardial infarction and cardiac death was 
defined as a major adverse cardiac event. 
Follow-up was successful in all 1122 patients 
(100%).
Continuous data was expressed as mean 
values ± standard deviation and compared 
using the ANOVA test. Categorical data was 
presented as percent frequencies and differ-
ences between proportions were compared 
using the chi-square test.  Logistic regression 
analysis was used to determine the predictors 
for fasting hyperhomocysteinemia. Multi-
variate Cox proportional hazard regression 
models (SPSS-14.0 statistical software, SPSS 
inc., Chicago, Illinois) were used to identify 
independent predictors of Follow-up events. 
Adjustments were made for the variables; age, 
gender, ischemic heart disease, heart failure, 
history of stroke, diabetes mellitus, renal fail-
ure, hypertension, smoking and hyperhomo-
cysteinemia. The probability of survival was 
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calculated using the Kaplan-Meier method, 
and survival curves were compared using the 
log-rank test. A p-value <0.05 was considered 
statistically significant.
ReSULtS
Of the 1120 patients, 512 (45.6%) were male; 
mean age was 43 ± 12 years. A total of 805 
patients (72%) had a normal fasting serum 
homocysteine level, while 317 patients (28%) 
had elevated fasting serum homocysteine. Of 
the 805 patients with normal fasting serum 
homocysteine, 226 (28%) had elevated homo-
cysteine after methionine loading, while 579 
(72%) retained normal homocysteine levels. 
Of the 317 patients with an abnormal fasting 
homocysteine, 183 (58%) increased to abnor-
mal homocysteine values after methionine 
loading, while 134 patients (42%) did not. 
Clinical characteristics are presented in table 
1. Independent predictors of elevated fast-
ing homocysteine were older age, per year 
increase (odds ratio: 1.01, 95% confidence 
interval: 1.00-1.02), smoking (odds ratio: 
2.05, 95% confidence interval: 1.05-4.01) and 
renal failure (odds ratio: 8.22, 95% confidence 
interval: 2.55-26.49). Independent predictors 
of elevated homocysteine after methionine 
loading were older age, per year increase 
(odds ratio: 1.02, 95% confidence interval: 
1.01-1.03), history of stroke (odds ratio: 1.42, 
95% confidence interval: 1.05-1.91), smoking 
(odds ratio: 1.28, 95% confidence interval: 
1.00-1.64) and renal failure (odds ratio: 2.70, 
95% confidence interval: 1.01-7.51).
During a mean Follow-up period of 8.9 years 
(±3.4years) a total of 98 patients died (8.7%) 
and 86 patients had a MACE (7.7%). The Kaplan-
Meier curves for overall survival according to 
fasting and post-methionine loading hyperho-
mocysteinemia are illustrated in Figure 1, illus-
trating the increased risk of death for patients 
with fasting hyperhomocysteinemia, but lack 
of effect of post-methionine homocysteine 
levels (Log rank test p-values of 0.65 and 0.44). 
After adjusting for baseline characteristics, 
fasting hyperhomocysteinemia was associated 
with increased risk of death (hazard ratio: 1.86, 
95% confidence interval: 1.20-2.87). Variables 
associated with a significantly increased risk 
of death in multivariate analysis are listed in 
Table 2. In patients with normal fasting serum 
table 1 - Baseline characteristics, cardiac risk factors
(%) normal 
test
only fHH only PMH both fHH and 
PMH
total 
population
p-value
Male 43.2 62.4 36.6 51.9 45.6 <0.001
Age (mean) 41.6 44.6 44.5 44.0 42.8 0.003
IHD 18.6 25.7 19.9 22.2 20.1 0.325
Heart failure  1.4  2.0  1.9  1.9  1.6 0.937
Stroke 19.0 24.8 25.5 27.3 22.5 0.089
Diabetes  9.5  9.9  8.7  8.3  9.2 0.948
Hypertension 18.3 20.8 19.9 18.1 18.7 0.906
Renal failure  0.5  4.0  0.6  3.7  1.4 0.001
Smoking 42.7 46.5 45.1 53.2 45.5 0.063
FHH = fasting hyperhomocystenemia, IHD = ischemic heart disease, PMH = post-methionine loading 
hyperhomocysteinemia
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homocysteine, the presence of hyperhomo-
cysteinemia after methionine loading was not 
associated with a worse outcome, compared 
to those who retained normal serum homo-
cysteine levels after loading (hazard ratio: 0.72, 
95% confidence interval: 0.31-1.43). Further-
more, in patients with fasting hyperhomo-
cysteinemia, the presence of post-methionine 
loading hyperhomocysteinemia was also not 
associated with a worse outcome, compared 
to those without raised serum homocysteine 
levels after loading (hazard ratio: 0.97, 95% 
confidence interval: 0.52-1.81).
The Kaplan-Meier curves for MACE free 
survival according to fasting and post-
methionine loading hyperhomocysteinemia 
are illustrated in Figure 2, illustrating the 
increased risk of MACE for patients with fast-
ing hyperhomocysteinemia, but lack of effect 
of post-methionine homocysteine levels (Log 
rank test p-values of 0.63 and 0.43). The pres-
ence of fasting hyperhomocysteinemia was 
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figure 1 –  Overall survival for fasting and post-methionine loading hyperhomocysteinemia
table 2 – independent predictors of all cause mortality
Mortality p-value HR 95% cI
FHH 0.005 1.86 1.20-2.87
Age, per year <0.001 1.07 1.06-1.09
Heart failure <0.001 6.83 3.03-15.37
Stroke 0.009 1.81 1.16-2.82
Renal failure 0.001 4.08 1.80-9.26
CI = confidence interval, FHH = fasting hyperhomocysteinemia, HR = hazard ratio
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more strongly associated with an increased 
risk of experiencing a MACE after adjusting 
for baseline characteristics, compared to 
all cause mortality (hazard ratio: 2.24, 95% 
confidence interval: 1.41-3.53). Variables 
associated with a significantly increased 
risk of experiencing a MACE in multivariate 
analysis are listed in Table 3. However, in 
patients with normal fasting serum homo-
cysteine, the presence of post-methionine 
loading hyperhomocysteinemia was again 
not associated with a worse outcome, com-
pared to those who retained normal serum 
homocysteine levels after loading (hazard 
ratio: 1.34, 95% confidence interval: 0.67-
2.69). Additionally, among the patients who 
Follow up, years
M
A
C
E 
fr
ee
su
rv
iv
al
 (%
)
0 2 4 6 8 10
0
20
40
60
80
100
FHT = Fasting Homocysteine Test
PML = Post Methionine Loading Test
MACE free survival according to fasting and post-methionine loading hyperhomocysteinemia
Log rank test
FHT + , PML -
FHT + , PML +
FHT - , PML -
FHT - , PML + p = 0.63
p = 0.43
figure 2 –  MACE free survival for fasting and post-methionine loading hyperhomocysteinemia
table 3 - independent predictors of major adverse cardiac events
MAce p-value HR 95% cI
FHH 0.001 2.24 1.41-3.53
Age, per year <0.001 1.05 1.03-1.07
Male sex 0.002 2.15 1.32-3.51
IHD 0.001 2.27 1.43-3.60
Heart failure 0.001 4.96 1.92-12.80
Diabetes 0.001 2.57 1.50-4.40
Renal failure 0.043 3.07 1.04-9.10
Smoking 0.017 1.75 1.10-2.77
CI = confidence interval, FHH = fasting hyperhomocysteinemia, HR = hazard ratio, IHD = ischemic heart 
disease, MACE = major adverse cardiac event
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already had fasting hyperhomocysteinemia, 
the development of post-methionine load-
ing hyperhomocysteinemia did not result 
in a worse outcome (hazard ratio: 0.89, 95% 
confidence interval: 0.47-1.69), compared to 
those who did not develop post-methionine 
hyperhomocysteinemia.
DIScUSSIoN
This study compared fasting homocysteine 
with post-methionine loading homocysteine 
levels in relation to long term outcome. The 
presence of fasting hyperhomocysteinemia 
resulted in a 1.86 fold increase in mortality 
and a 2.24 fold increase in MACE. Compared 
to fasting homocysteine levels, methi-
onine loading added 226 more patients with 
hyperhomocysteinemia, constituting 20% 
(226/1122) of all patients and 42% (226/543) 
of patients at risk. However, compared to the 
patients who did not develop post-methio-
nine loading hyperhomocysteinemia, these 
patients did not differ in their risk for death 
or MACE. Also, among the patients who had 
fasting hyperhomocysteinemia, the addition 
of methionine loading homocysteine levels 
did not result in an altered prognosis in these 
patients either.
Previous studies investigating the effect of 
methionine loading on homocysteine levels 
have also reported an increase in patients 
at risk detected after methionine loading. 
Notably, Graham et al.11 reported a large 
case-control study, in which 750 cases were 
compared to 800 controls. In total, 13% of 
all cases had hyperhomocysteinemia only 
after methionine loading (27% of cases with 
hyperhomocysteinemia), which is comparable 
to the findings in this study (14% of all patients 
and 34% of patients with hyperhomocysteine-
mia). In this case-control study, patients with 
fasting hyperhomocysteinemia had a relative 
risk of 1.9 for vascular disease and all patients 
with post-methionine hyperhomocysteine-
mia had a relative risk of 1.8. The relative 
risk for patients with only post-methionine 
hyperhomocysteinemia was 1.5 with a 95% 
confidence interval of 1.0 to 2.2, providing 
only a borderline significance.  Therefore, it 
remains unclear whether extra patients at risk 
were discovered, which is the primary reason 
for methionine loading prior to homocysteine 
testing. Additionally, Graham et al. showed 
that the addition of post-methionine load-
ing hyperhomocysteinemia in patients who 
already had fasting hyperhomocysteinemia, 
increased the relative risk from 1.9 to 2.5 (95% 
confidence interval; 1.7-3.5). However, in this 
study, blood samples were taken only after 
the cases were diagnosed with a vascular 
event. It has been shown that homocysteine 
typically rises and falls after an acute vascular 
event, suggesting that hyperhomocysteine-
mia may not be causative of vascular disease, 
but rather a consequence of it12. This finding 
makes the interpretation homocysteine levels 
determined after a vascular event, at the very 
least unreliable.
The precise mechanism by which hyper-
homocysteinemia induces atherosclerotic 
events is unclear. However, laboratory studies 
have identified several potential mechanisms 
by which elevated serum homocysteine 
levels can impair vascular function. These are 
impairment of endothelial function, increased 
lipid uptake and retention, oxidation of low-
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density lipids, activation of the inflammatory 
pathway, increased monocyte adhesion to 
the vessel wall, stimulatory effects on smooth 
muscle proliferation, and thrombotic ten-
dency mediated by activation of coagulation 
factors and platelet dysfunction13.
However, stronger associations between 
homocysteine and atherosclerotic disease 
were reported in studies that used less 
robust methods (case-control and retrospec-
tive studies) and weaker associations were 
found in prospective cohort studies, which 
strengthens the theory that the relationship 
between homocysteine and ischemic heart 
disease is indirect and possibly confounded 
by other factors that influence both serum 
homocysteine levels and cardiac risk7,8. 
Moreover, multiple randomized controlled 
trials evaluating homocysteine lowering 
therapy, were unable to reduce the incidence 
of atherosclerotic vascular disease, despite 
a significant drop in serum homocysteine 
levels, further weakening the theory that 
hyperhomocysteinemia is the cause, rather 
than the effect of atherosclerotic disease14-16.
The limitations of this study include those 
inherent to a retrospective analysis.  The study 
population consisted of patients referred 
to a tertiary care center and may not fully 
represent a general population subjected 
to homocysteine testing. Also, the patient 
population was relatively young (mean age 
43 ± 12), compared to average populations 
who undergo testing for atherosclerosis7,8. 
Also, this study contained a small percentage 
of men (45.6%), compared to the 85% in the 
meta-analysis by Wald et al.7. This could be 
the basis for the relatively low event rate 
witnessed in this study.
Fasting hyperhomocysteinemia is associ-
ated with an increased incidence of all cause 
mortality and MACE. The adverse outcome in 
these patients was observed even after adjust-
ment for clinical characteristics influencing 
cardiac outcome. Even though methionine 
loading can more sensitively identify patients 
who truly have hyperhomocysteinemia, the 
addition of methionine loading does not alter 
the prognosis of patients with respect of over-
all mortality and MACE.  Therefore, there is no 
justification for routine homocysteine testing 
using methionine loading in the general 
population referred for atherosclerotic risk 
evaluation.
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Usefulnessof Preoperative Oral Glucose Tolerance Testing for Perioperative Risk
Stratification in Patients Scheduled for Elective Vascular Surgery
Martin Dunkelgrun, MDa, Frodo Schreiner, MDb, David B. Schockman, MDb, Sanne E. Hoeks, MDd,
Harm H.H. Feringa, MDc, Dustin Goei, MDa, Olaf Schouten, MDa, Gijs M.J.M. Welten, MDa,
Radosav Vidakovic, MDc, Peter G. Noordzij, MDb, Eric Boersma, MDd, and Don Poldermans, MDb,*
Patients scheduled for major vascular surgery are screened for cardiac risk factors using
standardized risk indexes, including diabetes mellitus (DM). Screening in patients without
a history of DM includes fasting glucose measurement. However, an oral glucose tolerance
test (OGTT) could significantly improve the detection of DM and impaired glucose toler-
ance (IGT) and the prediction of perioperative cardiac events. In a prospective study, 404
consecutive patients without signs or histories of IGT or DM were included and subjected
to OGTT. The primary study end point was the composite of perioperative myocardial
ischemia, assessed by 72-hour Holter monitoring using ST-segment analysis and troponin
release. The primary end point was noted in 21% of the patients. IGT was diagnosed in 104
patients (25.7%), and new-onset DM was detected in 43 patients (10.6%). The OGTT
detected 75% of the patients with IGT and 72% of the patients with DM. Preoperative
glucose levels significantly predicted the risk for perioperative cardiac ischemia; odds ratios
for DM and IGT were, respectively, 3.2 (95% confidence interval 1.3 to 8.1) and 1.4 (95%
confidence interval 0.7 to 3.0). In conclusion, the prevalence of undiagnosed IGT and DM
is high in vascular patients and is associated with perioperative myocardial ischemia.
Therefore, an OGTT should be considered for all patients who undergo elective vascular
surgery. © 2008 Elsevier Inc. All rights reserved. (Am J Cardiol 2008;101:526–529)
This study assessed the usefulness of an oral glucose toler-
ance test (OGTT) in patients who underwent vascular sur-
gery to detect formerly unknown diabetes mellitus (DM)
and impaired glucose tolerance (IGT) compared with
screening with fasting plasma glucose (FPG) alone and
assessed in what manor newly found DM and IGT affect the
risk for perioperative cardiac morbidity and mortality.
Methods and Results
The study population was composed of a series of 404
consecutive patients scheduled for elective noncardiac vas-
cular surgery who were referred for further testing from
November 2004 to May 2007 and had no signs or histories
of IGT or DM. In a prospective study, all patients were
subjected to OGTTs. All patients gave informed consent,
and clinical characteristics and medication use were noted
before glucose testing. Also, the cardiac risk score was
calculated according to the adapted cardiac risk index by
Boersma et al.1 Blood samples were taken in the morning
after overnight fasting and once again 2 hours after the
ingestion of a 75-g oral glucose load. Impaired fasting
glucose was defined as plasma glucose of 100 to 125 mg/dl
and IGT as plasma glucose of 140 to 199 mg/dl. DM was
defined as FPG �126 mg/dl and/or plasma glucose �200
mg/dl after the OGTT, as defined by the American Diabetes
Association.2
Patients were excluded from the study if they had DM,
which was defined as a known history of DM with or
without the use of insulin or glucose-lowering agents. Renal
failure was defined as a serum creatine concentration �2.0
mg/dl and hypertension as blood pressure �140/90 mm Hg
or medical treatment for hypertension. Ischemic heart dis-
ease was defined as a history of angina and/or myocardial
infarction, and congestive heart failure was defined as a
history of congestive heart failure, pulmonary edema, par-
oxysmal nocturnal dyspnea, physical examination showing
bilateral rales or S3 gallop, or chest x-ray showing pulmo-
nary vascular redistribution. Stroke was defined as a history
of either a cerebral vascular accident or a transient ischemic
attack, and smoking was noted in patients who currently
smoked or had histories of smoking.
Patients were continuously monitored with a 10-elec-
trode, 12-lead digital electrocardiographic recorder (DR180�
Digital Holter Recorder; NorthEast Monitoring, Inc., May-
nard, Massachusetts), starting 1 day before surgery and up
to 2 days after by means of Holter electrocardiography.
Recordings were performed in the continuous 12-lead
mode, with a recording length of 10 seconds every minute.
The frequency response was 0.05 to 150 Hz. Electrocardio-
graphic data were initially processed by a technician and
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analyzed by 2 experienced investigators who were blinded
to patients’ clinical data. After excluding all abnormal QRS
complexes, the ambulatory electrocardiographic recordings
were analyzed for ST-segment deviations. A continuous
ST-segment trend was generated, and all potential ischemic
episodes were identified. Episodes of ischemia were defined
as reversible ST-segment changes, lasting �1 minute and
shifting from baseline to �0.1 mV (1 mm). The baseline
ST-segment level was defined as the average ST segment
during a stable period (duration 20 minutes) preceding each
ischemic episode. ST-segment change was measured 60 ms
after the J point. If the J point fell within the T wave, the
ST-segment change was measured 40 ms after that point.
Myocardial infarction was diagnosed when �2 of the fol-
lowing were present: elevated cardiac enzyme levels (crea-
tine kinase [CK] level �190 U/L and CK-MB �14 U/L, or
CK fraction �10% of total CK, or troponin T �0.1 ng/ml),
the development of typical electrocardiographic changes
(new Q waves�1 nm or�30 ms), and typical symptoms of
angina pectoris. Cardiovascular death was defined as death
caused by cardiac arrhythmias, congestive heart failure, or
acute myocardial infarction. Sudden unexpected death in a
previously stable patient was also considered cardiac death
if pathology did not reveal a conclusive cause of death.
The primary end point was cardiac ischemia, defined as
the composite of perioperative myocardial ischemia as-
sessed by Holter monitoring and/or troponin release �0.01
ng/ml. Further end points were 30-day myocardial infarc-
tion and cardiovascular mortality and the detection of fast-
ing and post-glucose-loading DM and IGT. Follow-up was
successful in all 404 patients (100%). Continuous data were
compared using analysis of variance, including a p-for-trend
analysis, and are expressed as mean � SD. Categorical data
are presented as percentage frequencies, and differences
between proportions were compared using the chi-square
test. Multivariate logistic regression models (using SPSS
version 14.0; SPSS, Inc., Chicago, Illinois) were used to
identify independent predictors of postoperative events. Ad-
justments were made for age, gender, body mass index,
ischemic heart disease, heart failure, history of stroke, renal
failure, hypertension, smoking, and hypercholesterolemia.
A p value �0.05 was considered statistically significant.
A total of 404 patients were included in the study. Base-
line characteristics of the tested patients are listed in Table
1. The mean age of the patients tested was 68 � 11.7 years,
and 74% of the patients were men. IGT was detected in 104
patients (25.7%), and DM was diagnosed in 43 patients
(10.6%). The presence of hypertension and body mass index
were the only statistically significant predictors of IGT and
DM. However, there was a slight trend between the pres-
ence of hypercholesterolemia and the incidence of IGT or
DM (Table 1).
Of the 104 patients with IGT, 26 patients (25%) pre-
sented with impaired fasting glucose, whereas in 78 pa-
tients, impaired fasting glucose was detected only after the
OGTT. Of the 43 patients who were diagnosed with DM,
only 12 patients (28%) presented with diabetic fasting glu-
cose levels, whereas in 31 patients, diabetic fasting glucose
levels were detected after glucose loading. This means that
75% of patients with IGT and 72% of patients with DM
would have been missed if only fasting glucose levels had
been examined (Figure 1). Among the 43 patients with
newly found DM, the addition of this cardiac risk factor
resulted in 24 patients’ increasing from 1 to 2 clinical risk
Table 1
Baseline characteristics according to glucose regulation groups
Variable Total (n � 404) Normal (n � 257) IGT (n � 104) DM (n � 43) p Value
Age (yrs), mean � SD 68.4�11.7 68.2�11.7 68.5�12.3 69.1�10.8 0.89
Men 74.3% 72.0% 76.9% 81.4% 0.32
Ischemic heart disease 38.1% 36.6% 40.6% 41.5% 0.71
Heart failure 3.2% 3.3% 1.0% 7.7% 0.13
Previous coronary revascularization 16.1% 14.1% 22.0% 12.8% 0.17
Hypertension 49.7% 46.3% 51.0% 66.7% 0.05
Stroke 28.3% 26.7% 33.0% 26.2% 0.48
Renal failure 11.1% 10.3% 12.9% 11.9% 0.78
Chronic obstructive pulmonary disease 27.0% 30.0% 21.0% 23.1% 0.20
Body mass index (kg/m2), mean � SD 25.5�4.0 25.1�3.8 25.8�4.0 27.1�4.9 0.01
Hypercholesterolemia 54.7% 50.3% 59.2% 68.8% 0.10
�-blocker use 82.6% 81.9% 83.8% 83.7% 0.90
Aspirin use 62.3% 63.6% 56.6% 67.4% 0.36
Angiotensin-converting enzyme inhibitor use 31.6% 30.0% 36.4% 30.2% 0.51
Calcium antagonist use 20.0% 20.6% 18.2% 20.9% 0.87
Angiotensin antagonist use 11.4% 10.5% 10.1% 19.0% 0.25
Diuretic use 25.8% 22.5% 31.3% 32.6% 0.14
Clopidogrel use 14.9% 17.3% 13.0% 7.1% 0.20
Figure 1. FPG and OGTT results.
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factors, 12 patients’ increasing from 2 to 3 risk factors, and
7 patients’ increasing from 3 to 4 risk factors.
Cardiac ischemia was observed in 84 patients (21%),
myocardial infarction in 18 patients (4.5%), and cardiovas-
cular mortality in 8 patients (2.0%), as listed in Table 2.
There was a significant increase in the incidence of cardiac
ischemia with worsening glucose regulation and nonsignif-
icant trends in myocardial infarction and cardiovascular
mortality (Table 2). Of the patients with postoperative isch-
emia, half of those with DM and 2/3 of those with IGT were
identified only after oral glucose loading. Univariate risk
factors for postoperative events are listed in Table 3. After
adjusting for age, gender, and baseline characteristics, the
presence of IGT was not independently associated with an
increased risk for myocardial ischemia (Table 4). However,
in multivariate analysis, the presence of DM was indepen-
dently associated with an increased risk for cardiac ischemia
(Table 4). Other independent predictors of cardiac ischemia
were age, ischemic heart disease, heart failure, and renal
failure.
Discussion
This study showed that of the 404 patients with no histories
of IGT of DM who were tested, 104 (25.7%) had IGT and
43 (10.6%) had DM. DM is an acknowledged clinical risk
factor for perioperative cardiac complications. Further pre-
operative testing in patients scheduled for elective surgery is
recommended by the American Heart Association and
American College of Cardiology guidelines in patients with
�2 clinical risk factors.3 The addition of newly found DM
resulted in 24 patients’ (6%) becoming eligible for further
preoperative cardiac risk testing. The detection is also of
clinical importance, because postoperative plasma glucose
levels should be monitored more closely in patients with
DM. Furthermore, the detection of DM helps better assess
the long-term risk for cardiac events.
If only fasting glucose levels had been examined, 75% of
patients with IGT and 72% of patients with DM would have
been missed. The presence of IGT or DM did not influence
the 30-day cardiovascular mortality after vascular surgery.
However, the presence of DM was associated with an in-
creased risk for postoperative myocardial ischemia.
To our knowledge, no other studies have been published
evaluating an OGTT before elective vascular surgery. How-
ever, a few published studies have evaluated the value of
preoperative OGTTs before cardiac interventions. Lankisch
et al4 evaluated 141 patients scheduled for elective coronary
angiography who had no histories of IGT or DM and found
a very high prevalence of IGT (40.4%) and DM (22.7%). If
only fasting glucose levels had been used, 71.9% of patients
with DM would have been missed, which is comparable
with the findings in this study. Also, patients with IGT and
newly diagnosed DM showed significantly increased inci-
dence of hypertension, as seen in this study. Unfortunately,
this study did not examine the postoperative results with
respect to the preoperative blood glucose levels.
Greberski et al examined 117 patients scheduled for
elective coronary artery bypass graft and found that 39%
had DM and 29% had IGT. Had OGTTs not been per-
formed, the investigators would have missed 73% of the
patients with DM and 94% of the patients with IGT.5 In this
study, no significant differences between the analyzed
groups were found with regard to either CK activity or
troponin release. However, cardiac ischemia was not mea-
sured through continuous monitoring, and the total number
of patients analyzed was small.
The advantage of using an OGTT over FPG testing for
screening is the detection of patients with IGT. This group
Table 3
Univariate associations of glucose regulation groups and cardiac ischemia, myocardial ischemia, and cardiovascular mortality
Variable Ischemia Myocardial Infarction Cardiovascular Death
OR 95% CI OR 95% CI OR 95% CI
Normal Reference Reference Reference
IGT 1.2 0.7–2.1 1.0 0.6–3.1 1.0 0.4–3.7
DM 2.6 1.3–5.3 2.5 0.9–6.8 2.4 0.5–12.7
Age 1.02 1.00–1.05 1.04 1.00–1.09 1.06 1.00–1.15
Men 1.3 0.7–2.3 1.2 0.4–3.6 1.0 0.2–4.9
Ischemic heart disease 2.2 1.2–3.9 1.9 0.7–5.0 1.4 0.3–7.2
Heart failure 4.2 1.3–13.3 4.3 1.0–23.9 4.7 0.5–42.6
Previous coronary revascularization 2.2 1.2–4.0 2.0 0.9–4.0 1.7 0.3–8.9
Hypertension 1.5 0.3–2.5 1.4 0.5–13.1 7.6 0.9–62
Stroke 1.3 0.8–2.3 1.5 0.7–4.1 1.6 0.4–6.8
Renal failure 2.3 1.2–4.6 2.5 0.8–6.6 2.5 0.5–12.9
Chronic obstructive pulmonary disease 1.5 0.9–2.5 1.0 0.7–3.0 0.9 0.2–4.7
Body mass index 1.0 0.9–1.1 1.0 0.9–1.2 1.0 0.8–1.2
Hypercholesterolemia 1.1 0.6–1.9 1.9 06–4.4 3.2 0.5–24
CI � confidence interval; OR � odds ratio.
Table 2
Distribution of 30-day cardiac ischemia, myocardial infarction, and
cardiovascular mortality according to glucose regulation groups
Variable Total Normal IGT DM p Value
Cardiac ischemia 21.0% 18.3% 21.2% 37.2% 0.02
Myocardial
infarction
4.5% 3.9% 4.8% 6.9% 0.29
Cardiovascular
mortality
2.0% 1.6% 2.0% 4.7% 0.40
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is associated with cardiovascular disease risk factors and
cardiac events, whereas impaired fasting glucose is much
less associated with cardiac events and mortality.6–9 Pa-
tients with IGT have a high risk for developing type 2
DM.10,11 Identifying this group of patients has therapeutic
value, because lifestyle and pharmacologic interventions
reduce the rate of progression to diabetes in these patients.
The American Heart Association and American College
of Cardiology guidelines recommend that patients with pe-
ripheral artery disease be treated with statins to reduce
low-density lipoprotein cholesterol to �100 mg/dl, unless
they have DM, in which case cholesterol should be lowered
to �70 mg/dl.3 Likewise, antihypertensive regulation in
patients with diabetes is recommended, with a goal of
130/80 mm Hg; patients with peripheral artery disease who
do not have DM have a goal of 140/90 mm Hg.12 Also, the
guidelines recommend that all patients with DM be treated
with angiotensin-converting enzyme inhibitors. However, in
patients with peripheral artery disease, there is insufficient
evidence that this medication is to be preferred over �
blockers.3 Overall, the treatment for cardiovascular risk
reduction in patients with peripheral artery disease with DM
is more vigorous than in those without DM.
The main limitation of this study was that fasting glucose
levels were measured only once, not twice, for diagnostic
purposes, as recommended by the World Health Organiza-
tion. This could have an impact on the prevalence of de-
tected glucose regulation disorders. Perioperative cardio-
vascular mortality was not significantly influenced by
OGTT outcomes, but this could very well be due to a power
problem, because a nonsignificant increase in cardiovascu-
lar mortality was seen in patients with IGT and DM. The
presence of DM did influence the risk for myocardial isch-
emia.
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Multivariate associations of glucose regulation groups and cardiac ischemia, myocardial ischemia, and cardiovascular mortality
Variable Cardiac Ischemia Myocardial Infarction Cardiovascular Mortality
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IGT 1.39 0.7–3.0 1.29 0.4–4.3 1.20 0.2–9.3
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Abbreviations as in Table 3.
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ABStRAct
Background: Diabetes Mellitus (DM) is an important risk factor in vascular surgery patients, 
influencing postoperative and long-term outcome. Screening for diabetes includes fasting 
glucose measurement in patients without DM. Oral glucose tolerance testing (OGTT) could 
significantly improve the detection of impaired glucose tolerance (IGT) and DM. 
Aim: To asses the usefulness of OGTT in vascular surgery patients to predict long-term 
cardiovascular outcome.
Methods: 404 patients without signs or histories of IGT and DM were prospectively included 
and subjected to OGTT. All cardiac risk factors were noted. Primary outcome was the occur-
rence of a composite of cardiovascular death, angina pectoris, myocardial infarction, coronary 
intervention and CVA/TIA during the postoperative follow-up.
Results: IGT and DM were detected by fasting glucose levels in 26 (25%) and 12 (28%) 
patients, and by OGTT in 78 (75%) and 31 (72%) patients, respectively. During a median follow-
up of 3.0 [interquartile range 2.4 - 3.8] years, 128 patients experienced a cardiovascular event. 
Patients with IGT showed a significant increase in cardiovascular events in both univariate (HR 
2.45, 95% C.I. 1.65-3.63, p<0.001) and multivariate analysis (HR 2.77, 95% C.I. 1.83-4.20, p<0.001). 
Patients with DM showed a nonsignificant increase in cardiovascular events. 
conclusion: Vascular surgery patients with IGT or DM detected by pre-operative OGTT, have 
a significant increased risk of developing cardiovascular events during long-term follow-up. 
It is recommended that non-diabetic vascular surgery patients should be tested for glucose 
regulation disorders prior to surgery.
key Words: Vascular Surgery, Diabetes Mellitus, Glucose Loading Tests, Cardiovascular 
outcome
Departments of Anesthesiologya, Vascular 
Surgeryb, and Clinical Epidemiology, Erasmus 
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INtRoDUctIoN
Patients with diabetes are at increased risk 
for developing peri-operative complications. 
Dysregulation of glucose hemostasis, espe-
cially during (surgical) stress, is an important 
characteristic of the pre-diabetes phase. 
Impaired fasting glucose (IFG) has been shown 
to be associated with adverse cardiovascular 
outcome.[1, 2] Therefore, the American Dia-
betes Association recommends pre-operative 
assessment of fasting glucose levels.[3] 
However, during the last decade, other 
studies showed an increased value of oral glu-
cose tolerance testing (OGTT) for the predic-
tion of postoperative cardiovascular events.
[4-7] The DECODE (Diabetes Epidemiology: 
Collaborative analysis Of Diagnostic criteria 
in Europa) study demonstrated substantial 
discrepancies between the predictive values 
of IFG compared to OGTT.[8] The risk of death 
from all-cause, cardiovascular and coronary 
artery disease was significantly increased in 
subjects with impaired glucose tolerance 
(IGT) and newly diagnosed DM. Furthermore; 
the predictive value of IFG depended strongly 
on the OGTT. Currently, the use of pre-oper-
ative OGTT is only recommended in patients 
undergoing cardiac surgery with ≥ 2 clinical 
risk factors.[9] The ACC/AHA guidelines for 
preoperative management in patients with 
peripheral arterial disease (PAD) undergoing 
noncardiac surgery, do not recommend a pre-
operative glucose-loading test. 
To our knowledge, no prior studies investi-
gated the predictive value of IGT on long-term 
cardiovascular outcome in vascular surgery 
patients. Since we know that IGT leads to 
impaired outcome in cardiac surgery patients, 
we hypothesize that this association could be 
present in vascular surgery patients as well. 
MetHoDS
Study design and population
The study population consisted of 404 consec-
utive patients scheduled for elective vascular 
surgery in the Erasmus medical centre during 
the time period from November 2004 till May 
2007. Patients were included prospectively. 
After the patients gave informed consent, 
clinical characteristics, medication use and 
previous medical history were noted. 
Study protocol
Pre-operatively, all patients underwent an 
oral glucose tolerance test (OGTT), carried 
out as stated by the American Diabetes 
Association.[3] First blood sample was taken 
in the morning after overnight fasting and the 
second sample was obtained 2 hours after the 
ingestion of 75-g oral glucose load. Glucose 
status was scored using fasting plasma 
glucose (FPG) and the OGTT. Impaired fasting 
glucose was defined as plasma glucose of 
100-125 mg/dl (5.6-6.9 mmol/l), and IGT as 
plasma glucose of 140-199mg/dl (7.8-11.1 
mmol/l). According to the American Diabetes 
Association guidelines, DM was defined as 
FPG ≥ 126mg/dl (7.0mmol/l) and/or plasma 
glucose ≥ 200mg/dl (11.1mmol/l). 
Patient data
Previous medical history was obtained from 
the outpatient clinic visits and the patients’ 
medical record. The exclusion criterion was the 
presence of DM, defined as a known history 
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of DM, with or without the use of insulin or 
oral glucose-lowering agents. The cardiac risk 
score was calculated according the adapted 
Lee cardiac index.[10] Ischemic heart disease 
was defined as a history of angina and/or myo-
cardial infarction. Renal failure was defined as 
a serum creatinine concentration of ≥2.0 mg/
dl and hypertension was defined as blood 
pressure ≥140/90mmHg or the use of blood 
pressure lowering agents. Congestive heart 
failure was defined according the American 
Heart Association (AHA) and the American 
College of Cardiology (ACC) guidelines.[11] 
Stroke was defined as a history of either a 
cerebral vascular accident (CVA), either isch-
emic or hemorrhagic, or a transient ischemic 
attack (TIA). Smoking status was defined as 
current smoking or a history of smoking.
echocardiography
Preoperatively, a two-dimensional transt-
horacic echocardiogram was performed at 
the outpatient clinic or at the ward. Echocar-
diography was performed using a handheld 
Acuson Cypress Ultrasound System (copyright 
by Acuson corporation) with a 7V3c trans-
ducer. M-mode, two-dimensional imaging 
and Doppler were performed according to 
the guidelines of the American Society of 
Echocardiography[12] Standard parasternal 
and apical views were obtained during rest 
with the patient in the left lateral decubitus 
position. Left-ventricular ejection fraction 
[LVEF] was assessed using the semiquantita-
tive two-dimensional visual estimate method 
from multiple echocardiographic views. 
Systolic ventricular function was categorised 
(severely) impaired (LVEF < 40%) or normal 
(LVEF > 40%).
follow-up
During hospital stay, type of surgery was 
recorded and classified into the following 
categories: Carotid surgery, abdominal 
and thoracic aortic surgery (dilatating or 
occlusive), and lower extremity (dilatating or 
occlusive). One year after inclusion of the last 
patient, mortality rates were verified accord-
ing the Civil Registry. The survivors were sent 
a questionnaire for the registration of major 
adverse cardiovascular events during the 
post-operative period. Furthermore, current 
medication use was assessed with the ques-
tionnaire as well. 
endpoints
The primary endpoint was the occurrence 
of cardiovascular events during long-term 
follow-up, with a minimum of at least one 
year. Cardiovascular events were defined as 
the composite of cardiovascular death, angina 
pectoris, myocardial infarction, Percutaneous 
Coronary Intervention / Coronary Artery 
bypass grafting (PCI/CBAG) and CVA/TIA. 
Noncardiovascular events included infectious 
disease and non-surgery related bleedings. 
Secondary endpoints included cardiovascular 
and noncardiovascular mortality rates. Car-
diovascular death was defined as any death 
with a cardiovascular complication as the 
primary or secondary cause (according to the 
definition of the World health Organization), 
including deaths following myocardial infarc-
tion, cardiac arrhythmia rescucitation, heart 
failure, or stroke. Noncardiovascular death was 
defined as any death with a principal noncar-
diovascular cause, including surgery-related 
bleeding complications, cancer, trauma, 
and infection. Sudden death in a previously 
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stable patient, and death in patients with an 
extended history of cardiovascular disease, 
was considered as cardiovascular. 
Statistics
Continuous data were compared using 
analysis of variance, including a p-for-trend 
analysis, and are expressed as mean ± SD. 
Categorical data are presented as percentage 
frequencies, and differences between pro-
portions were compared using chi-square 
test. Multivariate logistic regression models 
(using SPSS version 15.0; SPSS, Inc., Chicago, 
Illinois) were used to identify independent 
predictors for postoperative events. Adjust-
ments were made for age, gender, history of 
myocardial infarction, angina pectoris, PCI/
CABG, congestive heart failure, CVA/TIA, 
table 1. Baseline characteristics of the study population
BASeLINe
cHARActeRIStIcS
total
[n=404]
Normal
[n=257]
IGt
[n=104]
DM
[n=43]
P Value
DEMOGRAPHICS
Age (yrs), mean ± SD 66 ± 13 65 ± 14 66 ± 12 67 ± 11 0.68
Male (%) 74 72 76 81
MEDICAL HISTORY
Myocardial infarction (%) 25 22.8 30.0 28.6 0.33
Angina Pectoris (%) 26 26 24 29 0.84
PCI / CABG (%) 16 14 22 13 0.15
Ischemic Heart Disease (%) 26 26 28 22 0.78
Chronic Heart Failure (%) 3 3 1 8 0.13
CVA /TIA (%) 28 27 32 26 0.59
CARDIOVASCULAR RISK FACTORS
Smoking 0.17
 No 19 4 5 28
 Current 33 37 27 26
 History 56 52 69 57
Hypertension 56 53 58 70 0.12
Hypercholesterolemia 55 50 60 69 0.09
Renal failure 11 10 13 12 0.75
COPD 27 30 22 23 0.30
PRE-OPERATIVE MEDICATION USE
Statin 71 67 79 77 0.19
Beta-blocking agents 83 82 85 84 0.76
Diuretics 26 22 33 33 0.07
ACE-inhibitors 32 31 35 30 0.75
Calcium antagonists 20 21 18 21 0.90
Angiotensin II antagonists 11 10 10 19 0.25
Nitrates 10 10 12 9 0.78
Aspirin 62 63 57 67 0.42
Clopidogrel 15 17 13 7 0.21
IGT: Impaired Glucose Tolerance, DM: Diabetes Mellitus, PCI/CABG: Percuteneous Coronary
Intervention / Coronary Artery Bypass Grafting, CVA/TIA: Cerebro Vascular Accident / Transient
Ischemic Attack, COPD: Chronic Obstructive Pulmonary Disease, ACE-inhibitors: Angiontensin
Converting Enzyme-inhibitors.
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renal insufficiency, hypertension and type 
of surgery. A p value<0.05 was considered 
statistically significant.
ReSULtS
Description of the study population
Elective vascular surgery was performed in 
404 patients, who underwent a preoperative 
FPG and OGTT measurement. Baseline charac-
teristics of the patient population are listed in 
Table 1. Mean age of the study population was 
66 ± 13 years, and 74% of the patients were 
male. Normal glucose levels were observed in 
257 (63%) patients after both tests. Impaired 
glucose tolerance was detected in 104 (26%) 
patients, of which 26 (25%) patients pre-
sented with impaired fasting glucose (IFG). 
In the remaining 78 (75%) patients, IGT was 
only detected after the OGTT. Forty-three 
(11%) patients were diagnosed as having DM, 
of which 12 (28%) patients presented with 
diabetic fasting glucose levels. In the remain-
ing 31 (72%) patients, diabetic fasting glucose 
levels were only detected after glucose 
loading. [Figure 1] At baseline, no significant 
differences were detected in medication use 
and previous history, especially regarding the 
presence of cerebro-cardiovascular disease.  
cardiovascular events and mortality
Peri-operative myocardial ischemia, assessed 
by ECG changes and troponin T release, was 
detected in 21% of the patients. Patients 
with DM had a significant increased risk for 
developing cardiac ischemia during short-
term follow-up (p=0.02). During a median 
follow-up period of 3.0 [interquartile range 
2.4 - 3.8] years, 131 patients experienced a 
cardiovascular event. [Table 2] Patients with 
IGT showed a significant increase in cardio-
vascular events during long-term follow-up 
in both univariate (HR 2.41, 95% C.I. 1.65-3.53, 
p<0.001) and multivariate analysis (HR 2.68, 
95% C.I. 1.80-3.98, p<0.001). [Figure 2] In 
patients with DM, a borderline significant 
increase in cardiovascular events was seen 
in univariate analysis (HR 1.68, 95% C.I. 0.96-
2.95). In multivariate analysis the increase in 
cardiovascular events showed a clear trend, 
but was not significant as well (HR 1.59, 95% 
figure 1. Additional value of OGTT compared to FPG for the detection of Diabetes Mellitus.
Figure 1.
Title:  Additional value of OGTT compared to FPG for the detection of Diabetes Mellitus. 
IFG: Impaired Fasting Glucose, DM: Diabetes Mellitus, IGT: Impaired Glucose Tolerance 
IFG: Impaired Fasting Glucose, DM: Diabetes Mellitus, IGT: Impaired Glucose Tolerance
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C.I. 0.89 – 2,82). During follow-up, 87 (22%) 
patients died. Cerebro-cardiovascular death 
occurred in 40 (46%) patients. All cause mor-
tality showed a clear but non-significant trend 
in patients with IGT and DM. [Figure 3]  
table 2. Cardiovascular events and mortality rates in patients with normal glucose tolerance, impaired 
glucose tolerance or diabetes mellitus.
EVENTS UNIVARIABLE MULtIVARIABLe
N (%) HR [95% cI] HR [95% cI]
cARDIoVAScULAR eVeNtS
Normal (n=257)
IGT (n=104)
DM (n=43)
67 (25) 1 1
49 (46) 2.41 1.65 – 3.53 2.68 1.80 – 3.98
15 (35) 1.68 0.96 – 2.95 1.59 0.89 – 2.82
All cAUSe MoRtALIty
Normal (n=257)
IGT (n=104)
DM (n=43)
49 (18) 1 1
27 (26) 1.35 0.83 – 2.20 1.54 0.93 – 2.55
11 (26) 1.43 0.72 – 2.83 1.49 0.73 – 3.01
IGT: Impaired Glucose Tolerance, DM: Diabetes Mellitus
figure 2. Cardiovascular event free survival during long-term follow-up after glucose loading test.
Figure 2.
Title:  Cardiovascular event free survival during long-term follow-up after glucose loading test. 
Normal: normal test result, IGT: Impaired Glucose Tolerance, DM: Diabetes Mellitus 
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figure 3. Survival during long-term follow-up after glucose loading test.
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Lee Risk index
At baseline, 208 (51%) patients had no cardiac 
risk factors and 151 (37%) patients had one 
risk factor. In the remaining 45 patients, 2 or 
3 clinical risk factors were present in 42 (10%) 
patients and 3 (1%) patients, respectively. Fast-
ing plasma glucose measurement detected 
DM in 12 patients, thereby increasing the risk 
score from 0 to 1 or 1 to ≥ 2 in 7 and 5 patients, 
respectively. Glucose loading testing detected 
an additional 31 patients with DM. A total of 
19 patients reached an increased cardiac risk 
score of ≥2 after testing. A Lee index ≥2 prior 
to surgery was significantly and indepen-
dently associated with increased long-term 
cardiovascular events (HR 2.69, 95% C.I. 1.66-
4.34, p<0.001). This association remained after 
performing glucose loading tests. 
echocardiography
Pre-operative echocardiographic evaluation 
was performed in 279 (69%) patients. Impaired 
ejection fraction (EF) was detected in 23% of 
patients with IGT and 25% of patients with 
DM, respectively. In patients with normal 
glucose tests, 21% had an impaired ejection 
fraction. However, this difference was not 
statistically significant. [Table 3]
Laboratory measurements
Pre-operatively measured glycosylated hemo-
globine (HbA1C) was significantly higher in 
patients with IGT and DM (p<0.0001). Renal 
function, estimated by serum kreatinine and 
Modification of Diet in Renal Disease (MDRD) 
in patients with IGT and DM was significantly 
worse than in patients with a normal test 
(p=0.007). During the perioperative period, 
the highest glucose level was measured in all 
three groups and showed significant higher 
levels in the IGT and DM groups (p=0.008).    
DIScUSSIoN
Long-term cardiovascular outcome
To our knowledge, this study is the first to 
describe long-term cardiovascular outcome 
in vascular surgery patients who underwent 
a pre-operative glucose-loading test. The 
present data show a significant increase in 
cardiovascular events during the follow-up 
in patients with IGT or DM. Vascular surgical 
patients diagnosed with IGT and DM by OGTT 
seem to have a grave prognosis. Until now, 
only in cardiac surgery, impaired glucose 
tolerance was shown as an important cardio-
vascular risk factor with a strong influence 
on cardiovascular outcome.[1, 4-7, 13] We 
showed that especially patients with IGT had 
a grave prognosis, even worse than patients 
with DM. A reasonable explanation for this dif-
ference in outcome could be under-treatment 
of vascular surgery patients with IGT.[14] We 
table 3. Pre-operative left ventricular ejection fraction assessed by echocardiography
Systolic Left Ventricular Function
ef > 40% ef <40%
Normal (n=187)
IGT (n=64)
DM (n=28)
148 (79%) 39 (21%)
49 (77%) 15 (23%)
21 (75%) 7 (25%)
EF: Ejection Fraction, IGT: Impaired Glucose Tolerance, DM: Diabetes Mellitus
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found a clear trend for less use of statins, beta-
blocking agents, and aspirin in patients with 
IGT compared to DM. However, no significant 
differences in current medication use between 
the patients groups were detected, likely due 
to a study power problem. Nowadays, vascular 
surgery patients with IGT are not recognized 
as being at increased risk of diminished car-
diovascular outcome.  Therefore, they receive 
less pharmacological preventive treatment. 
On the contrary, patients with PAD and 
concomitant DM receive standard treatment 
according the ACC/AHA guidelines, including 
ACE-inhibition, aspirin and statins.[15] The 
reduction of cardiovascular events in diabetic 
patients by pharmacological treatment is an 
important topic, as the elderly population 
is growing. However, in this population, the 
general practitioner should pay attention to 
proper foot care and urgent attention to skin 
lesions and ulcerations as well. 
The Action to Control Cardiovascular Risk 
in Diabetes (ACCORD) study group showed 
an increased mortality and no reduction in 
cardiovascular events in intensive regulated 
DM type 2.[16] However, in this study, treat-
ment was only directed at strict regulation 
of glycosylated hemoglobin levels. Other 
important studies, like the ongoing Outcome 
Reduction with an Initial Glargine Interven-
tion (ORIGIN) trial, are focusing on a broader 
scale of pharmacological interventions.[17] 
Mortality
During the follow-up period, 87 (22%) patients 
died. There was a clear, non-significant, trend 
for higher mortality rates in patients with IGT 
and DM. Cardiovascular and non-cardiovas-
cular death were nearly equally distributed 
among the patient groups. Although in this 
study no significant increase in mortality was 
shown, this is very likely to be a power prob-
lem. The DECODE study showed an increased 
risk of death in patients with OGTT compared 
to patients with only fasting plasma glucose 
measured.[4] These findings were confirmed 
in several other trials, all showing a superiority 
of 2-hour glucose loading to fasting glucose 
in assessing the risk of future cardiac events.
[1, 6]
IfG vs IGt
Impaired glucose tolerance was found in 
104 (26%) patients, and DM in 43 (11%). In 
this study we used the cutoff values for IFG 
according the 2003 guidelines of the Ameri-
can Diabetes Association (ADA). The ADA 
lowered, in 2003, the cutoff value of plasma 
glucose for IFG from 6.1 mmol/l to 5.6 mmol/l.
[18, 19] There has been debate about the 
influence of this lower cutoff for the predic-
tion of cardiovascular events. Nowadays, the 
new cutoff is used in most studies comparing 
IFG and 2-hr glucose loading.[2] 
In this study, use of OGTT showed a clear 
additional effect on diagnosing IGT and DM. 
Seventy-five percent of the patients with IGT 
and 72% of patients with DM would have 
been missed, if only the fasting glucose levels 
were measured. The OGTT provides additional 
prognostic information and enables detection 
of individuals with IGT.[8]
Lee Risk Index
The ACC/AHA identified DM as an athero-
sclerotic risk factor for perioperative cardiac 
complications in patients with PAD scheduled 
for vascular surgery.[9, 11] Pre-operative risk 
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stratification according to the Lee cardiac 
index has a proven association with periop-
erative outcome.[10] The detection of IGT and 
DM has a significant clinical relevance, both 
in pre-operative cardiovascular risk stratifica-
tion and treatment. In the present study, DM 
was detected in 43 patients. Addition of this 
clinical risk factor to the pre-operative cardiac 
risk score increased the risk score to ≥2 in 19 
patients. Use of the OGTT provides the physi-
cian to make more accurate risk stratification 
and the possibility to perform additional 
pre-operative (non-) invasive testing and 
subsequent treatment. These patients with 
newly found DM need additional treatment, 
compared to PAD patients without DM. Target 
blood pressure should be lowered to 130/80 
mmHG in stead of 140/90mmHg, using ACE-
inhibitors and Beta-blocking agents. The 
presence of DM deserves attention during 
the perioperative and postoperative phase 
as well. Plasma glucose levels need to be 
closely monitored.[11] In a recent study by 
Hoeks et al. the pre-operative Lee Risk Index 
was shown to be an important prognostic 
factor for late mortality and impaired health 
status in patients with PAD.[20] The present 
study confirmed these results by showing a 
significant increase in cardiovascular events 
during long-term follow-up if ≥2 clinical risk 
factors are present at baseline.
Currently, the use of pre-operative OGTT 
is only recommended in patients undergoing 
cardiac surgery with ≥2 clinical risk factors.
[9] The ACC/AHA guidelines for pre-operative 
management in patients with peripheral 
arterial disease (PAD) undergoing noncardiac 
surgery, do not recommend a pre-operative 
glucose-loading test. This study showed that 
patients with IGT and DM have a worse prog-
nosis following vascular surgery both during 
short –and long-term follow-up. Therefore, 
pre-operative glucose loading testing and 
subsequent expanded medical treatment 
should be recommended.
Study Limitations
The main limitation of this study was the 
single measurement of fasting glucose levels. 
The World Health Organization recommends 
a repeated measurement for diagnostic 
purposes. This could have influenced the 
prevalence of the detected glucose regula-
tion disorders. Cardiovascular events were not 
significantly increased in patients with DM, 
however a clear trend was shown. As patients 
with IGT showed a significant increase in 
cardiovascular events in multivariate analysis, 
the lack of significance in the DM group is 
very likely due to a study power problem. This 
same trend was shown regarding mortality 
rates.
coNcLUSIoN
Patients scheduled for vascular surgery with 
IGT or DM detected by pre-operative glucose 
loading test, have a significantly increased risk 
of developing cardiovascular events during 
long-term follow-up. Therefore, It is recom-
mended that non-diabetic vascular surgery 
patients should be tested for glucose regula-
tion disorders prior to surgery and receive 
adequate pharmacological treatment. 
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Anemiaas an Independent Predictor of Perioperative and
Long-Term Cardiovascular Outcome in Patients Scheduled for
Elective Vascular Surgery
Martin Dunkelgrun, MDa, Sanne E. Hoeks, MsCb, Gijs M.J.M. Welten, MDa,
Radosav Vidakovic, MDc, Tamara A. Winkel, MDa, Olaf Schouten, MDa,
Ron T. van Domburg, PhDb, Jeroen J. Bax, MDe, Ruud Kuijper, MDd, Michael Chonchol, MDf,
Hence J.M. Verhagen, MDa, and Don Poldermans, MDd,*
Anemia is common in patients scheduled for vascular surgery and is a risk factor for
adverse cardiac outcome. However, it is unclear whether this is an independent risk factor
or an expression of underlying co-morbidities. In total, 1,211 patients (77% men, 68 � 11
years of age) were enrolled. Anemia was defined as serum hemoglobin levels <13 g/dl for
men and <12 g/dl for women and was divided into tertiles to compare mild (men 12.2 to
13.0, women 11.2 to 12.0), moderate (men 11.0 to 12.1, women 10.2 to 11.1), and severe
(men 7.2 to 11.0, women 7.5 to 10.1) anemia with nonanemia. Outcome measurements were
30-day and 5-year major adverse cardiac events (MACEs; cardiac death or myocardial
infarction). All risk factors were noted. Multivariable logistic and Cox regression analyses
were used, adjusting for all cardiac risk factors, including heart failure and renal disease.
Data are presented as hazard ratios with 95% confidence intervals. In total, 74 patients
(6%) had 30-day MACEs and 199 (17%) had 5-year MACEs. Anemia was present in 399
patients (33%), 133 of whom had mild anemia, 133 had moderate anemia, and 133 had
severe anemia. Presence of anemia was associated with renal dysfunction, diabetes, and
heart failure. After adjustment for all clinical risk factors, 30-day hazard ratios for a MACE
per anemia group were 1.8 for mild (0.8 to 4.1), 2.3 for moderate (1.1 to 5.4), and 4.7 for
severe (2.6 to 10.9) anemia, and 5-year hazard ratios for MACE per anemia group were 2.4
for mild (1.5 to 4.2), 3.6 for moderate (2.4 to 5.6), and 6.1 for severe (4.1 to 9.1) anemia. In
conclusion, the presence and severity of preoperative anemia in vascular patients are
significant predictors of 30-day and 5-year cardiac events, regardless of underlying heart
failure or renal disease. © 2008 Elsevier Inc. All rights reserved. (Am J Cardiol 2008;101:
1196–1200)
Anemia is not included as a factor for cardiac risk assess-
ment in preoperative screening because it is unknown
whether anemia is a primary risk factor for poor cardiac
outcome, caused by decreased physiologic reserve, or
whether it is secondary to other underlying co-morbidities.
Currently, available data do not describe in detail the exact
relation between degree of preoperative anemia and periop-
erative and long-term risk of cardiac morbidity and mortal-
ity in vascular surgery patients. Also, it remains unclear
whether preoperative anemia predicts adverse cardiac out-
comes independently from other prognostic factors, such as
heart failure and renal dysfunction, and other confounders.
The main goal of the present study was to assess the inde-
pendent contribution of anemia to the risk of perioperative
and long-term cardiac mortality and morbidity in vascular
surgery patients. Furthermore, this study assessed the rate of
risk increase due to extent of anemia in relation to other risk
factors, including extent of renal dysfunction and presence
of heart failure. Our hypothesis is that the rate of risk
increase due to extent of anemia is independent of renal
dysfunction and heart failure, as a predictor of perioperative
and long-term cardiac outcome.
Methods
In a retrospective study, a series of 1,363 patients scheduled
for elective noncardiac open vascular surgery with known
or suspected coronary artery disease who were referred for
preoperative testing from February 1990 to August 2006 to
the Erasmus Medical Centre, Rotterdam, The Netherlands,
were analyzed. Preoperative testing included laboratory
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measurement, echocardiography, and assessment of base-
line characteristics. A total of 152 patients were treated at
another hospital and were excluded from this study. The
final study population consisted of 1,211 patients. The pro-
tocol was approved by the hospital ethics committee and all
patients gave informed consent.
Preoperative hemoglobin value was defined as the he-
moglobin measured during a patient’s last preoperative out-
patient screening before surgery. Preoperative anemia was
defined by the definition put forward by the World Health
Organization, which is a serum hemoglobin level �13 g/dl
for men and a level �12 g/dl for women.1 Patients with
preoperative anemia were divided into tertiles to compare
mild, moderate, and severe anemia, using nonanemic pa-
tients as reference. Tertiles were calculated for men and
women separately, after which the 2 gender groups of mild,
moderate, and severe anemic patients were joined together
for analysis. This method was used instead of using contin-
uous hemoglobin levels to decrease confounding by differ-
ences in normal hemoglobin levels in men and women.
Preoperative serum creatinine levels were used to esti-
mate glomerular filtration rate (GFR) according to the equa-
tion from the Modification of Diet in Renal Disease
(MDRD) study. Estimated GFR (milliliters per minute per
1.73 m2) was categorized into 4 groups, namely �90, 60 to
89, 30 to 59, and �30. GFR �90 was considered normal
and was used as reference for the other groups. Chronic
kidney disease was defined as a GFR �60. Patients under-
went a 2-dimensional echocardiographic examination at
rest. Left ventricular end-diastolic and end-systolic volumes
were obtained from apical 4- and 2-chamber views by using
the Simpson rule formula, from which the ejection fraction
was calculated. Presence of heart failure was defined as a
left ventricular ejection fraction �35%.
All clinical risk factors were noted. Diabetes mellitus
was defined as a fasting glucose level �7.0 mmol/L (126
mg/dl) or the use of insulin or oral glucose-lowering agents,
and hypertension as a blood pressure �140/90 mm Hg or
medical treatment for hypertension. Coronary heart disease
was defined as a history of angina and/or myocardial in-
farction, stroke was defined as a previous cerebral vascular
accident or transient ischemic attack, chronic obstructive
pulmonary disease was defined as a forced expiratory vol-
ume in 1 second �70% of age- and gender-predicted value
or medication use, and smoking was noted in patients who
currently smoked or had a history of smoking.
Follow-up data collection was performed by review of
hospital records, contacting patients’ general practitioners,
and obtaining patients’ vital status from the office of civil
registry. Clinical information was obtained by outpatient
visits and reviewing hospital records. Nonfatal myocardial
infarction was diagnosed when �2 of the following were
present: increased cardiac enzyme levels (creatine kinase
level �190 U/L and creatine kinase-MB level �14 U/L, or
creatine kinase-MB fraction �10% of total creatine kinase,
or cardiac troponin T �0.1 ng/ml), development of typical
electrocardiographic changes (new Q waves�1 mm or�30
ms), and typical symptoms of angina pectoris. Death certif-
icates and autopsy reports were reviewed, and general prac-
titioners were approached to ascertain cause of death. Car-
diac death was defined as death caused by acute myocardial
infarction, cardiac arrhythmias, or congestive heart failure.
Sudden unexpected death in previously stable patients was
considered cardiac death. The composite of nonfatal myo-
cardial infarction and cardiac death was defined as a major
adverse cardiac event (MACE). Outcome measurements
were 30-day and 5-year MACEs. Follow-up was successful
in all 1,211 patients (100%).
Continuous data were expressed as mean � SD and
compared using analysis of variance. Categorical data were
presented as percent frequencies, and differences between
proportions were compared using chi-square test. Logistic
regression analysis (SPSS 14.0, SPSS, Inc., Chicago, Illi-
nois) was used to identify predictors of 30-day MACEs, and
multivariate Cox proportional hazard regression was used to
identify predictors of 5-year MACEs. Adjustments were
made for the variables anemia, renal dysfunction, heart
failure, age, gender, type of vascular surgery (central or
peripheral open procedure), diabetes mellitus, chronic ob-
structive pulmonary disease, hypertension, ischemic heart
disease, and stroke.
Interactions between anemia and renal dysfunction and
between anemia and heart failure were evaluated by forcing
these interaction terms in the multivariable regression
model. Because the interaction terms were not significant
for prediction of 30-day or 5-year MACEs, it was not
included in the final logistic regression or Cox proportional
hazard regression analysis models. Probability of survival
was calculated using the Kaplan-Meier method, and sur-
vival curves were compared using log-rank test. A p value
�0.05 was considered statistically significant.
Results
Of the 1,211 patients included in the study, 877 were men
(77%) and mean age was 68 � 11 years. At baseline,
anemia was present in 399 patients (33%), of which tertiles
were calculated, resulting in 133 patients with mild anemia,
133 with moderate anemia, and 133 with severe anemia.
Mean hemoglobin levels were 14.5� 1.1 g/dl in nonanemic
patients, 12.4 � 0.5 g/dl in patients with mild anemia, 11.3
� 0.5 g/dl in patients with moderate anemia, and 9.8 � 0.8
g/dl in patients with severe anemia. In total, 239 patients
(21%) were diagnosed with heart failure and 381 patients
(33%) had renal dysfunction. Estimated GFR �90 was
present in 202 patients (17%), GFR 60 to 89 in 547 patients
(45%), GFR 30 to 59 in 389 patients (32%), and GFR �30
in 73 patients (6%).
Clinical characteristics of patients are presented in Table
1. Statistically significant independent clinical predictors of
anemia were diabetes mellitus (p � 0.001), heart failure (p
� 0.02), and GFR �60 (p �0.001). A clear yet nonsignif-
icant trend for increased anemia was seen in patients with a
history of stroke (p � 0.06) and patients with older age (p
� 0.06). When comparing the increasing severity of ane-
mia, a statistically significant increase in percentage was
seen in the number of patients with diabetes mellitus and
renal dysfunction. Notably, no correlation was seen between
medication use (most importantly the use of aspirin, angio-
tensin-converting enzyme inhibitors, or � blockers) and
incidence of anemia.
At 30 days postoperatively, 59 patients (5.2%) had a
1197Miscellaneous/Preoperative Anemia
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myocardial infarction and 31 patients (2.7%) died due to
cardiovascular death. In total, the incidence of 30-day
MACEs was 74 patients (6%). At 5-year follow-up, a total
of 80 patients (7.0%) had a myocardial infarction and 146
patients (12.8%) died due to cardiovascular death. In total,
the incidence of 5-year MACEs was 199 patients (16.4%).
Mean follow-up was 3.4 years (range 0.0 to 16.3). Distri-
butions of 30-day and 5-year MACEs according to preop-
erative hemoglobin level are listed in Table 2. Kaplan-Meier
curves for 30-day and 5-year MACE-free survivals are
displayed in Figures 1 and 2, respectively, illustrating the
increased risk of MACEs in patients with increasing sever-
ity of preoperative anemia compared with those without
anemia (log-rank tests, p �0.001).
After multivariate logistic regression analysis, adjusting
for age, gender, and clinical characteristics, the presence of
moderate and severe preoperative anemias was associated
with increased risk of 30-day MACEs, with odds ratios of
2.3 and 4.7, respectively (Table 3). Compared with nonane-
mic patients, mild preoperative anemia showed only a non-
significant trend toward a worse outcome (Table 3). Addi-
tionally, heart failure and a decreasing GFR were associated
with a significantly increased risk of 30-day MACEs (Ta-
ble 3).
After multivariate Cox proportional hazard regression
analysis, adjusting for age, gender, and clinical characteris-
tics, all 3 severity groups of preoperative anemia were
associated with increased risk of 5-year MACEs compared
with nonanemic patients (odds ratios 2.4 mild anemia, 3.6
moderate anemia, and 6.1 severe anemia), as presented in
Table 3. Additionally, heart failure and a decreasing GFR
were associated with a significantly increased risk of 5-year
MACEs (Table 3).
Discussion
This study showed that extent of preoperative anemia and
worsening renal function were strong predictors of periop-
erative and long-term MACEs, even after adjusting for
known confounders. The association was graded, with in-
creasing severity of anemia and renal dysfunction correlat-
ing with an increasing risk for MACEs. At 30 days postop-
eratively, only moderate and severe anemias were
significantly associated with increased risk of MACEs.
However, this could be due to the power of the study
because a clear trend was seen for mild preoperative anemia
at 30 days. At 5 years postoperatively, anemia and worsen-
ing renal function were increasingly and significantly asso-
ciated with a worse outcome. Additionally, heart failure was
significantly associated with worse 30-day and 5-year out-
comes.
Anemia is a common and inter-related finding in chronic
heart failure and kidney disease. Lower hemoglobin levels
can be caused by hemodilution (pseudoanemia) in heart
failure2 or can be caused and/or worsened by various dif-
ferent mechanisms, including renal dysfunction,3 malnutri-
tion,4 iron or vitamin deficiencies,4 bone marrow depression
due to increased levels or proinflammatory cytokines,5 and
certain medications.1,4–9 Low hemoglobin levels have been
associated with lower exercise tolerance10,11 and increased
risk of cardiac events.2,3,7,12,13 Several mechanisms may
contribute to anemia as a risk factor for cardiac events.
Subclinical coronary disease may decrease the tolerance for
anemia because coronary vasodilatation is not possible in
the presence of significant stenosis and the cardiac oxygen
extraction ratio may be limited.14,15 Also, in patients with
decreased cardiac reserve, anemia may further decrease
regular physiologic compensatory capacity.16
However, it is not entirely clear whether this is caused by
anemia or whether anemia is secondary to the risk of con-
founding co-morbidities. Go et al17 studied the effects of
hemoglobin levels and extent of chronic kidney disease in
patients with chronic heart failure with regard to risk of
hospitalization and death. They demonstrated that extent of
anemia was increasingly associated with risk of hospitaliza-
tion and death, independent of underlying renal dysfunction
and other co-morbidities. Furthermore, Kulier et al18 dem-
onstrated preoperative anemia to be an independent predic-
tor of adverse outcome in patients undergoing coronary
artery bypass surgery. In 4,804 patients undergoing elective
coronary artery bypass surgery, they found that preoperative
anemia was associated with an increased risk in postopera-
tive events, starting at hemoglobin levels �11 g/dl in a
dose-dependent fashion. Moreover, preoperative anemia has
been shown to be an independent predictor of adverse out-
come in patients undergoing other vascular or extensive
surgery.6,19 In a recent study, Wu et al20 examined the effect
of preoperative hematocrit levels and postoperative out-
comes in elderly patients undergoing noncardiac surgery. In
this large retrospective study, 310,311 patients were in-
cluded and main outcomes were 30-day mortality and the
composite of 30-day mortality and cardiac events. Mortality
Table 1
Baseline characteristics according to presence or absence of anemia
Variable Total
(n � 1,211)
Normal
(n � 812)
Anemia
(n � 399)
p
Value
Age (yrs),
mean � SD
68.3 � 10.7 67.9 � 10.4 69.1 � 11.2 0.06
Male gender 77.1% 76.1% 78.6% 0.27
Diabetes mellitus 23.3% 20.3% 28.8% 0.001
Coronary heart
disease
54.2% 52.7% 56.9% 0.18
Heart failure 21.1% 18.8% 24.9% 0.02
Previous coronary
revascularization
13.4% 14.1% 12.1% 0.41
Hypertension 53.0% 52.2% 54.6% 0.43
Stroke 18.0% 16.4% 20.9% 0.06
Chronic kidney
disease
16.8% 24.7% 38.6% �0.001
Chronic obstructive
pulmonary disease
39.3% 37.8% 42.1% 0.17
Hypercholesterolemia 42.2% 42.4% 41.9% 0.85
Central arterial
surgery
57.4% 59.1% 54.4% 0.13
� Blocker 58.4% 57.6% 59.9% 0.45
Aspirin 39.1% 39.7% 37.8% 0.53
ACE inhibitor 39.7% 38.8% 41.4% 0.40
Calcium antagonist 38.0% 36.6% 40.6% 0.19
Warfarin 29.9% 28.9% 31.6% 0.35
Diuretics 27.6% 26.4% 29.8% 0.21
ACE � angiotensin-converting enzyme.
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and cardiac event rates increased with positive or negative
deviations from the reference hematocrit levels. After mul-
tivariate analysis, every percentage point deviation of he-
matocrit from the normal range was associated with a 1.6%
increase in mortality. They concluded that even mild de-
grees of preoperative anemia or polycythemia were associ-
ated with an increased risk of mortality and cardiac events
in elderly patients undergoing major noncardiac surgery.
The main limitation if this study was that all data were
gathered using the National Surgical Quality Improvement
Program and not by using hospital records. Furthermore,
renal dysfunction was expressed only in creatinine levels
and known history of kidney disease, not as GFR, and no
adjustments were made for differences in normal hematocrit
levels in men and women. However, because the sample
was so large, even mild preoperative anemia was signifi-
cantly associated with 30-day mortality and cardiac events,
supporting the trend found in this study. Furthermore,
Diehm et al21 reported anemia to be an independent risk
factor for decreased long-term survival in patients with an
abdominal aortic aneurysm undergoing endovascular repair.
Anemia could therefore not just be a marker of other
co-morbidities that increase the risk of perioperative cardiac
events, but could be an independent and modifiable clinical
marker. Although the clinical evidence is limited for
whether treatment of anemia can improve clinical outcome,
multiple studies have shown promising results.11,22,23 In a
prospective, randomized, placebo-controlled trial, Corwin
et al24 studied the effects and safety of epoetin-� treatment
in 1,460 critically ill patients. They found a lower mortality
in patients using epoetin-� compared with those who did
not, which could have clinical implications. However, treat-
ment with epoetin-� was also associated with an increase in
thrombotic events. If this is converted to the perioperative
setting, serious care should be taken because peripheral
bypass surgery is associated with a high rate of thrombotic
complications. With respect to long-term treatment, van
Veldhuisen et al25 conducted a prospective, randomized,
placebo-controlled trial in which they found that, in patients
with chronic heart failure and anemia, the use of darbepo-
etin-� was successful in increasing hemoglobin levels and
improving certain quality-of-life indexes. Furthermore, in a
randomized, open-label trial, Provenzano et al26 showed
Table 2
Thirty-day and five-year major adverse cardiac events according to severity of anemia
Variable Degree of Anemia (hemoglobin g/dl) p Value
None (men �13.0,
women �12.0)
Mild (men 12.2–13.0,
women 11.2–12.0)
Moderate (men 11.0–12.1,
women 10.2–11.1)
Severe (men 7.2–11.0,
women 7.5–10.1)
30-day MACEs 3.4% 6.8% 9.1% 20.0% �0.001
5-yr MACEs 9.1% 21.4% 29.8% 42.2% �0.001
Figure 1. Thirty-day MACE-free survival for severity of preoperative
anemia.
Figure 2. Five-year MACE-free survival for severity of preoperative
anemia.
Table 3
Multivariable associations among extent of anemia, level of estimated
glomerular filtration rate, heart failure, and risks of 30-day and five-year
major adverse cardiac events
Variable 30-day MACEs*† 5-yr MACEs*‡
Severity of anemia
None Reference Reference
Mild 1.8 (0.8–4.1) 2.4 (1.5–4.2)
Moderate 2.3 (1.1–5.4) 3.6 (2.4–5.6)
Severe 4.7 (2.6–10.9) 6.1 (4.1–9.1)
GFR (ml/min/1.73 m2)
�90 Reference Reference
60–89 1.3 (0.7–2.8) 1.5 (1.0–2.5)
30–59 3.0 (1.4–4.9) 2.2 (1.2–4.0)
�30 4.7 (2.2–7.1) 2.6 (1.5–4.9)
Heart failure
Left ventricular ejection
fraction �35%
2.5 (1.5–4.6) 2.4 (1.5–3.6)
* Adjustments were made for anemia, GFR, heart failure, age, gender,
type of vascular surgery, diabetes mellitus, hypertension, coronary heart
disease, stroke, and chronic obstructive pulmonary disease.
† Values are odds ratios (95% confidence intervals).
‡ Values are hazards ratios (95% confidence intervals).
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that treatment with epoetin-� was safe and effective in
increasing hemoglobin in patients with anemia and chronic
kidney disease. However, Drueke et al27 recently showed
that patients with severe renal disease (GFR �35 ml/min/
1.73m2) and mild anemia did not benefit from epoetin-�
therapy.
Limitations of this study include those inherent to a
retrospective analysis. The study population consisted of
patients referred to a tertiary care center and may not fully
represent a general population scheduled for elective vas-
cular surgery. Also, due to the observational nature of the
study, a causal relation could not be determined between
preoperative anemia and perioperative MACEs. Further-
more, the cause of the measured anemia remains unknown,
which could be important in determining possible preoper-
ative treatments.
1. Nutritional anaemias: report of a WHO scientific group. World Health
Organ Tech Rep Ser 1968;405:5–37.
2. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein
J. Anemia is associated with worse symptoms, greater impairment in
functional capacity and a significant increase in mortality in patients
with advanced heart failure. J Am Coll Cardiol 2002;39:1780–1786.
3. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in
heart failure and is associated with poor outcomes: insights from a
cohort of 12 065 patients with new-onset heart failure. Circulation
2003;107:223–225.
4. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN,
Yusuf S. Prognostic importance of weight loss in chronic heart failure
and the effect of treatment with angiotensin-converting-enzyme inhib-
itors: an observational study. Lancet 2003;361:1077–1183.
5. Weiss G. Pathogenesis and treatment of anaemia of chronic disease.
Blood Rev 2002;16:87–96.
6. Hogue CW Jr, Goodnough LT, Monk TG. Perioperative myocardial
ischemic episodes are related to hematocrit level in patients undergo-
ing radical prostatectomy. Transfusion 1999;39:657–660.
7. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN,
Levey AS, Sarnak MJ. Reduced renal function and anemia as risk
factors for mortality in patients with left ventricular dysfunction. J Am
Coll Cardiol 2001;38:955–962.
8. Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz
K, Mancini DM. Hemodilution is common in patients with advanced
heart failure. Circulation 2003;107:226–229.
9. Herrlin B, Nyquist O, Sylven C. Induction of a reduction in haemo-
globin concentration by enalapril in stable, moderate heart failure: a
double blind study. Br Heart J 1991;66:199–205.
10. Kalra PR, Bolger AP, Francis DP, Genth-Zotz S, Sharma R, Poni-
kowski PP, Poole-Wilson PA, Coats AJ, Anker SD. Effect of anemia
on exercise tolerance in chronic heart failure in men. Am J Cardiol
2003;91:888–889.
11. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne
AS. Effect of erythropoietin on exercise capacity in patients with
moderate to severe chronic heart failure. Circulation 2003;107:294–
299.
12. Kosiborod M, Smith GL, Radford MJ, Foody JM, Krumholz HM. The
prognostic importance of anemia in patients with heart failure. Am J
Med 2003;114:112–119.
13. Langston RD, Presley R, Flanders WD, McClellan WM. Renal insuf-
ficiency and anemia are independent risk factors for death among
patients with acute myocardial infarction. Kidney Int
2003;64:1398–1405.
14. Levy PS, Kim SJ, Eckel PK, Chavez R, Ismail EF, Gould SA, Ramez
Salem M, Crystal GJ. Limit to cardiac compensation during acute
isovolemic hemodilution: influence of coronary stenosis. Am J Physiol
1993;265(suppl):H340–H349.
15. Levy PS, Chavez RP, Crystal GJ, Kim SJ, Eckel PK, Sehgal LR,
Sehgal HL, Salem MR, Gould SA. Oxygen extraction ratio: a valid
indicator of transfusion need in limited coronary vascular reserve?
J Trauma 1992;32:769–774.
16. Duke M, Abelmann WH. The hemodynamic response to chronic
anemia. Circulation 1969;39:503–515.
17. Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM,
Shlipak MG. Hemoglobin level, chronic kidney disease, and the risks
of death and hospitalization in adults with chronic heart failure: the
Anemia in Chronic Heart Failure: Outcomes and Resource Utilization
(ANCHOR) study. Circulation 2006;113:2713–2723.
18. Kulier A, Levin J, Moser R, Rumpold-Seitlinger G, Tudor IC, Snyder-
Ramos SA, Moehnle P, Mangano DT, for the Investigators of the
Multicenter Study of Perioperative Ischemia Research Group, Isch-
emia Research and Education Foundation. Impact of preoperative
anemia on outcome in patients undergoing coronary artery bypass graft
surgery. Circulation 2007;116:471–479.
19. Carson JL, Duff A, Poses RM, Berlin JA, Spence RK, Trout R,
Noveck H, Strom BL. Effect of anaemia and cardiovascular disease on
surgical mortality and morbidity. Lancet 1996;348:1055–1060.
20. Wu WC, Schifftner TL, Henderson WG, Eaton CB, Poses RM, Uttley
G, Sharma SC, Vezeridis M, Khuri SF, Friedmann PD. Preoperative
hematocrit levels and postoperative outcomes in older patients under-
going noncardiac surgery. JAMA 2007;297:2481–2488.
21. Diehm N, Benenati JF, Becker GJ, Quesada R, Tsoukas AI, Katzen
BT, Kovacs M. Anemia is associated with abdominal aortic aneurysm
(AAA) size and decreased long-term survival after endovascular AAA
repair. J Vasc Surg 2007;46:676–681.
22. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E,
Brosh D, Laniado S, Schwartz D, Yachnin T, et al. The use of
subcutaneous erythropoietin and intravenous iron for the treatment of
the anemia of severe, resistant congestive heart failure improves car-
diac and renal function and functional cardiac class, and markedly
reduces hospitalizations. J Am Coll Cardiol 2000;35:1737–1744.
23. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R,
Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A.
The effect of correction of mild anemia in severe, resistant congestive
heart failure using subcutaneous erythropoietin and intravenous iron: a
randomized controlled study. J Am Coll Cardiol 2001;37:1775–1780.
24. Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An
R, Bowers PJ, Burton P, Klausner MA, Corwin MJ, for the EPO
Critical Care Trials Group. Efficacy and safety of epoetin alfa in
critically ill patients. N Engl J Med 2007;357:965–976.
25. van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman
SM, Baker N, Rosser D, Cleland JG, Ponikowski P. Randomized,
double-blind, placebo-controlled study to evaluate the effect of two
dosing regimens of darbepoetin alfa in patients with heart failure and
anaemia. Eur Heart J 2007;28:2208–2216.
26. Provenzano R, Bhaduri S, Singh AK, for the PROMPT Study Group.
Extended epoetin alfa dosing as maintenance treatment for the anemia
of chronic kidney disease: the PROMPT study. Clin Nephrol 2005;
64:113–123.
27. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsa-
kiris D, Burger HU, Scherhag A, for the CREATE Investigators.
Normalization of hemoglobin level in patients with chronic kidney
disease and anemia. N Engl J Med 2006;355:2071–2084.
1200 The American Journal of Cardiology (www.AJConline.org)
Risk Identification 
and Reduction 
Strategies in 
Surgical Patients
Risk Identification 
and Reduction 
Strategies in 
Surgical Patients
chapter 7
Association between serum uric acid and 
perioperative and late cardiovascular 
outcome in patients undergoing 
elective open vascular surgery.
Dunkelgrun M
Hoeks SE
Welten GM
Goei D
Vidakovic R
Winkel TA
Schouten O
van Doburg RT
van Gestel YR
Bax JJ
Verhagen HJ
Poldermans D
Am J Cardiol. 2008; 102: 797-80.

Association between serum uric acid and perioperative and late cardiovascular outcome 73
AssociationBetween Serum Uric Acid and Perioperative and Late
Cardiovascular Outcome in Patients With Suspected or Definite
Coronary Artery Disease Undergoing Elective Vascular Surgery
Martin Dunkelgrun, MDa, Gijs M.J.M. Welten, MDa, Dustin Goei, MDa, Tamara A. Winkel, MDa,
Olaf Schouten, MDa, Ron T. van Domburg, PhDb, Yvette R.B.M. van Gestel, MScb,
Willem-Jan Flu, MDc, Sanne E. Hoeks, MScb, Jeroen J. Bax, MDe, and Don Poldermans, MDd,*
The role of uric acid as an independent marker of cardiovascular risk is unclear. Therefore,
our aim was to assess the independent contribution of preoperative serum uric acid levels
to the risk of 30-day and late mortality and major adverse cardiac event (MACE) in
patients scheduled for open vascular surgery. In total, 936 patients (76% male, age 68 � 11
years) were enrolled. Hyperuricemia was defined as serum uric acid >0.42 mmol/l for men
and >0.36 mmol/l for women, as defined by large epidemiological studies. Outcome
measures were 30-day and late mortality and MACE (cardiac death or myocardial infarc-
tion). Multivariable logistic and Cox regression analysis were used, adjusting for age,
gender, and all cardiac risk factors. Data are presented as odds ratios or hazard ratios, with
95% confidence intervals. Hyperuricemia was present in 299 patients (32%). The presence
of hyperuricemia was associated with heart failure, chronic kidney disease, and the use of
diuretics. Perioperatively, 46 patients (5%) died and 61 patients (7%) experienced a MACE.
Mean follow-up was 3.7 years (range: 0 to 17 years). During follow-up, 282 patients (30%)
died and 170 patients (18%) experienced a MACE. After adjustment for all clinical risk
factors, the presence of hyperuricemia was not significantly associated with an increased
risk of 30-day mortality or MACE, odds ratios of 1.5 (0.8 to 2.8) and 1.7 (0.9 to 3.0),
respectively. However, the presence of hyperuricemia was associated with an increased risk
of late mortality and MACE, with hazard ratios of 1.4 (1.1 to 1.7) and 1.7 (1.3 to 2.3),
respectively. In conclusion, the presence of preoperative hyperuricemia in vascular patients
is a significant predictor of late mortality and MACE. © 2008 Elsevier Inc. All rights
reserved. (Am J Cardiol 2008;102:797–801)
Uric acid is the major product of purine metabolism and is
formed from xantine, a reaction catalyzed by dehydrog-
ynase/oxidase.1 The association between serum uric acid
levels and the risk of cardiovascular disease has been con-
firmed by numerous epidemiological studies.2–6 However,
it remains disputed whether uric acid is an independent risk
factor for cardiovascular disease; several studies have sug-
gested that hyperuricemia is merely associated with cardio-
vascular disease because of confounding risk factors.7,8 To
our knowledge, no studies have investigated the role of
preoperative hyperuricemia as a risk marker for cardiac
outcome in vascular surgery patients. In conclusion, the
goal of the present study was to assess the independent
contribution of serum uric acid levels to the risk of 30-day
and late mortality and major adverse cardiac events
(MACEs) in patients scheduled for open vascular surgery.
Methods
In a retrospective study, a series of 936 patients scheduled
for elective noncardiac vascular surgery with known or
suspected coronary artery disease who were referred for
preoperative testing between February 1990 and February
2007 to the Erasmus Medical Center, Rotterdam, the Neth-
erlands were analyzed. Patients undergoing endovascular
procedures were excluded from the study. Preoperative test-
ing included laboratory measurement and echocardiography
as well as assessment of baseline characteristics. The study
protocol was approved by the hospital ethics committee,
and all patients gave informed consent.
At study enrollment, a detailed cardiac history was ob-
tained and all clinical risk factors were noted. Hypertension
was defined as blood pressure �140/90 mm Hg or medical
treatment for hypertension, and diabetes mellitus was de-
fined as a fasting glucose level of �7.0 mmol/L (126 mg/
dL) or the use of insulin or oral glucose lowering agents.
Coronary heart disease was defined as an angina pectoris
and/or myocardial infarction; stroke was defined as a history
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of either a cerebral vascular accident or a transient isch-
emic attack; chronic obstructive pulmonary disease was
defined as a forced expiratory volume in 1 second (FEV1)
�70% of age- and gender-predicted value or medication
use; hypercholesterolemia was defined as a plasma low-
density lipoprotein (LDL) cholesterol �200 mg/dl or med-
ication use; and smoking was noted in patients who cur-
rently smoked or had a history of smoking. Patients
underwent a resting 2-dimensional echocardiographic ex-
amination. Left ventricular end-diastolic and end-systolic
volumes were obtained from the apical 4- and 2-chamber
views by using the Simpson’s rule formula, from which the
ejection fraction was calculated. The presence of heart fail-
ure was defined as a left ventricular ejection fraction of
�35%. Preoperative serum creatinine levels were used to
estimate the glomerular filtration rate according to the equa-
tion from the Modification of Diet in Renal Disease study.9
Chronic kidney disease was defined as glomerular filtration
rate �60. Finally, preoperative blood samples were used to
determine hyperuricemia, which was defined as serum uric
acid exceeding 0.42 mmol/L in men and 0.36 mmol/L in
women, as defined by large epidemiological studies.2–3
Follow-up data collection was performed by review of
hospital records, contacting the patients’ general practitio-
ners, and obtaining the patients’ vital status from the Office
of Civil Registry. Clinical information was obtained by
outpatients’ visits and reviewing hospital records. Nonfatal
myocardial infarction was diagnosed when at least 2 of the
following were present: elevated cardiac enzyme levels
(creatine kinase [CK] level �190 U/L and CK-MB �14
U/L, or CK-MB fraction �10% of total CK, or cardiac
troponin T �0.1 ng/mL), development of typical electro-
cardiographic changes (new Q waves �1 mm or �30 ms),
and typical symptoms of angina pectoris. Death certificates
and autopsy reports were reviewed, and general practitio-
ners were approached to ascertain the cause of death. Car-
Figure 1. Thirty-day all-cause, mortality-free survival for serum uric
acid levels.
Figure 2. Thirty-day MACE-free survival for serum uric acid levels.
Table 1
Baseline characteristics according to uric acid levels
Variable Uric Acid
Total
(936)
Normal
(637)
Abnormal
(299)
p Value
Age (yrs) (SD) 67.7 (10.9) 68.1 (10.5) 67. (12.3) 0.74
Men 76.0% 74.6% 81.4% 0.06
Diabetes mellitus 22.9% 22.7% 23.5% 0.82
Ischemic heart disease 54.7% 55.3% 52.5% 0.50
Heart failure 21.2% 19.2% 28.7% 0.006
Previous coronary
revascularization
14.4% 14.3% 15.1% 0.80
Hypertension 54.9% 54.8% 55.2% 0.90
Stroke 17.2% 17.4% 16.7% 0.82
Chronic kidney disease 30.6% 25.1% 49.5% �0.001
Chronic obstructive
pulmonary disease
41.0% 39.6% 46.3% 0.11
Hypercholesterolemia 41.5% 40.1% 47.0% 0.09
Central arterial surgery 58.4% 58.9% 56.3% 0.52
� blocker 55.4% 55.1% 56.3% 0.78
Aspirin 38.7% 39.0% 37.7% 0.75
Angiotensin-converting
enzyme inhibitors
40.4% 39.7% 43.2% 0.40
Calcium antagonist 39.0% 38.7% 39.9% 0.77
Warfarin 30.8% 30.3% 32.8% 0.52
Diuretics 28.7% 25.2% 42.1% 0.001
Table 2
Thirty-day and late mortality and major adverse cardiac events,
according to uric acid levels
Variable Uric Acid
Total Normal Abnormal p Value
30-day mortality 4.9 (%) 3.9 (%) 7.0 (%) 0.050
30-day MACE 6.5 (%) 4.9 (%) 9.8 (%) 0.006
Late mortality 43.8 (%) 41.2 (%) 49.1 (%) 0.026
Late MACE 24.2 (%) 20.5 (%) 32.1 (%) �0.001
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diac death was defined as death caused by acute myocardial
infarction, cardiac arrhythmias, or congestive heart failure.
Sudden unexpected death in previously stable patients was
considered cardiac death. MACE was defined as the com-
posite end point of nonfatal myocardial infarction and car-
diac death. Study end points were mortality and MACE
during the perioperative period (30-day period after sur-
gery) and during long-term follow-up (mean: 3.7 years). No
patients were lost to follow-up.
Continuous data was expressed as mean values � stan-
dard deviation and compared using the analysis of variance
test. Categorical data were presented as percent frequencies,
and differences between proportions were compared using
the chi-square test with Yates’ correction. Logistic regres-
sion analysis was used to identify predictors of 30-day
mortality and MACE, and multivariate Cox proportional
hazard regression was used to identify predictors of late
mortality and MACE. The interaction term of serum uric
acid level and diuretic use was tested in the Cox regression
models. In multivariable analysis, adjustments were made
for the variables of anemia, renal dysfunction, heart failure,
age, gender, type of vascular surgery (central or peripheral
open procedure), diabetes mellitus, chronic obstructive pul-
monary disease, hypertension, ischemic heart disease,
stroke, and the use of cardiovascular medication. The pres-
ence of interaction between serum uric acid levels and the
use of diuretics were evaluated by forcing these interaction
terms in the multivariable regression model. Because the
interaction terms were not significant for prediction of 30-
day or late mortality or major adverse cardiac events, they
were not included in the final logistic regression or Cox
proportional hazard regression analysis models. The prob-
ability of survival was calculated using the Kaplan-Meier
method, and survival curves were compared using the log-
rank test. Odds and hazard ratios are given with 95% con-
fidence intervals. For all tests, a value of p �0.05 (2-sided)
was considered significant. All analysis was performed us-
ing SPSS 15.0 statistical software (SPSS, Inc., Chicago,
Illinois).
Results
The mean age of the study population was 68 � 11 years,
and 76% were men. A total of 299 patients (32%) had hyper-
uricemia. Mean serum uric acid levels in hyperuremic patients
were 0.49 � 0.07 mmol/L for men and 0.48 � 0.21 mmol/L
for women. In patients without hyperuricemia, the mean se-
rum uric acid levels were 0.32 � 0.06 mmol/L for men and
0.27 � 0.06 mmol/L for women. Patients with hyperurice-
mia more frequently had a history of heart failure and
chronic kidney disease and more frequently used diuretics
compared with patients without hyperuricemia (Table 1).
No differences in age, gender, further cardiac risk factors, or
medication use were observed between the 2 groups, with
the exception of the use of diuretics (Table 1).
At 30 days after surgery, 46 patients (4.9%) had died and
61 patients (6.5%) experienced a MACE. The distributions
of 30-day mortality and MACE, according to serum uric
acid levels, are listed in Table 2. The Kaplan-Meier curves
for 30-day mortality and MACE-free survival are illustrated
in Figures 1 and 2, showing the difference in mortality and
MACE in patients with hyperuricemia compared with those
normal serum uric acid levels (log-rank tests; p � 0.05 and
p � 0.006, respectively). After multivariate logistic regres-
sion analysis, adjusting for age, gender, and clinical char-
acteristics, the presence of hyperuricemia was no longer
independently associated with an increased risk of 30-day
mortality or an increased risk of 30-day MACE (Table 3).
During long-term follow-up, a total of 282 patients
(30.2%) died and a total of 170 (18.2%) experienced a
MACE. Mean follow-up was 3.7 years with a range of 0
Figure 3. Long-term all-cause, mortality-free survival for serum uric acid levels.
Table 3
Multivariable associations between hyperuricemia and risk of 30-day
mortality and MACE
Variable 30-Day Outcome
All-cause Mortality MACE
Odds Ratio*
(95% Confidence Interval)
Odds Ratio*
(95% Confidence Interval)
Abnormal uric
acid
1.46 (0.77–2.82) 1.66 (0.95–2.95)
Age 1.04 (1.01–1.09) 1.02 (1.00–1.05)
Men 0.90 (0.43–1.93) 0.77 (0.39–1.49)
Central arterial
surgery
1.62 (0.81–3.26) 1.15 (0.64–2.09)
Chronic kidney
disease
1.65 (0.68–4.01) 1.79 (0.83–3.87)
Heart failure 2.24 (1.12–4.47) 2.78 (1.53–5.08)
Diabetes mellitus 1.56 (0.76–3.23) 1.66 (0.88–3.12)
Hypertension 1.36 (0.71–2.63) 1.31 (0.73–2.36)
Ischemic heart
disease
1.22 (0.62–2.36) 1.11 (0.61–2.04)
Stroke 1.71 (0.80–3.64) 1.35 (0.66–2.75)
* Adjustments were made for uric acid levels, age, gender, type of
vascular surgery, renal function, heart failure, diabetes mellitus, hyperten-
sion, ischemic heart disease, stroke and the use of cardiovascular
medication.
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to 17 years. The distributions of late mortality and MACE
according to serum uric acid levels are listed in Table 2.
The Kaplan-Meier curves for late mortality and MACE-
free survival are illustrated in Figures 3 and 4, showing
the increased risk of late mortality and MACE in patients
with hyperuricemia compared with those normal serum
uric acid levels (log-rank tests; p � 0.026 and p �0.001,
respectively).
After multivariate Cox proportional hazard regression
analysis, adjusting for age, gender and clinical characteris-
tics, the presence of hyperuricemia was associated with
increased risk of late mortality compared with patients with
normal serum uric acid levels, with a hazard ratio of 1.38
and 95% confidence interval of 1.10 to 1.73, as listed in
Table 4. Additionally, older age, a history of heart failure,
and chronic kidney disease were also associated with a
significantly increased risk of late mortality (Table 4). Fur-
thermore, after multivariate Cox proportional hazard regres-
sion analysis, the presence of hyperuricemia was associated
with an increased risk of late MACE compared with patients
with normal serum uric acid levels, with a hazard ratio of
1.72 and 95% confidence interval of 1.28 to 2.31 (Table 4).
Additionally, older age, a history of heart failure, chronic
kidney disease, and ischemic heart disease were also asso-
ciated with a significantly increased risk of late MACE.
Discussion
Preoperative cardiac risk evaluation is assessed by using clin-
ical risk factors. Commonly used is the revised cardiac risk
index, described by Lee et al,10 which includes congestive
heart failure and renal disease as risk factors. These co-mor-
bidities are also known to influence the uric acid concentra-
tions,11–13 which may therefore be an objective prognostic
marker for perioperative events. However, this study shows
that hyperuricemia is an independent predictor of long-term
mortality and MACE in patients after open vascular surgery.
To our knowledge, no other studies have been published
evaluating hyperuricemia before elective vascular surgery.
However, the relationship of serum uric acid and risk of
fatal coronary heart disease has been researched in multiple
cohort studies during the past decades.2–5,14,15 Although
hyperuricemia was associated with an increased risk of fatal
coronary heart disease in these investigations, the univariate
associations appeared to be largely explained by the relation
of serum uric acid with other CHD risk factors and mostly
disappeared after additional adjustment for confounding
factors. However, Fang et al16 reported in a follow-up study
from the First National Health and Nutrition Examination
Survey (NHANES 1), in which 5,926 subjects (mean age
48.1 years) were followed for a mean of 16.4 years, that in
addition to cardiovascular mortality, hyperuricemia was
also independently associated with an increased risk of
ischemic heart disease mortality.
Recently, Strasak et al17 studied the predictive role of
serum uric acid for the risk of all major forms of cardio-
vascular death in a prospective population-based cohort
study of 286,613 elderly women who were followed for a
median of 15.2 years. The mean age was 62.3 (�8.8) years,
comparable to the population in our study. The end points of
this study were death from congestive heart failure, stroke,
and coronary heart disease as well as from total cardiovas-
cular disease. The highest quartile of serum uric acid levels
(�0.32 mmol/L) was associated with mortality from total
cardiovascular disease, with adjusted hazard ratios for the
highest versus lowest quartile of 1.35 (1.20 to 1.52). Serum
uric acid levels were further significantly related to all other
end points, including coronary heart disease with an ad-
justed hazard ratio of 1.37 (1.15 to 1.63).
Additionally, in a cohort study performed by Niskanen
et al,6 in which 1,423 middle-aged, healthy Finnish men
without cardiovascular disease, cancer, or diabetes were pro-
Figure 4. Long-term MACE-free survival for serum uric acid levels.
Table 4
Multivariable associations between hyperuricemia and risks of late
mortality and major adverse cardiac events
Variable Late Outcome
All Cause Mortality MACE
Hazard Ratio*
(95% Confidence Interval)
Hazard Ratio*
(95% Confidence Interval)
Abnormal uric
acid
1.38 (1.11–1.72) 1.71 (1.25–2.30)
Age 1.04 (1.03–1.06) 1.03 (1.02–1.05)
Male gender 0.85 (0.65–1.10) 1.03 (0.72–1.49)
Central arterial
surgery
0.89 (0.70–1.10) 0.79 (0.59–1.05)
Chronic kidney
disease
1.61 (1.16–2.25) 1.70 (1.12–2.55)
Heart failure 1.65 (1.25–2.18) 1.94 (1.37–2.75)
Diabetes Mellitus 1.05 (0.81–1.37) 1.25 (0.89–1.76)
Hypertension 1.05 (0.86–1.36) 1.18 (0.89–1.53)
Ischemic heart
disease
1.22 (0.98–1.53) 1.27 (1.01–1.59)
Stroke 1.04 (0.78–1.40) 1.13 (0.78–1.66)
* Adjustments were made for uric acid levels, age, gender, type of
vascular surgery, renal function, heart failure, diabetes mellitus, hyper-
tension, ischemic heart disease, stroke and the use of cardiovascular
medication.
MACE � major adverse cardiac event.
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spectively followed, hyperuricemia (highest tertile) was inde-
pendently associated with an increased risk of cardiovascular
death with a relative risk of 2.5.
In regard to underlying pathophysiological mechanisms
explaining the association of serum uric acid levels and
increased risk of cardiovascular events, atherosclerotic
plaques have been shown to contain uric acid, and hyper-
uricemia may promote thrombus formation via purine me-
tabolism18,19 in addition to increasing the production of
oxygen-free radicals and facilitating lipid peroxidation.20
Furthermore, recent in vitro and in vivo studies suggest that
serum uric acid contributes to endothelial dysfunction by
inducing antiproliferative effects and impairing nitric oxide
production.21 Although it is not possible to conclude that
hyperuricemia is a causal risk factor because of the obser-
vational nature of this study, these results indicate a clinical
importance of monitoring hyperuricemia in patients sched-
uled for vascular surgery because these patients are at in-
creased risk for coronary heart disease.
This study has some potential limitations. The study
population consisted of patients referred to a tertiary care
center and may not fully represent a general population
scheduled for elective vascular surgery. Also, because of the
observational nature of the study, a causal relationship could
not be determined between hyperuricemia and 30-day and
long-term mortality and major adverse cardiac events. Ad-
ditionally, the influence of metabolic syndrome was not
incorporated in the multivariate analysis. Furthermore, the
etiology of the measured hyperuricemia, which could be an
important determinant of outcome, remains unknown.
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score was reduced by 3.3 points.  Conclusions: The use of the 
prolonged-release nicotinic acid Niaspan in patients with or 
at risk for atherosclerotic disease showed good tolerability, 
a marked increase in HDL cholesterol and a reduced cardio-
vascular risk score.  Copyright © 2008 S. Karger AG, Basel
 Introduction
 Atherosclerosis is a generalized disease affecting mul-
tiple organs and is associated with a poor cardiovascular 
outcome  [1, 2] . Current European guidelines for the man-
agement of elevated cardiovascular risk focus strongly on 
the control of low-density lipoprotein (LDL) cholesterol 
with HMG-CoA reductase inhibitors (statins)  [3, 4] . Nu-
merous trials in tens of thousands of patients have dem-
onstrated, beyond any doubt, that these drugs reduce the 
risk of adverse cardiovascular outcomes in a wide range 
of patients, whether or not LDL cholesterol was markedly 
elevated before treatment  [5] . However, the magnitude of 
benefit from statins appears to be limited: half or more of 
the initial cardiovascular risk remains unaddressed by 
statins, even where LDL cholesterol levels are reduced to 
2.0 mmol/l, or below  [6–8] . Additional approaches to con-
trol excess cardiovascular risk, which are suitable for use 
in combination with statins, are required.
 In the 1970s, the Framingham Study identified low 
levels of high-density lipoprotein (HDL) cholesterol as an 
 Key Words
 Atherosclerotic disease  � High-density lipoprotein 
cholesterol  � Dyslipidaemia  � Nicotinic acid, tolerability  � 
Niacin
 Abstract
 Objectives: High-density lipoprotein (HDL) cholesterol ele-
vation is associated with an improved outcome in patients 
with atherosclerotic disease. Niaspan � , a prolonged-release 
nicotinic acid, was evaluated during the Niaspan-Induced 
HDL Elevation for Optimizing Risk Control (NEMO) study in 
The Netherlands.  Methods: NEMO was a 6-month, prospec-
tive, observational, multicentre, open-label study. Niaspan 
was prescribed in statin-treated patients with known or sus-
pected atherosclerotic disease. The main outcome measures 
were treatment-related adverse drug reactions (ADRs) and 
effects on lipids and cardiovascular-risk score based on the 
algorithm derived from the Prospective Cardiovascular Mün-
ster  study.  Results: 612 patients were included in The Neth-
erlands. Flushing was the most common ADR (29% of pa-
tients during the first month of treatment). The main reasons 
for treatment discontinuation were flushing (10.5%), patient 
request (8.0%) and being lost to follow-up (6.0%). About half 
of all patients (52%) continued treatment after the study. Tol-
erability was rated ‘good’ or ‘very good’ in 54% of these pa-
tients. HDL cholesterol increased by 23% from baseline, and 
triglycerides were reduced by 16%, with little change in low-
density lipoprotein or total cholesterol. Cardiovascular risk 
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independent risk factor for cardiovascular disease (CVD) 
 [9] . This finding was subsequently confirmed by numer-
ous observational analyses  [10–15] . One of these, an epi-
demiological analysis of the UK Prospective Diabetes 
Study, ranked HDL cholesterol as the second most im-
portant variable determining overall cardiovascular risk 
in type 2 diabetes patients  [15] . Additionally, low HDL-
cholesterol has also been shown to be an independent risk 
factor for the progression of atherosclerotic disease, thus 
increasing cardiovascular risk  [16] .
 Nicotinic acid (niacin) increases HDL cholesterol by 
about 30% in patients with peripheral artery disease  [17] . 
Interventions to correct low HDL cholesterol in combina-
tion with this agent have resulted in significant improve-
ments in cardiovascular outcomes  [18] . A prolonged-re-
lease formulation of nicotinic acid (Niaspan � ) has been 
developed with the intention of providing once-daily ad-
ministration and reducing the incidence of flushing, the 
main tolerability issue with nicotinic acid  [19, 20] . Pro-
longed-release nicotinic acid is as effective as the stan-
dard formulation of nicotinic acid in increasing HDL 
cholesterol levels  [21] , and has been shown to induce re-
gression of atherosclerosis of the carotid artery when 
added to a statin  [22, 23] .
 The Niaspan-Induced HDL Elevation for Optimizing 
Risk Control (NEMO) study recently evaluated the safety 
and tolerability of prolonged-release nicotinic acid in pa-
tients already receiving a statin in the usual care setting 
in 4 European countries  [24] . We present a subgroup 
analysis of the NEMO study, in which we compare the 
therapeutic profile of prolonged-release nicotinic acid in 
patients with known or suspected atherosclerotic disease, 
who received treatment at centres in The Netherlands, 
and in the overall study population ( fig. 1 ).
 Patients and Methods
 The methodology of the NEMO study, a prospective, multicen-
tre, open-label, observational, uncontrolled trial, has been pre-
sented in detail elsewhere  [24] . This was not an interventional 
study, and patients received all treatments according to the usual 
care provided by their physicians. It was recommended that the 
dose of prolonged-release nicotinic acid should be titrated accord-
ing to its manufacturer’s recommendations  [25] . These include the 
recommendation that the dose should not be increased by more 
than 500 mg in a 4-week period where patients are already receiv-
ing a daily dose of at least 1,000 mg. The maximum recommended 
daily dose of prolonged-release nicotinic acid is 2,000 mg.
 The main objective of the study was to evaluate the tolerabil-
ity and safety of prolonged-release nicotinic acid under usual-
care conditions, in a 6-month observation period. Of particular 
interest were treatment-related adverse drug reactions (ADRs), 
which were defined as ADRs where a causal relationship with pro-
longed-release nicotinic acid could not be ruled out (possible, 
probable, not assessable or missing relationship to treatment). 
Standard definitions were used to define ADRs and serious ADRs. 
As a secondary objective, data on lipid parameters were collected 
and presented as a global cardiovascular-risk score based on the 
algorithm derived from the Prospective Cardiovascular Münster 
(PROCAM) study  [26] . The estimation of coronary risk in this 
algorithm is calculated by using 8 variables: age, LDL cholesterol, 
HDL cholesterol, triglycerides, systolic blood pressure, smoking 
status, family history of myocardial infarction, and presence or 
absence of diabetes mellitus. The PROCAM score can range from 
0 to 87, correlating with an estimated 10-year risk of a coronary 
event ranging from  ! 0.1 to 30%, respectively.
 All history of diagnosed atherosclerotic disease was docu-
mented, including peripheral arterial disease, history of stroke 
and transient ischemic attack, and coronary heart disease (de-
fined as a history of previous myocardial infarction), percutane-
ous transluminal coronary angioplasty/stent, or coronary artery 
bypass graft. Risk factors for CVD, such as hypertension and dia-
betes mellitus, were also documented.
 Eligible patients were aged  6 18 years, had started treatment 
with prolonged-release nicotinic acid within the previous 2 
months in addition to existing treatment with a statin and had 
HDL cholesterol  ! 1.3 mmol/l and/or triglycerides  1 1.7 mmol/l at 
baseline. All patients were at elevated atherosclerotic cardiovas-
cular risk due to 1 or more of the following: (a) proven or suspect-
ed atherosclerotic disease resulting in a 10-year PROCAM risk of 
myocardial infarction  1 20%, (b) coronary heart disease with at 
least 1 previous myocardial infarction or stroke, (c) coronary ar-
tery disease proven by prior coronary artery bypass graft or per-
cutaneous transluminal coronary angioplasty (including inser-
tion of a stent) applied to a coronary stenosis of at least 70%, as 
documented by angiography, or (d) type 2 diabetes mellitus.
 As this was not an interventional study, ethical approval or 
informed consent by patients was not required. Local authorities 
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 Fig. 1. Frequency and severity of flushing in patients receiving 
treatment with prolonged-release nicotinic acid in The Nether-
lands and in the overall NEMO population. Percentages relate to 
the overall safety population. The severity of flushing was rated 
by investigators.
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were informed of the study, which was performed in accordance 
with relevant legislation. All considerations regarding the protec-
tion of human subjects throughout the course of the study out-
lined in international agreements such as the Declaration of Hel-
sinki were upheld as far as applicable. The processing and han-
dling of patient observational data was compliant with EU 
Directive 5/46/EC on the processing of personal data and on the 
free movement of such data (24 October 1995). Data were anal-
ysed using descriptive statistics and no significance testing was 
performed. All percentages are based on the total number of pa-
tients who received treatment.
 Results
 Patients
 Of the 1,053 patients in the overall NEMO popula-
tion, 612 received treatment in The Netherlands. Princi-
pal reasons for premature treatment discontinuation 
during the study (The Netherlands/overall population) 
were: flushing (10.5/11.1% of the total populations for 
each analysis), ADRs unrelated to flushing (7.2/8.5%), 
patient declined further treatment (8.0/10.5%) and pa-
tient was lost to follow-up (6.0/6.2%). Data on the persis-
tency rate (the proportion of patients taking prolonged-
release nicotinic acid beyond the end of the study) were 
available from 496 patients (81% of the study popula-
tion): 52% of patients who received study treatment con-
tinued to take Niaspan beyond the study period and 29% 
did not.
 There were no marked differences in demographic or 
disease characteristics between The Netherlands and the 
overall population at baseline ( table 1 ). Both populations 
displayed an atherogenic dyslipidaemic phenotype, on 
average, with hypertriglyceridaemia and low HDL cho-
lesterol, without evidence of marked hypercholesterolae-
mia. In total, 83% of the Dutch patients had at least 1 di-
agnosed CVD: 15.8% had peripheral arterial disease, 
8.2% had a history of cerebrovascular disease (stroke 
8.0%) and 51% were suffering from coronary heart dis-
ease, of which 30.6% had a prior myocardial infarction, 
23% had received a percutaneous transluminal coronary 
angioplasty/stent, and 14% had received a coronary by-
pass graft. The remaining 17% of the population were at 
risk for atherosclerotic disease based upon clinical risk 
factors. In total, more than 50% of the patients had been 
diagnosed as having hypertension.
 The most common statins received by patients were 
atorvastatin (39% in The Netherlands and 38% in the 
overall population), rosuvastatin (23 and 16%, respective-
ly) and simvastatin (16 and 21%, respectively). Fluvastatin 
and pravastatin were each taken by  ! 10% of patients.
 Tolerability and Safety
 Flushing was the most common treatment-related 
ADR, with 29% of patients in The Netherlands flushing 
in the first month ( fig. 1 ). Most flushes were mild or mod-
erate in severity, as rated by the investigators, and this 
ADR occurred with similar frequency in patients in The 
Netherlands and in the overall population ( fig. 1 ). The 
overall incidence of flushing tended to decrease over time 
( fig. 2 ). The median number of flushes each month also 
declined during the study, from 10 in the first month to 4 
in the final month. However, this decrease may have part-
 Table 1. Demographic parameters and status of cardiometabolic 
risk at baseline
Patients in
The Netherlands
(n  =  612)
All patients
(n  =  1 , 053)
 Males, % 81.7 79.3 
 Mean age, years 57 8 11 58.4 8 10.9 
 Mean weight, kg 89 8 16 88.0 8 16.0 
 Ethnicity, % 
 White/Caucasian 93.5 94.5 
 Asian 3.6 2.6 
 Black 1.1 0.8 
 Other/not recorded 1.8 2.2 
 Total cholesterol, mmol/l 4.6 8 1.2 4.7 8 1.4 
 Triglycerides, mmol/l 3.6 8 2.9 3.2 8 2.5 
 LDL cholesterol, mmol/l 2.4 8 1.0 2.6 8 1.1 
 HDL cholesterol, mmol/l 0.9 8 0.3 0.9 8 0.3 
 Fasting plasma glucose, mmol/l 7.1 8 2.6 6.8 8 2.4 
 HbA 1C , % 6.7 8 1.4 6.6 8 1.4 
 Systolic blood pressure, mm Hg  137 8 19 136 8 19 
 Diastolic blood pressure, mm Hg 80 8 9 80 8 10 
 Hypertension, % 50.3 56.7 
 Coronary heart disease, % 50.8 53.0 
 Prior myocardial infarction, % 30.6 30.3 
 PTCA or stent, % 23.8 23.8 
 CABG, % 14.2 14.2 
 Cerebrovascular disease, % 8.2 10.3 
 Peripheral vascular disease, % 15.8 12.9 
 Diabetes, % 44.0 42.1 
 Metabolic syndrome, % 56.2 53.1 
 Family history for CVD, % 49.5 42.1 
 Smoking, % 
 Current smoker 23.2 21.7 
 Ex-smoker 41.7 38.8 
 Mean PROCAM score  45.4 8 10.3 45.6 8 10.1 
 HbA 1C  = Glycosylated haemoglobin A 1C ; PTCA = percutane-
ous transluminal coronary angioplasty; CABG = coronary artery 
bypass graft.  
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ly been caused by early discontinuation of the patients 
most prone to flushing. Between 34.1 and 37.8% of pa-
tients took a non-steroidal anti-inflammatory agent as 
prophylaxis for flushing in a given month. In total, 233 
patients (36.4%) were on aspirin therapy when starting the 
study, with 12 patients (2.0%) stopping and 25 patients 
(4.1%) starting during the study period. In total, 52 (23%) 
of the patients on aspirin therapy developed flushing in 
the first month, compared to 126 (32%) of the patients 
who were not on previous aspirin therapy (p = 0.02). How-
ever, during the rest of the study period, there were no 
significant differences in the incidence of flushing be-
tween patients taking and not taking aspirin therapy.
 Other ADRs occurred with similar frequency in The 
Netherlands and internationally ( table 2 ). The most com-
mon ADRs other than flushing occurred in the gastro-
intestinal and nervous systems, but the frequency of in-
dividual clinical ADRs was low in both cases. Only 1 pa-
tient (0.2%) reported a serious treatment-related ADR 
(gouty arthritis), which was considered possibly related 
to treatment by the investigator.
 Physicians rated the overall tolerability of Niaspan for 
435 patients (71%). In these patients, they rated tolerability 
as ‘poor’ for 25%, ‘acceptable’ for 22%, ‘good’ for 41% and 
‘very good’ for 13%. Corresponding figures for the overall 
study population were 27, 19, 36 and 18%, respectively.
 Lipid Profiles and Cardiovascular-Risk Score
 The main effects of prolonged-release nicotinic acid 
on the lipid profile were a marked elevation of HDL cho-
lesterol and a marked decrease in triglycerides ( fig. 2 ). In 
general, effects on lipid parameters in The Netherlands 
were similar to those observed in the overall population 
of the study. The PROCAM score (a score for the risk of 
experiencing a cardiovascular event in the following 10 
years; mean  8 SEM) was 45.4  8 0.5 at baseline and 41.8 
 8 0.6 at the study end, resulting in a mean decrease and 
improvement of 3.3  8 0.4 points. These values were sim-
ilar to those in the overall study population at baseline 
and at the study end (45.6  8 0.4 and 41.3  8 0.4, respec-
tively).
 Discussion
 Atherosclerotic disease is a major risk factor for car-
diovascular outcome and has been recognized as a grow-
ing worldwide health burden, with prevalence rates 
reaching up to 29% in the USA  [27, 28] . Among other clas-
sic risk factors, low HDL cholesterol had been shown to 
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 Fig. 2. Effects on lipid parameters. 
 Table 2. Treatment-related ADRs unrelated to flushing (% of pa-
tients)
ADR Patients in
The Netherlands
(n = 612)
All patients
(n = 1,053)
Skin and subcutaneous disorders (any) 3.8 4.1
Pruritus 2.9 2.7
Erythema 0.3 0.6
Gastro-intestinal disorders (any) 2.3 3.8
Upper abdominal pain – 1.1
Nausea 0.8 1.0
Diarrhoea 0.2 0.6
Abdominal pain 0.2 0.5
Nervous system disorders (any) 2.9 3.8
Headache 0.8 0.9
Burning sensation 0.5 0.7
Dizziness 0.3 0.6
Insomnia 0.2 0.6
Musculoskeletal/connective tissue
disorders (any) 1.5 1.2
Myalgia 1.1 0.8
General disorders/administration
site conditions 0.7 0.9
Cardiac disorders (any) 0.3 0.7
Palpitations 0.3 0.7
Psychiatric disorders (any) 0.5 0.6
Sleep disorders 0.2 0.3
ADRs that occurred in at least 0.5% of patients in any Medical Diction-
ary for Research Activities system organ class in the overall population are 
shown, with specific clinical ADRs within each body system that occurred 
in more than 0.5% of patients for either population (this approach lists 
ADRs that occurred in more than 3 patients in the population in The Neth-
erlands). Treatment-related ADRs were those for which investigators did 
not rule out a causal relationship with prolonged-release nicotinic acid.
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independently increase the progression of systemic ath-
erosclerosis, thus continually adding to the cardiovascu-
lar risk of the patient  [16] . In a double-blind trial, Rubins 
et al.  [29] showed that raising HDL cholesterol in 2,531 
men with coronary heart disease significantly reduced 
the risk of major cardiovascular events. Postulated mech-
anisms of improved outcome included the theory that 
HDL exerts an antithrombotic effect by transporting 
cholesterol out of the arterial wall and by transporting 
anti-oxidants to LDL, thus making it less susceptible to 
oxidation within the endothelium. Furthermore, niacin 
has been shown to effectively raise the levels of HDL cho-
lesterol in atherosclerotic patients treated for peripheral 
artery disease  [30] .
 The NEMO study was designed to evaluate the effects 
of prolonged-release nicotinic acid in a statin-treated 
population of patients with known or suspected athero-
sclerotic disease, who were at elevated cardiovascular risk 
due to established dyslipidaemia, cardiovascular disease, 
a cardiovascular heart disease equivalent (type 2 diabetes 
mellitus) or a markedly elevated global cardiovascular-
risk score. The study therefore set out to recruit patients 
typical of those presenting in routine clinical practice, 
who require intervention to manage their cardiovascular 
risk. The observational nature of the study, in which pa-
tients received the study treatment as part of the usual 
care provided by their physician, adds to the relevance of 
this trial to actual clinical practice.
 The publication of the overall results of the study did 
not include an evaluation of the study drug in patients 
treated within the individual countries that participated 
 [24] . Such information is useful, as the nature of the car-
diovascular risk is known to vary between countries in 
Europe  [31, 32] . Our data suggest that the patient popula-
tion in The Netherlands was typical of the overall popu-
lation of the NEMO study, with similar demographic and 
disease characteristics, a similar incidence of ADRs or 
serious ADRs (related or not to flushing), and similar ef-
fects on HDL cholesterol and triglycerides. The modest 
decrease in LDL cholesterol observed in the overall 
NEMO population is typical of the results of other clini-
cal trials with prolonged-release nicotinic acid  [19] , al-
though such an effect was not observed in The Nether-
lands. The reason for this difference is not clear.
 The need to intervene to correct low HDL cholesterol 
may be particularly strong in The Netherlands. A survey 
of lipid profiles in 8,545 patients under treatment for dys-
lipidaemia in 11 European countries, published in 2005, 
demonstrated a prevalence of low HDL cholesterol ( ! 1.03 
mmol/l for men and  ! 1.29 mmol/l for women) of 49%, 
compared with 37% for the European population as a 
whole  [31] . The results of this analysis provide specific 
information to guide the therapeutic application of pro-
longed-release nicotinic acid in high-risk, statin-treated 
dyslipidaemic patients with atherosclerotic disease in 
The Netherlands.
 International experts in Europe  [33] and the USA  [34] 
support the concept of correcting low HDL cholesterol as 
a therapeutic strategy for improving cardiovascular out-
comes. Initial clinical experience with the first of a new 
class of cholesteryl ester transfer protein inhibitors has 
been disappointing, however, with adverse effects on ath-
erosclerosis despite marked increases in HDL cholesterol 
 [35, 36] . It is important to note that this was likely not due 
to HDL cholesterol raising per se, and may have been due 
to increased blood pressure observed with this agent or a 
consequence of the mechanism by which this agent mod-
ulates cholesterol efflux from macrophages  [37, 38] .
 In conclusion, the use of the prolonged-release nico-
tinic acid Niaspan in patients with or at risk for athero-
sclerotic disease showed a good tolerability and a marked 
increase in HDL cholesterol and reduction in cardiovas-
cular risk score. Although its overall tolerability is mod-
erate, Niaspan is currently the only medicine available 
that increases HDL cholesterol levels with once-daily ad-
ministration. Correction of low HDL cholesterol with 
nicotinic acid or other treatments has been shown in nu-
merous studies to inhibit the progression of atherosclero-
sis and to improve cardiovascular outcomes  [18, 39] , and 
it remains a valid therapeutic target for the management 
of cardiovascular risk.
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Undergoing Major Vascular Surgery?
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SyNoPSIS
The cardioprotective effects of statins remain unclear in patients scheduled for major vascular 
surgery. In a prospective study, statin dose and cholesterol levels were recorded in 359 patients 
before major vascular surgery. After multivariate analysis, lower LDL-cholesterol was associated 
with lower myocardial ischemia, troponin T release, and 30-day and late cardiac events. Also, 
higher doses of Statins were associated with better cardiac outcome, even after adjusting for 
LDL-cholesterol.
Cardiac complications remain the leading cause of perioperative morbidity and mortality follow-
ing non-cardiac vascular surgery. Recently, statins have emerged as promising cardioprotective 
drugs in the primary prevention of cardiac events and mortality in patients undergoing major 
vascular surgery ([3], [4] and [5]).  The main effect of statins is the reduction of cholesterol levels, 
but may also have effects beyond their lipid-lowering properties (7), and may have a positive 
effect on the cardiac autonomous nervous system (8). Since decreased heart rate variability 
may trigger ischemic events, an improvement of heart rate variability by statins may be the 
mechanism of cardioprotection (9). This study was conducted to clarify whether higher statin 
doses and lower cholesterol levels are associated with reduced myocardial ischemia. Further-
more, we assessed whether higher statin doses and lower cholesterol levels were associated 
with improved clinical cardiac outcome, whether statins are cardioprotective independent of 
cholesterol levels; and if statins are associated with perioperative heart rate variability.
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PAtIeNtS AND MetHoDS
The study population consisted of 359 
patients undergoing elective non-cardiac 
vascular surgery, during the period of 2002 to 
2006. At study enrollment, all baseline cardiac 
risk factors were noted. In all patients, beta-
blockers were considered before surgery to 
obtain perioperative heart rates of 60 to 65 
beats/min. Before surgery, all patients under-
went dobutamine stress echocardiography 
for the assessment of coronary artery disease. 
Patients with positive dobutamine stress 
echocardiography results were referred for 
further cardiac management. Type, dose, and 
duration of statins were noted at enrollment 
in all statin users. The dose of statin therapy 
was converted to the percentage of maximum 
recommended therapeutic. The duration of 
statin therapy was calculated from time of 
prescription to time of surgery. Long-term 
statin therapy was defined as statin treat-
ment ≥3 months before surgery. All patients 
who presented with hypercholesterolemia at 
enrollment received statins. Patients contin-
ued statin treatment after hospital discharge. 
Patients were continuously monitored with 
a 10-electrode, 12-lead digital electrocardio-
gram recorder starting 1 day before surgery 
up to 2 days after. Episodes of ischemia were 
defined as reversible ST-segment changes, 
lasting at least 1 min and shifting from base-
line to more than 0.1 mV (1 mm).  Troponin T 
levels were measured on postoperative days 
1, 3, and 7, before discharge, and whenever 
clinically indicated by electrocardiogram 
changes. The recommended lower limit of 
0.03 ng/ml was used to define positive tro-
ponin T levels. Study end points were 30-day 
and long-term major cardiac events (cardiac 
death and nonfatal myocardial infarction). 
Cardiac death was defined as death caused 
by acute myocardial infarction, cardiac 
arrhythmias, congestive heart failure, or sud-
den death. Nonfatal myocardial infarction 
was diagnosed when at least the following 
were present: elevated cardiac enzyme levels, 
development of new Q waves (>1 mm or 
>30 ms), and typical symptoms of angina 
pectoris. No patients were lost to follow-up. 
Heart rate variability was computed for each 
subject. Consecutive 5-min recordings of 2-h 
periods were obtained. The average heart 
rate variability was calculated. We used stan-
dard time domain measures including the 
standard deviation of the normal-to-normal 
(NN) intervals (SDNN) and the square root of 
the mean squared differences of successive 
NN intervals (rMSSD). The standard deviation 
of the average NN intervals (SDANN) and the 
mean of the 5-min standard deviations (SDNN 
index) also were calculated for the first 24-h 
recording. Binary logistic regression analysis 
was used to evaluate the association of statin 
dose and cholesterol levels on perioperative 
myocardial ischemia, troponin T release, and 
30-day clinical cardiac outcome. Cox propor-
tional hazard analysis was used to assess the 
association of statin dose and cholesterol 
levels with late cardiac events. A propensity 
score for statin therapy was calculated to cor-
rect for selection bias, which was constructed 
using multiple logistic regression analysis. In 
multivariate analysis, adjustments were made 
for age, gender, baseline characteristics, 
and propensity scores. Analysis of variance 
techniques were used to compare heart rate 
variability between groups of patients with 
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different statin doses. Tests for heterogene-
ity were used to reveal a differential effect 
of statins between patients with or without 
perioperative myocardial ischemia and/or 
troponin T release.
ReSULtS
The mean age of the study population was 67 
± 10 years, and 79% were male. A total of 187 
(52%) patients received statin therapy. The 
following statins were used: simvastatin in 54 
patients, pravastatin in 42 patients, fluvastatin 
in 35 patients, atorvastatin in 49 patients, 
and rosuvastatin in 7 patients. Long-term 
statin therapy was recorded in 150 patients 
(42%). Statins were newly prescribed in 37 
patients (10%). The mean dose of statins was 
41 ± 32% of MRTD. Patients with statins more 
frequently had a history of cerebrovascular 
events, hypertension, and hypercholester-
olemia as compared with patients without 
statins (Table 1). Propensity analysis showed 
that patients were more likely to have statins 
if they had a history of cerebrovascular events 
(p < 0.001) and hypercholesterolemia (p < 
0.001). No further differences were observed 
between the 2 groups. A total of 187 ischemic 
episodes in 103 patients (29%) were detected 
during continuous electrocardiography. 
Univariate (Figure 1 and Figure 2, Table 2) and 
multivariate analysis (Table 2) showed that 
higher statin doses and lower LDL cholesterol 
levels were both significantly associated with 
a lower incidence of myocardial ischemia. 
table 1. Baseline Characteristics of the Study Population According to Statin Therapy (n = 359)
characteristic Statins (n = 187) No Statins (n = 172) p Value
Age (yrs) 66 ± 10 67 ± 10 0.8
Male 141 (75.4) 143 (83.1) 0.07
Angina pectoris 35 (18.7) 27 (15.7) 0.5
History of myocardial infarction 68 (36.4) 68 (39.5) 0.5
Previous coronary revascularization 33 (17.6) 21 (12.2) 0.2
History of congestive heart failure 9 (4.8) 5 (2.9) 0.4
History of cerebrovascular event 64 (34.2) 33 (19.2) 0.001
Renal failure 11 (5.9) 6 (3.5) 0.3
Diabetes 30 (16.0) 25 (14.5) 0.7
Hypertension 87 (46.5) 59 (34.4) 0.02
Hypercholesterolemia 107 (57.2) 22 (12.8) <0.001
Current or past smoking 113 (60.4) 105 (61.0) 1.0
Aspirin 102 (54.5) 93 (54.1) 1.0
Angiotensin-converting enzyme inhibitors 52 (27.8) 40 (23.3) 0.4
Beta-blockers 139 (74.3) 124 (72.7) 0.8
Calcium channel blockers 45 (24.1) 49 (28.5) 0.3
Stress-induced myocardial ischemia 36 (19.3) 42 (24.4) 0.2
Low-density lipoprotein cholesterol (mg/dl) 106 ± 38 136 ± 43 <0.001
High-density lipoprotein cholesterol (mg/dl) 50 ± 16 45 ± 17 0.02
Triglycerides (mg/dl) 152 ± 71 190 ± 101 <0.001
Total cholesterol (mg/dl) 175 ± 42 212 ± 51 <0.001
Values are expressed as mean (± SD) or n (%).
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figure 1. Incidence of Myocardial Ischemia and 
Troponin T Release
figure 2. Incidence of Myocardial Ischemia and 
Troponin T Release
table 2. Statin Therapy in Relation to Perioperative Ischemia and Troponin T Release in Patients 
Undergoing Major Vascular Surgery
Perioperative Myocardial Ischemia 
(n = 103) oR (95% cI)
Perioperative troponin t Release 
(n = 83) oR (95% cI)
characteristic Univariate Multivariate* Univariate Multivariate*
Statins
 Statin therapy (n = 187) 0.29 (0.17–0.47) 0.33 (0.18–0.60) 0.33 (0.19–0.55) 0.24 (0.12–0.47)
 Statin treatment <3 months† 
(n = 37)
0.22 (0.08–0.58) 0.52 (0.13–2.03) 0.25 (0.08–0.72) 0.75 (0.19–2.96)
 Statin treatment ≥3 months† 
(n = 150)
0.31 (0.18–0.51) 0.30 (0.17–0.53) 0.35 (0.18–0.62) 0.32 (0.17–0.59)
 Statin dose per 10% increase 
of MRTD
0.82 (0.75–0.89) 0.85 (0.76–0.93) 0.85 (0.77–0.94) 0.84 (0.76–0.93)
 Statin dose per 10% increase 
of MRTD (with adjustment for 
baseline LDL cholesterol)
0.87 (0.80–0.95) 0.88 (0.80–0.96) 0.90 (0.81–0.98) 0.87 (0.79–0.95)
Level of baseline cholesterol*
 LDL cholesterol (per 10-mg/dl 
decrease)
0.89 (0.83–0.96) 0.87 (0.80–0.95) 0.93 (0.87–1.00) 0.89 (0.82–0.96)
 HDL cholesterol (per 10-mg/dl 
decrease)
1.07 (0.91–1.25) 1.06 (0.88–1.28) 1.14 (0.95–1.37) 1.19 (0.96–1.47)
 Triglycerides (per 10-mg/dl 
decrease)
0.96 (0.93–0.99) 0.96 (0.93–0.98) 0.96 (0.93–0.98) 0.95 (0.93–0.98)
 Total cholesterol (per 10-mg/dl 
decrease)
0.87 (0.83–0.93) 0.86 (0.81–0.91) 0.93 (0.87–0.98) 0.91 (0.85–0.96)
CI = confidence interval; HDL = high-density lipoprotein; LDL = low-density lipoprotein; MRTD = 
maximum recommended therapeutic dose; OR = odds ratio.
* Adjusted for age, gender, coronary artery disease (according to medical history or stress test results), 
history of congestive heart failure, cerebrovascular disease, diabetes, renal failure, hypertension, type of 
surgery and cardiovascular medication (beta-blockers, aspirin, angiotensin-converting enzyme inhibitors, 
and calcium-channel blockers), and propensity scores.
† In comparison with patients with no statin treatment.
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Higher statin doses remained significantly 
associated with a lower incidence of periop-
erative myocardial ischemia, after adjusting 
for baseline cholesterol levels (Table 2).
The lowest incidence of myocardial 
ischemia and troponin T release in the peri-
operative period was observed in patients 
with statin doses of more than 50% of the 
maximum recommended therapeutic dose. 
The incidence of myocardial ischemia and 
troponin T release in the perioperative period 
was lowest in patients with baseline LDL-
cholesterol levels below 80 mg/dl. Troponin 
T release was detected in 83 patients (23%). 
Univariate (Fig. 1, Table 2) and multivariate 
analysis (Table 2) showed that higher statin 
doses and lower LDL cholesterol levels were 
both significantly associated with a lower 
incidence of troponin T release. Higher statin 
doses remained significantly associated with a 
table 3. Statin Therapy in Relation to Perioperative and Late Cardiac Outcome in Patients Undergoing 
Major Vascular Surgery
Perioperative cardiac Death or 
Nonfatal Q-Wave Myocardial 
Infarction (n = 15) oR (95% cI)
Late cardiac Death or Nonfatal 
Q-Wave Myocardial Infarction (n = 
64) HR (95% cI)
characteristic Univariate Multivariate* Univariate Multivariate*
Statins
 Statin therapy (n = 187) 0.31 (0.10–0.96) 0.32 (0.10–0.96) 0.42 (0.23–0.77) 0.41 (0.21–0.75)
 Statin treatment <3 
months† (n = 37)
‡ ‡ 0.75 (0.02–3.22) 0.81 (0.05–4.15)
 Statin treatment ≥3 
months† (n = 150)
0.24 (0.05–0.98) 0.25 (0.06–0.97) 0.50 (0.28–0.90) 0.52 (0.29–0.93)
 Statin dose per 10% 
increase of MRTD
0.60 (0.39–0.95) 0.62 (0.40–0.96) 0.75 (0.64–0.89) 0.76 (0.65–0.89)
 Statin dose per 10% 
increase of MRTD (with 
adjustment for baseline 
LDL cholesterol)
0.60 (0.37–0.95) 0.66 (0.42–0.98) 0.78 (0.65–0.96) 0.80 (0.67–0.94)
Level of baseline 
cholesterol*
 LDL cholesterol (per 10-
mg/dl decrease)
0.86 (0.76–0.98) 0.89 (0.78–1.00) 0.93 (0.86–0.99) 0.91 (0.84–0.96)
 HDL cholesterol (per 10-
mg/dl decrease)
1.05 (0.69–1.55) 1.10 (0.72–1.70) 0.92 (0.78–1.09) 1.05 (0.87–1.24)
 Triglycerides (per 10-mg/
dl decrease)
1.01 (0.93–1.08) 1.01 (0.93–1.08) 0.99 (0.97–1.02) 1.01 (0.97–1.03)
 Total cholesterol (per 10-
mg/dl decrease)
0.98 (0.87–1.12) 0.95 (0.85–1.07) 0.94 (0.90–1.01) 0.94 (0.88–1.00)
HR = hazard ratio; other abbreviations as in table 2.
* Adjusted for age, gender, coronary artery disease (according to medical history or stress test results), 
history of congestive heart failure, cerebrovascular disease, diabetes, renal failure, hypertension, type of 
surgery and cardiovascular medication (beta-blockers, aspirin, angiotensin-converting enzyme inhibitors, 
and calcium-channel blockers), and propensity scores.
† In comparison with patients with no statin treatment.
‡ No perioperative major cardiac events occurred in patients with statin treatment <3 months.
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lower incidence of troponin T release, irrespec-
tive of baseline cholesterol levels (Table 2).
Perioperative cardiac death and nonfatal 
Q-wave myocardial infarction occurred in 3% 
and 1% of patients, respectively. Late cardiac 
death and nonfatal Q-wave myocardial infarc-
tion occurred in 13% and 5% of patients, 
respectively. During follow-up, statins were 
discontinued in 2 patients (1%) because 
of side effects (myopathy in 1 patient and 
nausea and/or diarrhea in another). In multi-
variate analysis, higher statin doses and lower 
LDL cholesterol levels were both significantly 
associated with a lower incidence of 30-day 
and late cardiac events (Table 3). Higher statin 
doses remained significantly associated with 
lower 30-day and late cardiac events, after 
adjusting for absolute baseline cholesterol 
levels.
Heart rate variability was highest before 
and lowest during surgery (SDNN 47 ± 28 ms, 
34 ± 23 ms, and 39 ± 29 ms before, during, 
and after surgery, respectively [p = 0.007]). 
We found that lower heart rate variability 
before surgery (SDNN per 10 ms decrease) 
significantly predicted myocardial ischemia 
during or after surgery (OR 1.59, 95% CI 1.19 
to 2.13) and troponin T release after surgery 
(OR 1.54, 95% CI 1.17 to 2.01). Lower heart 
rate variability during surgery (SDNN per 
10-ms decrease) also significantly predicted 
myocardial ischemia after surgery (OR 1.71, 
table 4. Association Between Heart Rate Variability and Statin Therapy
characteristic
Statins >50% of MRtD 
(n = 53)
Statins 1% to 50% of MRtD 
(n = 134)
No Statins (n = 
172)
p Value
Before surgery
 SDNN (ms) 52 ± 29 48 ± 28 37 ± 19 <0.001
 rMSSD (ms) 40 ± 35 36 ± 31 28 ± 22 0.01
 Heart rate (beats/
min)
68 ± 11 67 ± 12 68 ± 12 0.7
During surgery
 SDNN (ms) 39 ± 27 32 ± 21 29 ± 19 0.002
 rMSSD (ms) 32 ± 31 26 ± 19 25 ± 23 0.06
 Heart rate (beats/
min)
73 ± 13 71 ± 14 72 ± 13 0.4
After surgery
 SDNN (ms) 48 ± 45 39 ± 24 36 ± 31 0.04
 rMSSD (ms) 34 ± 32 33 ± 30 29 ± 28 0.1
 Heart rate (beats/
min)
76 ± 13 77 ± 14 77 ± 14 0.8
First 24-h recording
 SDNN (ms) 139 ± 44 131 ± 45 119 ± 42 <0.001
 SDANN (ms) 116 ± 39 114 ± 39 88 ± 30 <0.001
 SDNN index (ms) 47 ± 28 40 ± 18 38 ± 17 0.002
 rMSSD (ms) 53 ± 47 49 ± 29 50 ± 37 0.3
 Heart rate (beats/
min)
72 ± 12 72 ± 13 72 ± 13 0.9
MRTD = maximum recommended therapeutic dose; rMSSD = square root of the mean squared 
differences of successive normal-to-normal intervals; SDANN = standard deviation of the average normal-
to-normal intervals; SDNN = standard deviation of the normal-to-normal intervals.
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95% CI 1.14 to 2.57) and troponin T release 
after surgery (OR 1.55, 95% CI 1.13 to 2.11). 
Higher statin doses correlated significantly 
with higher SDNN before, during, and after 
surgery (Table 4).
DIScUSSIoN
This study found that higher statin doses 
and lower LDL cholesterol levels were both 
significantly associated with a lower inci-
dence of perioperative myocardial ischemia, 
perioperative troponin T release, and 30-day 
and late cardiac events in patients undergo-
ing major vascular surgery. Higher statin 
doses remained significantly associated with 
improved cardiac outcome, irrespective of 
baseline cholesterol levels. Higher statin 
doses also correlated significantly with higher 
perioperative heart rate variability. These 
results suggest that statins are cardioprotec-
tive on a clinical and subclinical level and 
that they should be considered in all patients 
undergoing major vascular surgery.
The association between statin treatment 
and temporary or prolonged myocardial isch-
emia is not well known. Myocardial ischemia 
in the perioperative setting may arise either 
from increased myocardial oxygen demand or 
reduced supply. Factors that increase myocar-
dial oxygen demand are mainly tachycardia 
and hypertension resulting from surgical 
stress, postoperative pain, interruption of 
beta-blocker use, or the use of sympathomi-
metic drugs. In contrast, decreased supply 
may be the result of hypotension, vasospasm, 
anemia, hypoxia, or coronary artery plaque 
rupture. Experimental animal studies have 
shown that administration of statins before 
induction of myocardial ischemia improved 
myocardial viability, reduced the extent of 
inflammatory cell accumulation in the isch-
emic myocardium, and preserved coronary 
blood flow, which was attributed to a reduc-
tion in adhesion molecule expression of the 
endothelial monolayer and to an increase 
in the bioavailability of nitric oxide (12). The 
results of the current study support the view 
that myocardial ischemia is limited not only 
by cholesterol-lowering properties of statin 
therapy, but also by potential mechanisms 
such as endothelial function improvement 
and increase in nitric oxide with preservation 
of coronary blood flow (13).
Large trials have consistently shown that 
statins reduce cardiovascular morbidity and 
mortality in high-risk patients ([14], [15], [16] 
and [17]). Marked reductions in perioperative 
cardiovascular events have also been shown 
in patients undergoing major vascular 
surgery ([3], [4] and [5]). The reduction of 
acute thrombotic events may be explained 
by atherosclerotic plaque attenuation and 
stabilization. Intensive statin therapy can 
result in significant regression of atheroscle-
rosis, as shown in the ASTEROID (A Study 
to Evaluate the Effect of Rosuvastatin on 
Intravascular Ultrasound-Derived Coronary 
Atheroma Burden) trial (18). In human carotid 
plaques, statins have been shown to decrease 
lipids, lipid oxidation, inflammation, matrix 
metalloproteinase-2, and cell death and to 
increase tissue inhibitor of metalloproteinase 
1 and collagen (7). According to the current 
results, every 10-mg/dl reduction in baseline 
LDL cholesterol was significantly associated 
with a 13% lower risk of perioperative cardiac 
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events. Moreover, a sustained beneficial effect 
of high-dose statins and low LDL cholesterol 
levels was observed for late cardiac events.
Reduced heart rate variability during sur-
gery is most probably the result of anesthetic 
agents and can be a sign of increased sym-
pathetic or reduced vagal activity. Reduced 
heart rate variability has been associated 
with sudden arrhythmic cardiovascular and 
noncardiovascular mortality in many stud-
ies. A recent study showed that a temporal 
decrease in heart rate variability, i.e., vagal 
withdrawal, can act as a precipitating factor 
for myocardial ischemia (9). High-frequency 
components of heart rate variability showed 
a consistent decrease before an ischemic 
event and before the electrocardiographic 
appearance suggestive of coronary spasm 
(9). We also observed that lower heart rate 
variability in the period preceding myocardial 
ischemia and troponin T release significantly 
predicted its occurrence in the period after 
this measurement. The beneficial effect of 
statins on autonomic function has been sug-
gested in previously published studies ([8], 
[19] and [20]). Our results showed that higher 
statin doses were significantly associated 
with higher SDNN. Heart rate, a determinant 
of heart rate variability, was similar between 
patients with different statin doses. These 
observations led us to the hypothesis that in 
situations of decreased heart rate variability 
and increased myocardial oxygen demand, 
statins may exert an anti-ischemic effect by 
modulating the autonomic nervous system.
An important observation in this study 
was that statins were only prescribed in 52% 
of patients. This reflects the need for evidence 
supporting the benefit of statin treatment 
in patients undergoing major vascular 
surgery and the need for awareness among 
physicians. Statins have not yet been recom-
mended as perioperative medical treatment 
by the American College of Cardiology/
American Heart Association (21). Coronary 
atherosclerosis is highly prevalent among 
patients undergoing major vascular surgery, 
with angiographic coronary abnormalities 
observed in up to 92% of patients (22). Surgery 
places the patient at additional increased risk 
of perioperative events (23). Therefore, the 
recommendations to achieve LDL cholesterol 
levels <100 mg/dl in people with (risk equiva-
lents of ) coronary artery disease according 
to the guidelines of the National Cholesterol 
Education Program Adult Treatment Panel III 
and the European guidelines on cardiovas-
cular disease prevention in clinical practice 
should be extrapolated to patients undergo-
ing major vascular surgery ([24] and [25]). The 
current study further provides evidence that 
additional risk reduction can be achieved by 
achieving LDL cholesterol levels <80 mg/dl.
Several limitations should be addressed. 
In this observational study, statins were not 
assigned randomly; however, the 2 groups 
were comparable in demographics and car-
dioprotective drugs. In addition, multivariate 
analysis and propensity scores were used to 
adjust for possible confounding factors. Sec-
ond, the results apply to patients undergoing 
major noncardiac vascular surgery, and our 
findings may not be generalized to patients 
undergoing general or low-risk surgery. Third, 
a lower cutoff level of 0.03 ng/ml was used to 
define positive troponin T levels. Lower tro-
ponin T levels were not used because they do 
not meet the imprecision criteria (coefficient 
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of variation) of <10%. Finally, carotid artery 
surgery has been associated with heart rate 
change secondary to baroreceptor reflexes. 
The inclusion of these patients may potentially 
have confounded the heart rate variability 
results.
coNcLUSIoNS
Higher statin doses and lower LDL cholesterol 
levels were both significantly associated 
with a lower incidence of perioperative 
myocardial ischemia during continuous 
12-lead electrocardiographic monitoring, 
perioperative troponin T release, and 30-day 
and late cardiac events. Analysis of the 72-h 
12-lead electrocardiographic recordings 
further showed that perioperative heart rate 
variability was significantly higher in patients 
with higher statin doses. These results suggest 
that statins are cardioprotective on a clinical 
and subclinical level.
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Bisoprolol and fluvastatin for the 
reduction of perioperative cardiac 
mortality and myocardial infarction in 
intermediate-risk patients undergoing 
non-cardiovascular surgery; a randomized 
controlled trial (DecReASe-IV).
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ABStRAct
Aims: Beta-blockers and statins reduce perioperative cardiac events in high-risk patients under-
going vascular surgery by restoring the myocardial oxygen supply/demand balance and/or 
stabilizing coronary plaques. This study evaluated the effectiveness and safety of these agents 
in intermediate-risk patients.
Methods and Results: Prior to surgery, 1066 patients were assigned to bisoprolol, fluvastatin, 
combination treatment or control therapy. Intermediate-risk patients were defined by an esti-
mated risk of perioperative cardiac death and myocardial infarction (MI) of 1-6%, using clinical 
data and type of surgery. Starting dose of bisoprolol was 2.5mg daily, titrated to a perioperative 
heart rate of 50-70 beats per minute. Fluvastatin was prescribed in a fixed dose of 80mg. The 
primary endpoint was the composite of 30-day cardiac death and MI.  Patients randomized 
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to bisoprolol (N=533) had a lower incidence 
of the endpoint than those randomized to 
bisoprolol-control (2.1% vs. 6.0% events; HR 
0.34; 95% CI: 0.17-0.67; p=0.002). Patients 
randomized to fluvastatin experienced a 
lower incidence of the endpoint than those 
randomized to fluvastatin-control therapy 
(3.2% vs. 4.9% events; HR 0.65; 95% CI 0.35-
1.10), but statistical significance was not 
reached (p=0.17).
Conclusion: Bisoprolol was associated with 
a significant reduction of 30-day cardiac com-
plications, while fluvastatin showed a trend 
for improved outcome.
Word count: 200
Key Words: beta-blocker, statin, prevention, 
non-cardiac surgery, cardiac death, myocar-
dial infarction
INtRoDUctIoN
Roughly 3.8% of the Netherlands’ popula-
tion undergo non-cardiac surgery annually1. 
Cardiac events are a major cause of periop-
erative morbidity and mortality, resulting in a 
mortality rate of 1%2. A myocardial infarction 
(MI) accounts for 10 - 40% of postoperative 
fatalities3. Both beta-blockers and statins 
reduce perioperative cardiac events in high-
risk patients4-7. The pathophysiology of a fatal 
MI is complex. It can be related to myocardial 
oxygen demand/supply mismatch, due to 
perioperative surgical stress, tachycardia, 
hypertension, and pain8. Alternatively, 
coronary plaque instability and subsequent 
rupture may lead to infarction9. Drugs that 
influence plaque stability and myocardial 
oxygen balance may influence the incidence 
and severity of perioperative MI. Beta-blockers 
improve myocardial oxygenation by decreas-
ing heart rate and myocardial contractility10. 
Additionally, by reducing mechanical and 
shear stresses, beta-blockers may also pro-
mote coronary plaque stability. Additionally, 
beta-blockers might have anti-inflammatory 
effects11. Statins aim at coronary plaque sta-
bilization by decreasing lipids, lipid oxidation, 
inflammation, matrix metalloproteinase and 
cell death, and increasing tissue inhibitor of 
metalloproteinase and collagen12. Both thera-
pies have been associated with improved 
outcome in high-risk surgery. However, 
the vast majority of patients scheduled for 
surgery are at low- and intermediate-risk; 
perioperative incidence of cardiac death and 
MI of <1 and 1-6 percent, respectively. In this 
population, the effect of perioperative beta-
blockers and statins remains undefined. Our 
primary goal was to assess the effectiveness 
and safety of beta-blockers, statins and their 
combination, on the incidence of periopera-
tive cardiac death and myocardial infarction 
in intermediate-risk surgical patients under-
going non-cardiovascular surgery.
MetHoDS
Study design
The DECREASE-IV study was a prospective, 
open-label, multicenter, randomized, con-
trolled trial and was done in accordance with 
the Declaration of Helsinki. The protocol was 
approved by all hospital ethics committees. 
All patients gave written informed consent.
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Study population
The design of DECREASE-IV has been pub-
lished13. Briefly, patients aged ≥ 40 years, who 
were scheduled for elective non-cardiovas-
cular surgery and had an estimated risk for a 
perioperative cardiovascular event between 
≤ 5 % were eligible. The risk-estimation was 
based on clinical characteristics and an elec-
trocardiogram (ECG) 2. Exclusion criteria for 
enrolment were: the use of or a contraindica-
tion for beta-blocker or statin use; emergency 
surgery; inability to provide written informed 
consent; and previous participation in this 
trial. The exclusion of patients on beta-
blocker or statin therapy was based on ethical 
considerations, being unable to withhold the 
use of these medications in the presence of 
an existing indication.
treatment
A 2x2 factorial study design was used14. After 
signing informed consent, patients were ran-
domized on a 1: 1 ratio to receive beta-blocker 
therapy (bisoprolol, Merck KGaA, Darmstadt, 
Germany) or beta-blocker control. Patients 
were also randomized on a 1: 1 ratio to receive 
statin therapy (fluvastatin XL, Novartis, Basel, 
Switzerland) or statin control. Hence, there 
were 4 treatment groups: bisoprolol alone, 
fluvastatin alone, both, or neither (double 
control). Randomization was applied by using 
a computer algorithm, and was stratified 
according to hospital. Study medication was 
started immediately after randomization and 
continued until 30 days after surgery.
The starting dose of bisoprolol was 2.5 mg 
orally per day, if resting heart rate was >50 
bpm. During hospitalization, resting heart 
rate was evaluated on a daily basis and drug 
dose was modified with steps of 1.25 or 2.5 
mg per day, up to a maximum dose of 10 mg, 
aiming at a heart rate of 50 - 70 bpm. The use 
of an open-label design was therefore neces-
sary in order to titrate the bisoprolol dose to 
the therapeutic heart rate. Patients unable to 
take bisoprolol orally received intravenous 
metoprolol until the patient was able to 
switch back to oral medication. Bisoprolol 
administration was temporarily withheld 
if any of the following developed: resting 
heart rate <50 bpm; systolic blood pressure 
<100 mmHg; heart failure; bronchospasm; 
PR interval >0.30 s; second or third degree 
AV block. Fluvastatin was prescribed in a 
fixed daily dose of 80 mg. The “slow-release” 
statin fluvastatin 80 XL was chosen, to over-
come problems in those patients who could 
not take statins early after surgery orally. If 
patients used nasogastric feeding, standard 
fluvastatin therapy was administered. Peri-
operatively, patient treatment was left to the 
attending physician’s discretion as needed, 
with no restrictions imposed.
endpoints
The primary efficacy endpoint was a com-
posite of cardiac death and non-fatal MI until 
30-days after surgery13. MI was defined on the 
basis of cardiac troponins and ECG-measure-
ments, which were systematically collected on 
days 1, 3 and 7 postoperatively and whenever 
clinically indicated. Secondary efficacy end-
points included all-cause mortality, cardiac 
arrythmias, acute heart failure, and coronary 
revascularization. Safety endpoints included 
stroke, clinically significant bradycardia and 
hypotension (bisoprolol), clinically significant 
liver dysfunction or myopathy (fluvastatin). All 
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endpoints that occurred since randomisation 
until 30 days after surgery were counted.
Sample size calculation
The incidence of the primary efficacy endpoint 
in patients randomized to double control was 
estimated at 6.0%. We anticipated a 30% rela-
tive risk reduction (odds ratio 0.7) associated 
with bisoprolol as well as fluvastatin therapy. 
The combination of bisoprolol and fluvastatin 
was anticipated to result in a 50% relative 
risk reduction (odds ratio 0.7*0.7=0.49), 
compared to double control therapy. A total 
of 6000 patients are needed (1500 per group) 
to detect the anticipated risk reduction with a 
power of 81% and a two-sided α of 5%.
In the participating hospitals a total 
of 10,000 patients undergo elective non-
cardiovascular surgery annually. We had 
anticipated that 2,000 of them would be 
eligible and provide informed consent, so 
that patient enrolment would be completed 
within 3 years. Actual enrolment started in 
July 2004 and ended in February 2008. The 
study was terminated early because of slow 
patient recruitment. During the study period, 
roughly 45,000 patients were screened, of 
whom 6,460 met the inclusion criteria. How-
ever, 78% of these otherwise eligible patients 
were receiving beta-blocker or statin therapy, 
instead of the anticipated 20%. Of the remain-
ing patients, 355 did not provide informed 
consent or had previously participated in the 
study, leaving 1066 patients to be included.
Data analysis
The time to the first occurrence of the primary 
efficacy endpoint was determined according 
to the Kaplan-Meier method, and differences 
between allocated groups were evaluated 
by log-rank statistics. The Cox proportional 
hazards (PH) model was applied to obtain 
treatment effects on the primary efficacy end-
point, which are presented as hazard ratio’s 
(HR) and 95% confidence intervals (CI). Cox 
PH models including interaction terms were 
applied to evaluate the effects of bisoprolol 
and fluvastatin treatment in each other’s 
presence or absence. Analyses of other end-
points were based on contingency tables and 
chi-square tests. All analyses were performed 
according to the intention-to-treat principle. 
All statistical tests were 2-sided, and a p-value 
<0.05 was considered significant.
ReSULtS
Patients
A total of 264 patients were randomized to 
bisoprolol therapy, 265 to fluvastatin therapy, 
269 to combination therapy and 268 patients 
to double control therapy. Patient character-
istics are presented in tables 1 and 2. The key 
characteristics were as follows: median age 64 
years; 60% male; 11% diabetes mellitus; 6% 
angina pectoris; 5% prior MI; 4% prior stroke. 
Most common types of surgery were general 
(39%), urological (19%), orthopedic (16%), and 
ear-nose-throat (12%). General anesthesia 
was used in 94%, and 91% of patients were in 
ASA class 1 or 2. The treatment groups did not 
differ with respect to baseline or operative 
characteristics (Tables 1-2).
outcome
The median time between starting medica-
tion and surgery was 34 (21-53) days, with 
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no differences between treatment groups 
(Table 3). Two patients died from non-cardiac 
complications while awaiting surgery. Twenty 
four patients died within 30 days after sur-
gery. Five patients suffered cardiac death and 
38 patients had nonfatal MI within 30 days. 
Thus, 43 (4.0%) patients reached the primary 
efficacy endpoint of cardiac death or nonfatal 
MI (Table 3). Time-to-event curves for the 
primary end point, by treatment group, are 
presented in Figure 1. The incidence of the pri-
mary outcome differed significantly between 
allocated groups, being lowest in the patients 
randomized to bisoprolol alone (1.9%) and 
highest in the patients randomized to double 
control (7.8%).
table 1 – Baseline characteristics, medication use and preoperative 12-lead ECG findings per treatment 
group
Variable Total
(N=1066)
bisoprolol
only
(N=264)
fluvastatin 
only
(N=265)
combination
therapy 
(N=269)
Double 
control
(N=268)
Baseline characteristics
 Male gender (%) 369 (60.0) 160 (60.8) 163 (61.5) 163 (60.8) 153 (57.1)
 Age, years (*IQR) 65.4 (57,74) 66.8 (58,74) 65.4 (59,73) 63.8 (56,74) 65.6 (57,74)
 Diabetes Mellitus (%) 115 (10.8) 29 (11.0) 32 (12.1) 30 (11.2) 24 (9.0)
 Angina Pectoris (%) 55 (5.6) 11 (4.2) 15 (5.7) 14 (5.2) 15 (5.6)
 Myocardial infarction (%) 54 (5.1) 16 (6.1) 16 (6.0) 13 (4.8) 9 (3.4)
 Chronic heart failure (%) 8 (0.8) 3 (1.1) 3 (1.1) 2 (0.7) 0
 Stroke (%) 46 (4.3) 11 (4.2) 10 (3.8) 13 (4.8) 12 (4.5)
 Renal failure (%) 11 (1.0) 2 (0.8) 3 (1.1) 2 (0.7) 4 (1.5)
Medication use
 Diuretics (%) 102 (9.6) 24 (9.1) 20 (7.6) 29 (10.8) 29 (10.8)
 Aspirin (%) 102 (9.6) 26 (9.6) 27 (10.2) 25 (9.3) 24 (9.0)
 Calcium antagonists (%) 34 (3.2) 8 (3.0) 7 (2.6) 11 (4.1) 8 (3.0)
 ACE inhibitors (%) 96 (9.0) 23 (8.7) 26 (9.8) 23 (8.6) 24 (9.0)
 Angiotensin II inhibitors (%) 58 (5.4) 11 (4.2) 16 (6.0) 15 (5.6) 16 (6.0)
 Anticoagulants (%) 48 (4.5) 11 (4.2) 16 (6.0) 12 (4.5) 9 (3.4)
 Antiarrythmics (%) 9 (0.8) 1 (0.4) 2 (0.8) 4 (1.5) 2 (0.8)
 Nitrates (%) 11 (1.0) 1 (0.4) 4 (1.5) 2 (0.7) 4 (1.5)
 Digoxin (%) 15 (1.4) 3 (1.1) 6 (2.3) 1 (0.4) 5 (1.9)
 Oral antidiabetics (%) 78 (7.3) 21 (8.0) 19 (7.2) 20 (7.4) 18 (6.7)
 Insuline (%) 48 (4.5) 7 (2.7) 18 (6.8) 11 (4.1) 12 (4.5)
 Glucocorticoids (%) 88 (8.3) 18 (6.8) 19 (7.2) 31 (11.5) 20 (7.5)
Preoperative 12-lead ECG findings
 Abnormal ECG (%) 487 (45.7) 122 (46.2) 122 (46.0) 124 (46.1) 119 (44.4)
 Atrial fibrillation (%) 15 (1.4) 4 (1.5) 5 (1.9) 3 (1.1) 3 (1.1)
 Right bunble branch block (%) 90 (8.4) 18 (6.8) 21 (7.9) 20 (7.4) 31 (11.6)
 Left bundle branch block (%) 74 (6.9) 18 (6.8) 19 (7.2) 22 (8.2) 15 (5.6)
 Q-waves (%) 103 (9.7) 22 (8.3) 32 (12.1) 27 (10.0) 22 (8.2)
 Left ventricle hypertrophy (%) 83 (7.8) 24 (9.1) 21 (7.9) 22 (8.2) 16 (6.0)
 Right ventricle hypertrophy (%) 1 (0.1) 1 (0.4) 0 0 0
 Preventricular contractions (%) 78 (7.3) 20 (7.6) 24 (9.1) 23 (8.6) 11 (4.1)
*IQR = interquartile range
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comparison of the 533 patients 
allocated to bisoprolol therapy 
with the 533 patients allocated to 
bisoprolol-control therapy
Baseline heart rate was similar in patients 
randomized to bisoprolol and the patients 
randomized to bisoprolol-control, but pre-
operative heart rate was significantly lower in 
patients randomized to bisoprolol (Table 2), 
indicating adequate drug compliance. On the 
day of surgery, the bisoprolol dose was 2.5 mg 
in 99% of patients and 5.0 mg in 1%.
table 2. Surgery details per treatment group
Variable Total
(N=1066)
bisoprolol
only
(N=264)
fluvastatin 
only
(N=265)
combination
therapy
(N=269)
Double
control
(N=268)
Anesthesia
 General (%) 1001 (93.9) 249 (94.3) 246 (92.8) 253 (94.1) 253 (94.4)
 Spinal (%) 29 (2.7) 8 (3.0) 7 (2.6) 7 (2.6) 7 (2.6)
 Local (%) 36 (3.4) 7 (2.7) 12 (4.8) 9 (3.3) 8 (3.0)
Specialism
 General surgery (%) 514 (38.9) 97 (36.9) 96 (36.2) 106 (39.4) 116 (43.3)
 Urology (%) 205 (19.3) 58 (22.1) 53 (20.0) 46 (17.1) 48 (17.9)
 Orthopedics (%) 174 (16.3) 50 (19.0) 43 (16.2) 48 (17.8) 33 (12.3)
 Ear-nose-throat (%) 133 (12.4) 30 (11.4) 30 (11.3) 35 (13.0) 38 (14.2)
 Gynecology (%) 53 (5.0) 8 (3.0) 13 (4.9) 17 (6.2) 15 (5.6)
 Plastic surgery (%) 55 (5.1) 12 (4.6) 22 (8.3) 9 (3.4) 12 (4.5)
 Dental surgery (%) 10 (0.9) 1 (0.4) 4 (1.5) 2 (0.7) 3 (1.1)
 Ophthalmology (%) 10 (0.9) 4 (1.5) 3 (1.1) 1 (0.4) 2 (0.8)
 Other  (%) 10 (0.9) 3 (1.1) 1 (0.4) 5 (1.9) 1 (0.4)
*ASA score
 1 (%) 392 (36.8) 95 (36.0) 96 (36.2) 105 (39.0) 96 (35.8)
 2 (%) 573 (53.8) 144 (54.6) 140 (52.8) 140 (52.0) 149 (55.6)
 3 (%) 101 (9.5) 25 (9.5) 29 (11.0) 24 (8.9) 23 (8.6)
*ASA = American Society of Anesthesiologists
Days after surgery
Cardiac death or myocardial infarction
7.8 % double control
2.2 % combination
4.1 % fluvastatin
1.9 % bisoprolol
0%
2%
4%
6%
8%
0 7 14 21 28
Log-rank p-value 0.001
figure 1 : Incidence of primary study end point by treatment group
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A total of 11 (event rate according to 
the Kaplan-Meier method 2.1%) patients 
allocated to bisoprolol therapy reached the 
primary efficacy endpoint, compared to 32 
(6.0%) allocated to bisoprolol-control (Figure 
2). Hence, bisoprolol therapy was associated 
with a 67% relative reduction in the incidence 
of cardiac death or MI (HR 0.34; 95% CI: 
0.17-0.67; p = 0.002). There was no evidence 
of heterogeneity in the beneficial effect of 
bisoprolol between patients randomized to 
fluvastatin versus fluvastatin-control (p-value 
associated with the interaction term 0.26).
Ischemic stroke occurred in 7 (0.7%) 
patients, of which 4 (0.8%) were randomized 
to bisoprolol and 3 (0.6%) to bisoprolol-
control (p = 0.68). In total, 3 (0.6%) patients 
randomized to bisoprolol reached one other 
beta-blocker-related safety endpoint (heart 
failure clinically significant bradycardia or 
hypotension), compared to 2(0.4%) patients 
randomized to bisoprolol-control (p = 0.65).
comparison of the 534 patients 
allocated to fluvastatin therapy 
with the 532 patients allocated to 
fluvastatin-control therapy
A total of 17 (event rate according to the 
Kaplan-Meier method 3.2%) patients allocated 
to fluvastatin therapy reached the primary 
endpoint, compared to 26 (4.9%) allocated to 
therapy without fluvastatin (Figure 2). Hence, 
a reduction in the incidence of the primary 
endpoint was observed in favor of fluvastatin 
therapy, but statistical significance was not 
reached (HR: 0.65; 95% CI: 0.35-1.20; p = 0.17).
A stroke occurred in 3(0.6%) patients who 
were randomized to fluvastatin therapy and 
in 4 (0.7%) patients randomized to fluvastatin-
control (p = 0.71). In total, 8(1.5%) patients 
Days after surgery
bisoprolol vs. 
bisoprolol-control
Days after surgery
fluvatatin vs. 
fluvastatin-control
Log-rank p-value 0.002 Log-rank p-value 0.17
0%
2%
4%
6%
8%
0 7 14 21 28
0%
2%
4%
6%
8%
0 7 14 21 28
bisoprolol-control
bisoprolol
fluvastatin
fluvastatin-control
figure 2 : Incidence of primary study end point for each individual treatment vs. control
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randomized to fluvastatin therapy had clini-
cally significant liver dysfunction compared 
to 11(2.1%) on fluvastatin-control therapy (p 
= 0.48). No patient experienced myopathy.
DIScUSSIoN
The DECREASE-IV study convincingly dem-
onstrates that treatment with bisoprolol, 
titrated to a perioperative heart rate of 
50-70 beats per minute and initiated at a 
median of 34 days prior to surgery, resulted 
in a significant reduction of perioperative 
cardiovascular complications, particularly MI. 
Only 26 patients need to receive bisoprolol 
prophylaxis to prevent one perioperative 
cardiac event. This study was not able to 
demonstrate a significant reduction in cardio-
vascular complications by fluvastatin therapy. 
However, we appreciate that – due to its early 
termination – DECREASE-IV lacked statistical 
power to reveal clinically relevant differences 
in this respect. Slow enrolment occurred due 
to the fact that 78% of the patients who met 
the inclusion criteria were on beta-blocker 
and/or statin therapy, as opposed to the esti-
mated 10% of patients receiving beta-blocker 
and 10% receiving statin therapy.
Beta-blocker therapy for 
perioperative cardiac risk reduction
Although widely prescribed, there is still 
considerable debate about the protective 
effect of beta-blockers, with several studies 
showing a benefit of perioperative beta-
blocker treatment 2-5, while others found no 
cardioprotective effect15-17. The POISE study 
showed, similar to DECREASE-IV, that beta-
blocker therapy reduced the risk of MI but 
increased the incidence of stroke and overall 
mortality, a finding that was not confirmed in 
DECREASE-IV18,19. There are two major design 
differences between DECREASE-IV and POISE 
that may explain the differential findings: 
dose titration and timing of therapy.
It is well-known that initiation time and 
dose titration influence the effectiveness 
of perioperative beta-blocker therapy. The 
effects of acute beta-blockade include a 
reduction of myocardial oxygen demand. 
However, a beneficial effect of beta-blockade 
on coronary plaque stability, related to 
sustained mechanical and anti-inflammatory 
effects, might require weeks to develop. 
Prolonged beta-blockade has been shown to 
decrease the level of inflammatory cytokines 
both in the myocardium and the systemic 
circulation11,20,21, as well as decreasing the 
progression of coronary atherosclerosis22. 
Additionally, it seems crucial to continue beta-
blockers postoperatively. It has been shown 
that withdrawal of beta-blocker therapy early 
after surgery was associated with a 2.7-fold 
increased risk of 1-year mortality compared 
to patients not using beta-blockers23.
In addition to initiation time, dose adjust-
ment for heart rate control is important in 
beta-blocker therapy24. Accordingly, the 
new ACC/AHA guidelines on perioperative 
care strongly recommend achieving and 
maintaining a heart rate of 60-65 beats per 
minute25. The POISE trial initiated meto-
prolol treatment just before surgery and the 
maximum recommended therapeutic dose 
(MRTD) was achieved within the first day of 
treatment18. In contrast, the DECREASE stud-
ies employed a relatively low bisoprolol dose 
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(12.5% of MRTD) that was carefully titrated 
during approximately 30 days5,13,26. Notably, 
the POISE trial observed a 1% incidence of 
stroke in the group randomized to metoprolol 
compared to 0.5% in the control group. In 
comparison the incidence of stroke was 0.4% 
in the DECREASE studies, with no difference 
between groups.
The outcome of these studies suggest 
that two different treatment protocols apply-
ing beta-blockers are effective in reducing 
perioperative cardiac complications; one 
prescribing a high dose immediately prior to 
surgery, the other a dose titration approach 
over a prolonged period. However, the car-
dioprotective effect of the high dose regimen 
comes at the cost of an increased incidence of 
side effects, such as stroke.
Statin therapy for perioperative 
cardiac risk reduction
Statins are widely prescribed in patients with 
or at risk of coronary artery disease (CAD) 
because of their lipid lowering capacity. 
Beyond this property, statins may stabilize 
coronary artery plaque and thereby prevent 
plaque rupture and subsequent MI in the 
perioperative period27.
Multiple large clinical trials and observa-
tional studies have demonstrated a beneficial 
effect of perioperative statin use6,7,28-30. The 
first prospective, randomized controlled, 
clinical trial evaluating the effects of statin 
therapy on perioperative cardiovascular 
complications was performed by Durazzo et 
al.7 After six months follow-up, the incidence 
of cardiovascular events was more than 3-fold 
higher with placebo than with atorvastatin 
(26% vs. 8%, p=0.031).
A major concern of statin therapy is the 
potential for side effects including myopathy 
and rhabdomyolysis. In a retrospective study, 
Schouten et al. studied the potential risk of 
myopathy from perioperative statin therapy31. 
After correcting for cardiac risk factors and 
clinical risk factors for myopathy, length of 
surgery remained the only factor indepen-
dently associated with creatine kinase eleva-
tions. Rhabdomyolysis was not observed31. 
Considering that the risk of perioperative 
cardiovascular complications is far greater 
than the risk of statin-induced myopathy 
and rhabdomyolysis, the potential benefits 
of perioperative statin use seem to outweigh 
the hazards. However, despite a numerical 
reduction in cardiac events in patients on 
fluvastatin therapy, statistical significance was 
not achieved in this study. Larger randomized 
controlled trials investigating perioperative 
statin therapy are indicated.
Limitations
A potential limitation of this study was is its 
open-label design and lack of blinding, with 
a consequent risk of treatment bias. However, 
since beta-blocker therapy cannot be titrated 
to heart rate in a double-blind setting, an 
open-label design was employed. In addition, 
the recognizable hemodynamic effects of 
bisoprolol potentially decrease the effective-
ness of a double-blind design. The statin arms 
of this study were also not blinded as this 
would severely complicate the 2 by 2 study 
design.  Finally, the study was terminated 
before the target sample size was achieved, 
with a resultant decrease in statistical power. 
This may explain the failure to achieve 
statistical significance regarding the efficacy 
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of fluvastatin therapy. Therefore, further 
large, randomized controlled trials of statin 
therapy are indicated. Finally, our results are 
applicable only to intermediate-risk patients 
undergoing non-cardiovascular surgery and 
are not applicable to the large population of 
low-risk patients.
coNcLUSIoN
Although, the identification of patients at risk 
has improved recently, no widely applicable 
perioperative cardiovascular risk reduction 
strategies for intermediate-risk patients have 
been developed. The current trial demon-
strates that bisoprolol treatment, begun one 
month preoperatively, and titrated to heart 
rate, significantly reduces the incidence of 
perioperative cardiac death and MI, without 
increasing morbidity or non-cardiac mortal-
ity. This represents a significant advance 
in the management of this sizable patient 
population.
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APPeNDIx
The members of the DECREASE (Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress 
Echocardiography) IV Study Group and the participating centers were as follows:
Steering Committee: D Poldermans, E Boersma, FJ ten Cate, J Klein, MRHM van Sambeek; Statistical 
analysis: E Boersma; Data-base management: M Dunkelgrun; Adverse-Events Committee: P Klootwijk, and D 
Poldermans; Safety Committee: ML Simoons, and H van Urk.
Participating centers:
-Rotterdam, the Netherlands: Erasmus University Medical Center (M Dunkelgrun, E Boersma, O Schouten, 
D Goei, S Hoeks, TA Winkel, RT van Domburg, YRBM van Gestel, GMJM Welten, W Siphanto, L Visser, D 
Poldermans);
-Dordrecht, the Netherlands: Albert Schweitzer Ziekenhuis (AWMM Koopman-van Gemeren);
-Delft, the Netherlands: Reinier de Graaf Gasthuis (F van Poorten);
-Utrecht, the Netherlands: University Medical Center Utrecht (C Kalkman);
-Winipeg, AB, Canada: University of Alberta (IR Thomson).
table 3. Treatment information, primary and secondary study end points per treatment group
Variable Total
(N=1066)
bisoprolol
only
(N=264)
fluvastatin 
only
(N=265)
combination
therapy
(N=269)
Double
control
(N=268)
p-value
Treatment information
 *Time to surgery, days (IQR) 34 (21,53) 34.5 (22,52) 36 (22,56) 35 (20,52) 34 (20,53) 0.88
 Heart rate at screening, bpm (IQR) 77 (70,85) 76.5 (71,84) 77 (68,85) 77 (72,85) 77 (67,87) 0.60
 Heart rate preoperative, bpm (IQR) 68 (62,76) 64 (60,68) 78 (68,84) 65 (62,68) 76 (68,84) <0.001
 Heart rate difference, bpm (IQR) -8 (-14,0) -12 (-21,-7) 0 (-7,6) -12 (-19,-8) 0 (-8,6) <0.001
Primary end points
†Cardiac death or MI (%)† 43 (4.0) 5 (1.9) 11 (4.1) 6 (2.2) 21 (7.8) 0.001
 Myocardial infarction (%) 38 (3.6) 5 (1.9) 9 (3.4) 6 (2.2) 18 (6.7) 0.01
 30-day total mortality (%) 26 (2.4) 3 (1.1) 7 (2.6) 7 (2.6) 9 (3.4) 0.41
  Cardiac (%) 5 (0.5) 0 2 (0.8) 0 3 (1.1) 0.15
  Sepsis (%) 11 (1.0) 3 (1.1) 2 (0.8) 4 (1.5) 2 (0.7) 0.80
  Other (%) 10 (0.9) 0 3 (1.1) 3 (1.1) 4 (1.5) 0.31
Secondary end points
 Hospital stay, days (IQR) 8 (5,15) 8.5 (5,14) 8 (5,15) 8 (5,14) 9 (5,15) 0.71
‡ICU admittance (%) 213 (20.0) 53 (20.1) 52 (19.6) 50 (18.6) 58 (21.6) 0.85
‡ICU stay, days (IQR) 2 (1,6) 2 (2,5) 3 (1,11) 2 (1,4) 2 (1,4) 0.68
 Arrhythmia (%) 9 (0.8) 2 (0.8) 3 (1.1) 1 (0.4) 3 (1.1) 0.74
 Heart failure (%) 3 (0.3) 1 (0.4) 1 (0.4) 0 1 (0.4) 0.79
 Revascularization (%) 1 (0.1) 0 1 (0.4) 0 0 0.39
* IQR = interquartile range, † MI = myocardial infacrtion, ‡ ICU = intensive care unit
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ABStRAct
Background: Perioperative beta-blocker therapy is associated with a reduction in cardiac 
events. However, concerns exist regarding beta-blocker use in patients undergoing esophagec-
tomy because of a possible increased risk of ischemia and leakage of the esophagogastric 
anastomosis. Therefore we selected patients from the randomized DECREASE IV undergoing 
esophagectomy and evaluated the efficacy and safety of beta-blocker therapy.
Method: A total of 101 patients scheduled for esophagectomy were randomized to beta-blocker 
therapy (n=52) or no beta-blocker therapy (n=49). Postoperatively data on troponin release 
and ECG were collected on day 1, 3, 7, before discharge, and on day 30. Results of radiology, 
gastroscopy, and clinical signs of ischemia or leakage of the esophagogastric anastomosis were 
noted.
Results: Beta-blocker use was associated with a reduction in the combination of myocardial 
damage, myocardial infarction and cardiac death (16% vs 4%, p=0.04). The rate of radiologic 
anastomotic leakage was similar in both groups (16% vs 16%, p=0.96), as well as the rate of 
ischemia at  gastroscopy (26% vs 17%, p=0.32) and the number of reoperations (16% vs 14%, 
p=0.69).
Conclusion: Perioperative beta-blocker use in patients undergoing esophagectomy is associ-
ated with a reduction in cardiac events and is not associated with an increased risk for ischemic 
complications.
1Department of Surgery, Erasmus MC, 
Rotterdam, the Netherlands; 2Department 
of Anesthesiology, Erasmus MC, Rotterdam, 
the Netherlands; 3Department of Cardiology, 
Erasmus MC, Rotterdam, the Netherlands
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INtRoDUctIoN
Patients undergoing major non-cardiac 
surgery are at significant risk of cardiovas-
cular morbidity and mortality. Although the 
perioperative event rate has declined over the 
past 30 years, 30-day cardiovascular mortality 
in major non-cardiac surgery remains as high 
as 3% to 6%1. Myocardial infarction (MI) is 
the most frequent fatal complication in this 
respect, accounting for up to 50% of postop-
erative fatalities2,3.
Due to the role of sympathetic activation 
in adverse perioperative cardiac outcomes, 
beta-adrenergic receptor blocking drugs 
have been proposed as a means for providing 
cardioprotection. Potential cardioprotec-
tive mechanisms of beta-blockers include a 
reduced heart rate and contractility and sub-
sequently lower myocardial oxygen demand; 
a shift in energy metabolism from free fatty 
acids to the more energy efficient glucose; 
anti-arrhythmic effects;  anti-renin/angio-
tensin properties; and anti-inflammatory 
effects possibly promoting plaque stability4,5. 
Several studies have suggested that periop-
erative beta-blocker use is indeed associated 
with a reduction of perioperative cardiac 
complications in patients at high cardiac 
risk6,7.
According to the recent ACC/AHA guidelines 
patients undergoing esophagectomy for 
cancer are at increased risk for perioperative 
events8. Therefore this group of patients 
might benefit from perioperative beta-blocker 
therapy. However, there are serious concerns 
on the safety of perioperative beta-blocker 
use in this patient population. The blood flow 
to the new esophagogastric anastomosis 
after esophagectomy is of critical importance 
and might be compromised by the use of 
beta-blockers. Consequently this might lead 
to an increased incidence of anastomotic 
leakage and reoperation, resulting in major 
morbidity.
The randomized Dutch Echocardiographic 
Cardiac Risk Evaluation Applying Stress 
Echocardiography IV study (DECREASE IV) was 
set up to test whether patients at intermediate 
cardiac risk benefit from perioperative beta-
blocker and/or statin therapy. We used data of 
patients undergoing esophagectomy in this 
study  to evaluate the possible cardioprotec-
tive effect of beta-blocker use and assess the 
safety of beta-blockers after esophagectomy.
MetHoDS
Patient population
The study design of the DECREASE IV study 
has been published previously9. A total of 
1,066 patients were randomized for the 
DECREASE IV trial and received either periop-
erative beta-blocker therapy, statin therapy, 
both or neither10. For the current study we 
selected those patients who underwent 
esophagectomy for cancer, either by means 
of extended transthoracic resection or by 
limited transhiatal resection, and compared 
patients who were allocated to perioperative 
beta-blocker therapy (with or without statins) 
or no beta-blocker therapy (with or without 
statins).
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Briefly, patients who were (1) aged 40 years 
or older, (2) scheduled for elective noncardiac 
surgery and (3) have an estimated risk for 
cardiovascualar death of more than 1%, were 
eligible for enrollment in in the DECREASE-IV 
trial. Importantly, according to the ACC/AHA 
2007 guidelines on perioperative cardiovas-
cular evaluation and care for noncardiac sur-
gery8 esophagectomy should be considered 
an intermediate risk surgical procedure with a 
cardiac risk of >1%.
Exclusion criteria for the trial were: (1) current 
use of beta-blockers, (2) contraindication for 
beta-blocker use, (3) the use of statins prior 
to randomisation, (4) a contraindication for 
statin use, (5) unstable coronary artery dis-
ease, (6) extensive stress induced myocardial 
ischemia suggestive for left main disease or 
equivalent, (7) emergency surgery, (8) previ-
ous participation in the same trial study, (9) 
unability or unwillingness to provide written 
informed consent.
Beta-blocker treatment regimen
The starting dose of bisoprolol, a so-called 
cardioselective beta-blocker, was 2.5 mg 
orally per day, if resting heart rate was >50 
bpm. During hospitalization, resting heart 
rate was evaluated on a daily basis and drug 
dose was modified with steps of 1.25 or 2.5 
mg per day, up to a maximum dose of 10 mg, 
aiming at a heart rate of 50 - 70 bpm. The use 
of an open-label design was therefore neces-
sary in order to titrate the bisoprolol dose to 
the therapeutic heart rate. Patients unable to 
take bisoprolol orally received intravenous 
metoprolol until the patient was able to 
switch back to oral medication. Bisoprolol 
administration was temporarily withheld if 
any of the following developed: resting heart 
rate <50 bpm; systolic blood pressure <100 
mmHg; heart failure; bronchospasm; PR inter-
val >0.30 s; second or third degree AV block.
efficacy endpoint
The efficacy endpoint for the current study 
was a composite of myocardial damage, 
assessed by cardiac troponin T (cTnT) release, 
cardiac death and non-fatal myocardial infarc-
tion (MI) until 30-days after surgery. Cardiac 
troponin T  was sampled systematically on 
days 1, 3 and 7 postoperatively and whenever 
clinically indicated. Additionaly ECGs were 
collected on the same days. Nonfatal MI 
required any of the following: (1) characteris-
tic ischemic symptoms lasting > 20 minutes; 
(2) ECG changes including acute ST elevation 
followed by appearance of Q waves or loss of 
R waves, or new left bundle branch block, or 
new persistent T wave inversion for at least 24 
hours, or new ST segment depression which 
persists for at least 24 hours; (3) a positive 
troponin T measurement with characteristic 
rise and fall11. All deaths were classified as 
either cardiovascular or non-cardiovascular. 
Cardiovascular death is defined as any death 
with a cardiovascular complication as the 
primary or secondary cause, and includes 
deaths following myocardial infarction, car-
diac arrhythmia, resuscitation, heart failure, or 
stroke. Non-cardiovascular death is defined as 
any death with a primary non-cardiovascular 
cause, including surgery-related bleeding 
complications, cancer, trauma and infection. 
Sudden death in a previously stable patient is 
considered as cardiovascular12.
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Safety endpoint
The safety endpoints for the current analysis 
consisted of radiologic anastomotic leakage, 
clinical anastomotic leakage or infection of 
the cervical wound requiring opening of the 
wound, signs of ischemia during gastroscopy, 
and reoperation. It should be noted that 
these endpoints were not pre-specified in the 
original DECREASE IV study design. Data on 
these safety endpoints were identified inde-
pendently by two investigators by meticulous 
screening of medical charts, radiology reports 
and reports of gastroscopy. If consensus 
could not be reached, the opinion of a third, 
independent investigator was final.
StAtIStIcAL ANALySIS
Continuous data are presented as median 
values and corresponding 25th and 75th 
percentiles, whereas dichotomous data are 
presented as percentages. Differences in 
clinical characteristics between patients with 
or without beta-blocker therapy evaluated by 
Wilcoxon’s nonparametric tests, Chi-square 
tests or Fisher’s exact tests, as appropriate. 
Differences in the incidence of the endpoints 
were evaluated by a Chi-square test or Fisher’s 
exact tests. The limit of statistical significance 
was set at P = 0.05 (two sided). All analysis 
was performed using the statistical software 
SPSS for Windows 15.0.1 (SPSS Inc., Chicago, 
Illinois, USA).
ReSULtS
Baseline characteristics
A total of 101 patients underwent esophagec-
tomy, 72 by transhiatal resection and 29 
by transthoracic resection. Baseline clinical 
characteristics are shown in table 1. Due to 
randomization there were no statistically 
significant differences in baseline charac-
teristics and medication use. Preoperative 
ECG abnormalities were found in 39 (39%) 
patients; q-waves in 10 (10)%, right bundle 
branch block in 8 (8%), left bundle branch 
block in 5 (5%), left ventricular hypertrophy 
in 4 (4%), and preventricular contractions 
in 6 (6%). Heart rate was similar at baseline 
in both groups, ie 77 ± 12.4 beats/min in 
patients allocated to beta-blocker therapy 
and 80 ± 12.7 beats/min in patients allocated 
to the control group. Importantly at the day 
of hospital admission, median 34 days after 
the start of beta-blocker therapy,  patients on 
beta-blocker therapy had a significantly lower 
mean heart rate (62 ± 7.4 beats/min vs 79 ± 
12.6 beats/min, p<0.001).
Perioperative cardiac outcome
A total of 10 (9.9%) patients reached the 
combined efficacy endpoint of myocardial 
damage, myocardial infarction and cardiac 
death. Patients on beta-blocker therapy had 
a significant reduced risk for perioperative 
events; 3.8% vs 16.3% (OR 0.21, 95% CI 0.04-
0.98, p=0.036, figure 1).  The majority of car-
diac events was asymptomatic. If no routine 
sampling of cTnT would have been performed 
8 out of 10 events would have been missed. 
Of the 10 patients who reached the com-
bined efficacy endpoint 5 met the criteria for 
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myocardial infarction. All of these patients 
were allocated to the control group.
Safety outcome
The safety outcomes are shown in table 2. Of 
the 101 patients 87 (86%) underwent X-ray 
with contrast. There was no difference in the 
incidence of radiological anastomotic leak-
age; 7/44 (15.9%) patients on beta-blockers 
vs 7/43 (16.3%) patients not on beta-blockers 
(p=0.96). Clinical leakage or infection of 
the cervical wound requiring opening of 
the wound was scored in 19 patients, 9/52 
(17.3%) vs 10/49 (20.4%) for users and non-
users respectively (p=0.69). Gastroscopy was 
performed in 91 (91%) patients. Ischemia was 
found in 8/48 (16.7%) using beta-blockers 
and in 11/43 (25.6%) of patients not using 
beta-blockers (p=0.32). In total 15 (16.8%) 
patients underwent reoperation, 7/52 (13.5%) 
beta-blocker users and 8/49 (16.3%) non-
users (p=0.69). Overall 41 (40.6%) patients 
had either a radiological and/or clinical 
anastomotic leakage and/or ischemia during 
gastroscopy or a reoperation. There was no 
difference in the incidence of the combined 
table 1. Baseline characteristics and medication use per treatment group.
Beta-blocker
(N=52)
control
(N=49)
P-value
Baseline characteristics
 Male gender (%) 46 (85) 37 (76) 0.23
 Age, years (IQR) 64.5 (56,72) 61.8 (57,71) 0.64
 Diabetes Mellitus (%) 3 (6) 5 (10) 0.48
 Angina Pectoris (%) 1 (2) 3 (6) 0.35
 Myocardial infarction (%) 2 (4) 3 (6) 0.67
 Chronic heart failure (%) 1 (2) 0 1
 Stroke (%) 1 (2) 0 1
 Renal failure (%) 0 0 1
Medication use
 Statins (%) 24 (46) 21 (42) 0.67
 Diuretics (%) 4 (8) 2 (4) 0.68
 Aspirin (%) 4 (8) 1 (2) 0.36
 Calcium antagonists (%) 2 (4) 0 0.50
 ACE inhibitors (%) 5 (10) 4 (4) 0.44
 Angiotensin II inhibitors (%) 3 (6) 2 (4) 1
 Anticoagulants (%) 1 (2) 1 (2) 1
 Oral antidiabetics (%) 1 (2) 1 (2) 1
 Insuline (%) 1 (2) 4 (8) 0.20
 Glucocorticoids (%) 4 (8) 4 (8) 1
*IQR denotes interquartile range; ACE denotes angiotensin converting enzyme
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safety endpoint between both groups; 38.5% 
vs 42.9% for users and non-users respectively 
(p=0.65).
DIScUSSIoN
The current study shows that perioperative 
beta-blocker therapy in patients undergoing 
esophagectomy for cancer is associated with 
a reduction in cardiac events. Importantly 
the blood flow to the gastroesophageal 
anastomosis seems not to be affected by the 
use of selective beta-blockers as the rate of 
anastomotic leakage and ischemia is similar 
in users and non-users.
Patients undergoing major non-cardiac 
surgery are at increased risk for perioperative 
cardiac events even if the number of clinical 
risk factors is limited. As described in the 
ACC/AHA guidelines esophagectomy should 
be considered an intermediate risk surgi-
cal procedure in terms of cardiac risk8. The 
pathophysiology of perioperative cardiac 
events is complex and not fully understood. 
However, similar to the non-operative setting 
two mechanisms seems to be involved in 
most cases: (1) coronary plaque rupture lead-
ing to thrombus formation and subsequnt 
vessel occlusion, and (2) increased myocar-
dial oxygen demand (e.g., tachycardia and 
increased contractility) leading to myocardial 
oxygen supply/demand mismatch that when 
sustained might lead to myocardial infarction. 
In patients undergoing noncardiovascular 
surgical procedures in particular the latter 
mechanism seems to play an important role. 
Due to the role of myocardial oxygen/supply 
mismatch in adverse perioperative cardiac 
outcomes, beta-adrenergic receptor blocking 
drugs have been proposed as a means for 
providing cardioprotection. In particular beta-
blockers reduce heart rate and contractility 
and subsequently lower myocardial oxygen 
demand, cause a shift in energy metabolism 
from free fatty acids to the more energy 
efficient glucose, have anti-arrhythmic effects 
and some other potentially cardioprotective 
characteristics.
Large series of patients undergoing 
esophagectomy have shown cardiac compli-
cation rates, such as myocardial infarction, 
of approximately 1%13-15. It must be noted 
however that in these studies there was no 
systematic screening for adverse cardiac 
events such as the frequent sampling of 
cardiac troponins which was performed in 
the current study. This might explain why the 
table 2. Safety outcome
Beta-blocker control P-value
Radiological anastomotic leakage 7/44 7/43 0.96
Clinical leakage or infection of the cervical wound 17.3% 20.4% 0.69
Ischemia at gastroscopy 8/48 11/43 0.32
Reoperation, any 13.5% 16.3% 0.69
Reoperation, because of ischemia 5.8% 6.1% 1.0
Combined 38.5% 42.9% 0.65
Combined is the comination of radiological anastomotic leakage, clinical leakage or infection of the 
cervical wound , ischemia at gastroscopy, and reoperation.
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event rate in the current study was higher 
than what has been reported in literature so 
far. It should be noted that 80% of periopera-
tive cardiac events in the current study would 
have been missed if routine sampling of cTnT 
had not been performed. In postoperative 
patients, symptoms of cardiac complications 
might very well be atypical or absent even 
when ECG and/or biomarkers are abnormal. It 
is important to realize that myocardial infarc-
tion might occur with atypical symptoms, 
or even without symptoms, being detected 
only by ECG, biomarker elevations, or cardiac 
imaging. Classical symptoms of myocardial 
ischemia include various combinations of 
chest, upper extremity, jaw, or epigastric 
discomfort with exertion or at rest. Often, 
the discomfort is diffuse, not localized, not 
positional, not affected by movement of 
the region, and it may be accompanied by 
dyspnea, diaphoresis, nausea, or syncope. 
Considering these classical symptoms it is 
hardly surprising that such a large number of 
episodes of myocardial ischemia and infarc-
tion are missed in the perioperative period 
because symptoms are masked by residual 
anaesthetic effects, administration of analge-
sic agents, competing somatic stimuli such as 
incisional pain, and other factors.
Though beta-blockers have shown to be 
effective in reducing the risk of cardiac 
events, they have also been linked to serious 
adverse events in the perioperative period. 
The recently published POISE trial showed 
that starting high doses of metoprolol hours 
before surgery resulted in an increased risk 
for postoperative stroke16. Most of these 
strokes seem to have been attributable to 
perioperative episodes of hypotension which 
might have been caused by beta-blocker use. 
On the other hand, in the DECREASE trials, 
starting bisoprolol at a relatively low dose 
of 2.5 mg approximately 30 days prior to 
surgery, there was no association between 
beta-blocker use and perioperative stroke17. 
Similar to the brain the new gastroesopha-
geal anastomosis after esophagectomy is 
vulnerable for hypotensive episodes. These 
episodes my may lead to a insufficient blood 
flow to the anastomosis resulting in ischemia 
and subsequently leakage of the anastomo-
sis. This fear might prevent the prescribtion of 
perioperative beta-blocker therapy in these 
patients. However, as shown in the current 
study, a regimen of perioperative beta-
blocker use starting low dose cardioselective 
beta-blockers approximately 30 days prior to 
surgery did not result in an increased risk for 
anastomotic leakage or ischemia nor in an 
increased risk for reoperation.
In conclusion, though the number of studied 
patients is relatively small, patients undergo-
ing esophagectomy seem to benefit from 
perioperative beta-blocker therapy as it is 
associated with improved cardiac outcome 
while the gastroesophageal anastomosis is 
not compromised.
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Summary and conclusion
In this thesis, factors influencing cardiac risk identification in patients scheduled for elective 
non cardiac surgery and medical interventions aimed at cardiac risk reduction are described.
Chapter one describes the pathophysiology of perioperative myocardial infarction (PMI). Peri-
operative myocardial infarction is one of the most important predictors of short- and long-term 
morbidity and mortality associated with non-cardiac surgery. Although the perioperative event 
rate has declined over the past decades as a result of achievements in anesthesiologic and surgi-
cal techniques, perioperative complications remain a significant problem. The pathophysiology 
of perioperative cardiac events is complex and not fully understood. However, similar to the 
non-operative setting two mechanisms seems to be involved in most cases: (1) coronary plaque 
rupture leading to thrombus formation and subsequnt vessel occlusion, and (2) increased myo-
cardial oxygen demand (e.g., tachycardia and increased contractility) leading to myocardial 
oxygen supply/demand mismatch that when sustained might lead to myocardial infarction. In 
patients undergoing non cardiac surgical procedures in particular the latter mechanism seems 
to play an important role.
cADIAc RISk IDeNtIfIcAtIoN
Chapter two describes a retrospective cohort study 3381 patients who underwent dobutamine 
stress echocardiography (DSE). A hypotensive response during DSE was defined as mild (MHR) 
when systolic blood pressure (SBP) dropped < 20 mmHg between rest and peak stress, and 
severe (SHR) when SBP dropped < 20 mmHg. End points were all cause mortality and major 
adverse cardiac events (MACE). MHR and SHR occurred in 936 (28%) and 521 (15%) patients, 
respectively. During follow-up of 4.5 (± 3.3) years, 920 patients died, of which 555 due to cardiac 
causes, and 713 patients experienced a MACE. After adjustment for baseline characteristics and 
DSE results SHR during DSE was independently associated with increased long term cardiac 
death (HR: 1.3, 95% CI: 1.03-1.6) and MACE (HR: 1.34, 95% CI: 1.1-1.6), while MHR was not associ-
ated with a worse outcome.
In chapter three, the effect of methionine loading on the predictive value of homocysteine 
serum testing is evaluated in a large observational cohort study in 1122 patients with suspected 
or known vascular disease. Elevated levels of homocysteine are associated with atherosclerotic 
disease. Methionine loading can be used to stress the homocysteine metabolism pathways and 
thereby detect mild disturbances in enzyme activity not registered by fasting homocysteine 
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levels alone. This study investigated the beneficial effect of methionine loading on the predic-
tive value of serum homocysteine testing for long term mortality and major adverse cardiac 
events. During a mean follow-up of 8.9 years, 98 patients died (8.7%), 86 had a major adverse 
cardiac event (7.7%). In multivariate analysis, overall survival and major adverse cardiac event 
free survival were significantly worse for those with fasting hyperhomocysteinemia, with hazard 
ratios of 1.86 (95% confidence interval; 1.20-2.87) and 2.24 (95% confidence interval; 1.41-3.53), 
respectively. The presence of post-methionine hyperhomocysteinemia did not significantly 
alter risk of death or major adverse cardiac events in patients with normal or raised fasting 
homocysteine levels, respectively. In conclusion, methionine loading does not improve the 
predictive value of homocysteine testing with regard to long-term mortality or major adverse 
cardiac events.
Preoperative screening in patients without a history of DM includes fasting glucose measure-
ment. However, an oral glucose tolerance test (OGTT) could significantly improve the detection 
of DM and impaired glucose tolerance (IGT) and the prediction of perioperative cardiac events. 
Chapter four describes a prospective study, in which 404 consecutive patients without signs 
or history of IGT or DM were included and subjected to OGTT. Primary study endpoint was the 
incidence of perioperative myocardial ischemia. The primary endpoint was noted in 21% of 
the patients.  IGT was diagnosed in 104 patients (25.7%) and new onset DM was detected in 
43 patients (10.6%). The OGTT detected 75% of the patients with IGT and 72% of the patients 
with DM. Preoperative glucose levels significantly predicted the risk for perioperative cardiac 
ischemia, odds ratios for DM and IGT were respectively 3.2, 95% CI: 1.3-8.1, and 1.4, 95% CI: 
0.7-3.0. In conclusion, prevalence of undiagnosed IGT and DM are high in vascular patients and 
is associated with perioperative myocardial ischemia. Therefore an OGTT should be considered 
for all patients undergoing elective vascular surgery.
Chapter five describes the long-term results of the patients evaluated in chapter four. During a 
median follow-up of 3.0 years, 128 patients experienced a cardiovascular event.  Patients with 
IGT showed a significant increase in cardiovascular events in both univariate (HR 2.45, 95% C.I. 
1.65-3.63, p<0.001) and multivariate analysis (HR 2.77, 95% C.I. 1.83-4.20, p<0.001). Patients with 
DM showed a non-significant increase in cardiovascular events, indicating an under-treatment 
of vascular surgery patients with IGT. In conclusion, vascular surgery patients with IGT or DM 
detected by pre-operative OGTT, have a significant increased risk of developing cardiovascular 
events during long-term follow-up. It is recommended that non-diabetic vascular surgery 
patients should be tested for glucose regulation disorders prior to surgery.
Anemia is common in patients scheduled for vascular surgery and is a risk factor for adverse 
cardiac outcome. Since it is unknown whether anemia is a primary risk factor for poor cardiac 
outcome, or whether it is secondary to other underlying comorbidities, anemia has not been 
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included as a factor for cardiac risk assessment in the preoperative setting. In chapter six, the 
independent contribution of anemia to the risk of perioperative and long term cardiac outcome 
was assessed in 1211 patients (77% male, age 68 ± 11 years). Anemia was divided into tertiles 
to compare mild (haemoglobin levels in men 12.2-13 g/dl, women 11.2-12g/dl), moderate 
(haemoglobin levels in men 11-12.1 g/dl, women 10.2-11.1 g/dl) and severe (haemoglobin 
levels in men 7.2-11 g/dl, women 7.5-10.1 g/dl) with non-anemic patients. Outcome measures 
were 30-day and 5-year MACE. The presence of anemia was associated with renal dysfunction, 
diabetes and heart failure. After adjustment for all clinical risk factors, patients with anemia had 
an independent increased risk for 30-day and 5-year MACE. Therefore, anemia might be used 
for preoperative cardiac risk assessment in vascular patients.
Hyperuricemia has been associated with an increased incidence of cardiovascular events. In 
chapter seven, the independent contribution of preoperative serum uric acid levels to the risk 
of 30-day and late mortality and MACE was examined in 936 patients (76% male, age 68 ± 11 
years) vascular surgery patients. Hyperuricemia was defined as serum uric acid >0.42 mmol/l 
for men and >0.36 mmol/l for women. Hyperuricemia was present in 299(32%) patients. The 
presence of hyperuricemia was associated with heart failure, chronic kidney disease and the 
use of diuretics. Perioperatively, 46(5%) patients died and 61(7%) patients experienced a MACE. 
Mean follow-up was 3.7 years (range: 0-17 years). During follow-up, 282 (30%) patients died and 
170(18%) patients experienced a MACE. After adjustment for all clinical risk factors, the presence 
of hyperuricemia was not significantly associated with an increased risk of 30-day mortality or 
MACE, but was a significant predictor of late mortality and MACE, Therefore, hyperuricemia 
should be added as a risk factor for long term cardiac risk assessment in vascular patients.
cARDIAc RISk ReDUctIoN
Niaspan®, a prolonged-release nicotinic acid, was evaluated during the Niaspan®-induced 
HDL-Elevation for Optimizing Risk Control (NEMO) study in the Netherlands and is described 
in chaspter eight.
NEMO was a 6-month, prospective, observational, multicentre, open-label study. Niaspan® 
was prescribed in statin-treated patients with known or suspected atherosclerotic disease. The 
main outcome was treatment-related adverse drug reactions (ADRs) and effects on lipids and 
cardiovascular risk score based on the algorithm derived from the Prospective Cardiovascular 
Münster [PROCAM] study.
In total, 612 patients were included in the Netherlands. Flushing was the most common 
ADR (29% of patients during the first month of treatment). Main reasons for treatment discon-
tinuation were flushing, patient request, and lost to follow-up. About half of all patients (52%) 
continued treatment after the study. Tolerability was rated “good” or “very good” in 54% of these 
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patients. HDL-cholesterol increased with 23% from baseline and triglycerides were reduced by 
16%, with little change in LDL- or total cholesterol. Cardiovascular risk score was reduced by 3.3 
score points. In conclusion, the use of the prolonged-release nicotinic acid Niaspan® in patients 
with or at risk for atherosclerotic disease showed good tolerability and a marked increase in 
HDL-cholesterol and reduced cardiovascular risk score.
Chapter nine examines whether higher statin doses and lower low-density lipoprotein (LDL)-
cholesterol are associated with improved cardiac outcome in vascular surgery patients. In a 
prospective study of 359 vascular surgery patients, statin dose and cholesterol levels were 
recorded preoperatively. Myocardial ischemia and heart rate variability were assessed by 
72-hour 12-lead electrocardiography starting 1 day before to 2 days after surgery. Troponin 
T was measured on postoperative day 1, 3, 7 and before discharge. Cardiac events included 
cardiac death or non-fatal myocardial infarction at 30 days and follow-up (mean: 2.3 years). 
Perioperative MI, troponin T release, 30-day and late cardiac events occurred in 29%, 23%, 4% 
and 18%, respectively. In multivariate analysis, lower LDL-cholesterol (per 10 mg/dL) correlated 
with lower myocardial ischemia (OR: 0.87, 95% CI: 0.80-0.95), troponin T release (OR: 0.89, 95% 
CI: 0.82-0.96), 30-day (OR: 0.89, 95% CI: 0.78-1.00) and late cardiac events (HR: 0.91, 95% CI: 
0.84-0.96). Higher statin doses (per 10% of maximum recommended dose) correlated with 
lower myocardial ischemia (OR: 0.85, 95% CI: 0.76-0.93), troponin T release (OR: 0.84, 95% CI: 
0.76-0.93), 30-day (OR: 0.62, 95% CI: 0.40-0.96) and late cardiac events (HR: 0.76, 95% CI: 0.65-
0.89), even after adjusting for LDL-cholesterol.
Beta-blockers and statins reduce perioperative cardiac events in high-risk patients undergoing 
vascular surgery by restoring the myocardial oxygen supply/demand balance and/or stabiliz-
ing coronary plaques. In chapter ten, the DECREASE IV study is described. This study evaluated 
the effectiveness and safety of these agents in intermediate-risk patients. Prior to surgery, 1066 
patients were assigned to bisoprolol, fluvastatin, combination treatment or control therapy. 
Intermediate-risk patients were defined by an estimated risk of perioperative cardiac death 
and myocardial infarction (MI) of 1-6%, using clinical data and type of surgery. Starting dose 
of bisoprolol was 2.5mg daily, titrated to a perioperative heart rate of 50-70 beats per minute. 
Fluvastatin was prescribed in a fixed dose of 80mg. The primary endpoint was the composite of 
30-day cardiac death and MI.  Patients randomized to bisoprolol (N=533) had a lower incidence 
of the endpoint than those randomized to bisoprolol-control (2.1% vs. 6.0% events; HR 0.34; 
95% CI: 0.17-0.67; p=0.002). Patients randomized to fluvastatin experienced a lower incidence 
of the endpoint than those randomized to fluvastatin-control therapy (3.2% vs. 4.9% events; 
HR 0.65; 95% CI 0.35-1.10), but statistical significance was not reached (p=0.17). Bisoprolol 
was associated with a significant reduction of 30-day cardiac complications, while fluvastatin 
showed a trend for improved outcome.
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While perioperative beta-blocker therapy may reduce cardiac events, concerns exist regarding 
beta-blocker use in patients undergoing esophagectomy because of a possible increased risk 
of ischemia and leakage of the esophagogastric anastomosis. In chapter eleven, we selected 
patients from the randomized DECREASE IV trial, undergoing esophagectomy and evaluated the 
efficacy and safety of beta-blocker therapy. A total of 101 patients scheduled for esophagectomy 
were randomized to beta-blocker therapy (n=52) or no beta-blocker therapy (n=49). Results 
of radiology, gastroscopy, and clinical signs of ischemia or leakage of the esophagogastric 
anastomosis were noted as well as cardiac complications. Beta-blocker use was associated with 
a reduction in the combination of myocardial damage, myocardial infarction and cardiac death 
(16% vs 4%, p=0.04). The rate of radiologic anastomotic leakage was similar in both groups 
(16% vs 16%, p=0.96), as well as the rate of ischemia at  gastroscopy (26% vs 17%, p=0.32) and 
the number of reoperations (16% vs 14%, p=0.69). In conclusion, perioperative beta-blocker 
use in patients undergoing esophagectomy is associated with a reduction in cardiac events and 
is not associated with an increased risk for ischemic complications.
coNcLUSIoN
Patients undergoing major surgery are at significant risk for perioperative and long term car-
diac complications. Preoperative cardiac risk stratification and optimization of perioperative 
management is of utmost importance. Selected patients could benefit from statin and  beta-
blocker therapy, as these appear to be independently associated with a reduction in cardiac 
complications, both perioperatively and for the long term. Athough perioperative medical 
therapy has been proven to improve cardiac outcome, it is still under discussion which patients 
should be treated and with which exact medicine. We hope that our research has contributed 
to the understanding of cardiac risk stratification and perioperative medical management.
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Samenvatting en conclusie
In dit proefschrift worden factoren beschreven die de kans op cardiale complicaties beïnvloeden 
bij patiënten die electieve niet-cardiale chirurgie ondergaan. Verder worden medicamenteuze 
interventies ten behoeve van het verlagen van de kans op cardiale complicaties onderzocht.
Hoofdstuk één beschrijft de pathofysiologie van het perioperatieve myocardinfarct (PMI). 
Perioperatieve myocardinfarcten zijn één van de belangrijkste voorspellers voor korte en lange 
termijn morbiditeit en mortaliteit na niet cardiale chirurgie. Ondanks dat de incidentie van 
PMI’s in de afgelopen tientallen jaren is gedaald door technische ontwikkelingen in de chirurgie 
en de anesthesiologie, blijven perioperatieve cardiale complicaties een significant probleem. 
De precieze pathofysiologie van het PMI is zeer complex en nog niet volledig begrepen. Er zijn 
waarschijnlijk, zoals bij myocardinfarcten in een niet-operatieve setting, twee mechanismen 
die bijdragen aan het tot stand komen van een PMI: (1) coronaire plaque ruptuur, die leidt 
tot thrombusformatie met daaropvolgend vaatocclusie en (2) verhoogde cardiale zuurstof-
behoefte (bijvoorbeeld op basis van tachycardie en/of verhoogde contractiliteit), resulterend 
in een myocard zuurstof aanbod/behoefte mismatch. Dit kan bij persisteren leiden tot een 
myocard infarct. In patiënten die een niet cardiale operatie ondergaan lijkt vooral het tweede 
mechanisme een belangrijke rol te spelen.
cARDIALe RISIcoScHAttING
In hoofdstuk twee wordt een retrospectieve cohortstudie van 3381 patiënten beschreven die 
een dobutamine stress echocardiografie (DSE) hebben ondergaan. Een hypotensieve reactie 
tijdens de DSE test werd gedefinieerd als mild, indien de systolische bloeddruk < 20 mmHg 
daalde tussen rust en piekstress tijdens de DSE. Een ernstige hypotensieve reactie werd gecon-
stateerd indien de systolische bloeddruk > 20 mmHg daalde tijdens de DSE. De eindpunten 
van de studie waren mortaliteit, cardiale dood en een ernstige cardiale complicatie. Milde en 
ernstige hypotensie werd gezien in respectievelijk 936 (28%) en 521 (15%) patiënten. Gedu-
rende een follow-up van 4.5 (± 3.3) jaar, overleden 920 patiënten (555 aan een cardiale oorzaak) 
en kregen 713 patiënten een ernstige cardiale complicatie. Multivariabele analyse liet zien dat 
een ernstige hypotensieve reactie tijdens de DSE geassocieerd is met een verhoogde kans 
op cardiale dood (HR: 1.3, 95% betrouwbaarheidsinterval [BI]: 1.03–1.6) en ernstige cardiale 
complicaties (HR: 1.3, 95% BI: 1.1–1.6), terwijl een milde hypotensieve reactie geen significante 
invloed had op de eindpunten.
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In hoofdstuk drie wordt het effect van het opladen met methionine bij het testen van serum 
homocysteïne geëvalueerd in een grote observationele cohort studie van 1122 patiënten 
met een verdenking op, of bewezen vaatlijden. Verhoogde waarden van homocysteïne zijn 
geassocieerd met een verhoogd risico op atherosclerose en cardiale complicaties. Het opladen 
met methionine kan het homocysteïne metabolisme activeren en zo milde afwijkingen in 
enzymactiviteit opsporen. In deze studie werd de toegevoegde waarde van het opladen met 
methionine voor het voorspellen van late mortaliteit en ernstige cardiale complicatie onder-
zocht. Gedurende een gemiddelde follow-up van 8.9 jaar, overleden 98 patiënten (8.7%) en 
kregen 86 patiënten een ernstige cardiale complicatie (7.7%). Uit multivariabele analyse bleek 
dat de incidentie van mortaliteit en ernstige cardiale complicatie significant verhoogd was voor 
patiënten met hyperhomocysteïnemie, met hazard ratio’s van 1.86 (95% BI; 1.20-2.87) en 2.24 
(95% BI; 1.41-3.53). De aanwezigheid van post-methionine hyperhomocysteïnemie had geen 
significante invloed op de incidentie van mortaliteit en ernstige cardiale complicatie, ongeacht 
de nuchtere homocysteïne serumwaarden. Concluderend geeft het opladen met methionine 
geen significante verbetering van de sensitiviteit van homocysteïne testen met betrekking tot 
mortaliteit en ernstige cardiale complicatie.
Nuchtere glucose meting is een onderdeel van preoperatief screenen van patiënten die niet 
bekend zijn met diabetes mellitus (DM). Een orale glucose tolerantie test (OGTT) zou DM en 
verstoorde glucose regulatie (VGR) mogelijk beter kunnen opsporen en perioperatieve cardiale 
complicaties kunnen voorspellen. Hoofdstuk vier beschrijft een prospectieve studie waarin 
404 opeenvolgende patiënten zonder bekende DM of VGR een preoperatieve OGTT hebben 
ondergaan. Het eindpunt van de studie was de incidentie van perioperatieve ischemie. Het 
eindpunt werd in 21% van de patiënten gediagnostiseerd. VGR werd in 104 patiënten (25.7%) 
geconstateerd en DM de novo in 43 patiënten (10.6%). 75% van de patiënten met VGR werden 
gediagnosticeerd met behulp van de OGTT en 72% van de patiënten met DM. Preoperatieve 
glucose waarden waren een significante voorspeller voor perioperatieve ischemie, met odds 
ratio’s voor DM en VGR van respectievelijk 3.2 (95% BI: 1.3-8.1) en 1.4 (95% BI: 0.7-3.0). De preva-
lentie van onbekende VGR en DM is hoog in vaatpatiënten en is geassocieerd met verhoogde 
kans op perioperatieve myocardischemie. Preoperatief testen door middel van een OGTT is 
daarom aan te raden voor patiënten die een electieve vasculaire ingreep ondergaan.
In hoofdstuk vijf worden de late resultaten van de patiënten die in hoofdstuk vier zijn geïnclu-
deerd beschreven. Gedurende een gemiddelde follow-up van 3.0 jaar, kregen 128 patiënten 
een cardiale complicatie. Patiënten met VGR hadden een significant hogere kans op cardiale 
complicaties in univariate (HR 2.45, 95% BI: 1.65-3.63) en multivariabele analyse (HR 2.77, 95% 
BI: 1.83-4.20). Patiënten met DM hadden geen significant verhoogd risico op het krijgen van car-
diale complicaties vergeleken met patiënten met normale bloedsuiker regulatie. Dit impliceert 
een gebrek aan behandeling van vaatpatiënten met VGR. Vaatpatiënten bij wie preoperatief 
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VGR of DM wordt vastgesteld, hebben een hoge incidentie van late cardiale complicaties. Het is 
aan te raden alle niet-diabetische vaatpatiënten middels een OGTT preoperatief te onderzoe-
ken op afwijkingen in de glucoseregulatie.
Anemie komt vaak voor bij vaatpatiënten en is een risicofactor voor een slechtere cardiale 
uitkomst. Aangezien het onbekend is of anemie een primaire risicofactor is voor een slechte 
cardiale prognose of secundair is aan het onderliggende lijden, wordt anemie niet gebruikt 
als een risicofactor voor cardiale risicostratificatie in preoperatieve screening. In hoofdstuk zes 
wordt de onafhankelijke bijdrage van anemie op het risico voor vroege en late cardiale com-
plicaties onderzocht in 1211 patiënten. Anemie werd verdeeld in tertielen om milde (serum 
hemoglobine 12.2-13 g/dl voor mannen, 11.2-12g/dl voor vrouwen), matige (mannen 11-12.1 
g/dl, vrouwen 10.2-11.1g/dl) en ernstige anemie (mannen 7.2-11 g/dl, vrouwen 7.5-10.1g/dl) 
te kunnen vergelijken. Eindpunten waren vroege (binnen 30 dagen) en late (binnen 5 jaar) 
ernstige cardiale complicaties. Een hogere incidentie van nierfalen, DM en hartfalen werd 
gevonden in patiënten met anemie. In multivariabele analyse hadden patiënten met anemie 
een onafhankelijk verhoogd risico voor vroege en late ernstige cardiale complicatie. Gezien 
deze bevindingen, zou preoperatieve anemie gebruikt kunnen worden voor de inschatting van 
de kans op cardiale complicaties bij vaatchirurgische patiënten.
Verhoogd urinezuur is geassocieerd met een verhoogde kans op cardiale complicaties. In 
hoofdstuk zeven wordt de onafhankelijke bijdrage van de waarde van preoperatief serum uri-
nezuur onderzocht op de kans op vroege en late ernstige cardiale complicatie in 936 vaatchi-
rurgische patiënten. Verhoogd urinezuur werd gedefinieerd als serum urinezuur >0.42 mmol/l 
voor mannen en >0.36 mmol/l voor vrouwen. Verhoogd urinezuur werd geconstateerd in 299 
(32%) patiënten. Verhoogd urinezuur was geassocieerd met hartfalen, nierfunctiestoornissen 
en het gebruik van diuretica. In totaal stierven 46 (5%) patiënten en kregen 61 (7%) patiënten 
een ernstige cardiale complicatie binnen 30 dagen na de operatie. De gemiddelde follow-up 
was 3.7 jaar (range: 0-17 jaar). Gedurende follow-up stierven 282 (30%) patiënten en kregen 
170 (18%) patiënten een ernstige cardiale complicatie. In multivariabele analyse was verhoogd 
urinezuur niet onafhankelijk geassocieerd met perioperatieve uitkomst, maar wel met late 
sterfte en ernstige cardiale complicatie. Verhoogd urinezuur zou daarom toegevoegd moeten 
worden als risicofactor voor cardiaal risicostratificatie op lange termijn.
cARDIALe RISIcoReDUctIe
Hoofdstuk acht beschrijft de Niaspan®-induced HDL-Elevation for Optimizing Risk Control 
(NEMO) studie, waarin Niaspan®, een langzame-afgifte nicotinezuur, in Nederland werd 
onderzocht. NEMO was een half jaar durende, prospectieve, observationele, multicentre, open 
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label studie. Niaspan® werd aan vaatpatiënten voorgeschreven die met een statine behandeld 
werden. De eindpunten waren de incidentie van behandelingsgerelateerde bijwerkingen en 
het effect op lipide- en cardiovasculaire risicoscore, welke berekend werd door middel van 
het algoritme uit de Prospective Cardiovascular Münster [PROCAM] studie. In totaal, zijn 612 
patiënten in Nederland geïncludeerd in de studie. Blozen was de meest voorkomende bijwer-
king (29% van de patiënten leed aan blozen in de eerste maand van behandeling). De meest 
voorkomende oorzaken voor vroegtijdig beëindigen van de studie waren blozen, het actief 
onttrekken van de studie door de patiënt en het niet verschijnen voor follow-up. Ongeveer 
de helft van de patiënten (52%) is na de studie met de medicatie doorgegaan. De tolerantie 
voor Niaspan® werd in 54% van de gevallen als goed of zeer goed aangegeven. HDL-cholesterol 
steeg met 23% van baseline en triglyceriden zakten met 16%, zonder significante verandering 
in LDL- of totale cholesterolwaarden. De cardiovasculaire risicoscore zakte met 3.3 punten. Con-
cluderend, liet het gebruik van Niaspan® in vaatpatiënten een goede tolerantie, een verhoging 
van HDL-cholesterol en een vermindering van cardiovasculaire risicoscore zien.
In hoofdstuk negen wordt onderzocht of hoge doses statinetherapie en laag LDL-cholesterol 
gehalte onafhankelijk geassocieerd zijn met een verminderde incidentie van cardiale complica-
ties in vaatchirurgische patiënten. In een prospectieve studie van 359 patiënten, werden peri-
operatieve statine dosis en cholesterolwaarden geregistreerd. Perioperatieve myocardischemie 
en hartvariabiliteit werden door middel van continu Holter-echocardiografie van één dag voor 
tot twee dagen na de operatie gemeten. Troponine T werd op dag 1, 3 en 7 postoperatief 
gemeten. Eindpunten waren perioperatieve en lange termijn (gemiddelde follow-up: 2.3 jaar). 
In multivariabele analyse was een lager LDL-cholesterol (per 10 mg/dl) geassocieerd met een 
lagere incidentie van myocardischemie (OR: 0.87, 95% BI: 0.80-0.95), troponine T stijging (OR: 
0.89, 95% BI: 0.82-0.96), perioperatieve ernstige cardiale complicatie (OR: 0.89, 95% BI: 0.78-
1.00) en late ernstige cardiale complicatie (HR: 0.91, 95% BI: 0.84-0.96). Een hogere dosis sta-
tinetherapie (per 10% van de maximale dosis) was onafhankelijk geassocieerd met een lagere 
incidentie van myocardischemie (OR: 0.85, 95% BI: 0.76-0.93), troponine T stijging (OR: 0.84, 
95% BI: 0.76-0.93), perioperatieve ernstige cardiale complicatie (OR: 0.62, 95% BI: 0.40-0.96) en 
late ernstige cardiale complicatie (HR: 0.76, 95% BI: 0.65-0.89).
Bètablokkers en statines verminderen de incidentie van perioperatieve cardiale complicaties 
in hoog risicopatiënten die vaatchirurgie ondergaan. In hoofdstuk tien wordt de DECREASE 
IV studie beschreven. In deze studie wordt de effectiviteit van deze medicijnen onderzocht 
in patiënten met een matig verhoogd cardiaal risico en die een niet cardiovasculaire operatie 
ondergaan. In totaal, zijn 1066 patiënten gerandomiseerd in vier groepen: bisoprolol, fluvasta-
tine, combinatietherapie of geen medicatie. Matig verhoogd risico werd gedefinieerd als een 
risico van 1-6% kans op perioperatieve cardiale dood of myocard infarct. De begindosis van 
bisoprolol was 2.5mg per dag, wat getitreerd werd naar een perioperatieve hartslag van 50-70 
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slagen per minuut. Fluvastatine werd in een dosis van 80mg per dag voorgeschreven. Het pri-
maire eindpunt van de studie was de combinatie van perioperatieve cardiale dood en myocard 
infarct.  Patiënten die bisoprolol kregen (N=533) hadden een significant lagere incidentie van 
het eindpunt vergeleken met patiënten zonder bisoprolol (2.1% vs. 6.0% events; HR 0.34, 95% 
BI: 0.17-0.67). Patiënten die fluvastatine kregen lieten een trend tot een lagere incidentie van 
het eindpunt zien vergeleken met patiënten zonder fluvastatine (3.2% vs. 4.9% events; HR 
0.65, 95% BI: 0.35-1.10). Concluderend, leverde het perioperatieve gebruik van bisoprolol een 
significant lagere incidentie van cardiale complicaties in patiënten met een matig verhoogd 
cardiaal risico.
Ondanks dat periopertief bètablokkergebruik de incidentie van cardiale complicaties kan 
verminderen, bestaat een terughoudendheid hiervoor bij patiënten die een oesofagusresectie 
ondergaan, omdat bètablokkers mogelijk meer ischemie en lekkage van de oesofagusanasto-
mose zouden kunnen veroorzaken. In hoofdstuk elf hebben we de patiënten uit de DECREASE 
IV trial geselecteerd, die een oesofagusresectie hebben ondergaan en hebben het effect en 
de veiligheid van bètablokkergebruik onderzocht. In totaal hebben 101 patiënten een oesofa-
gusresectie ondergaan (52 patiënten gerandomiseerd voor bètablokker therapie, 49 patiënten 
zonder). Uitslagen van radiologie, gastroscopie en klinische tekenen van ischemie of lekkage 
werden naast cardiale complicaties geregistreerd.
Het perioperatief gebruik van bètablokkers was geassocieerd met een vermindering van 
cardiale complicaties (16% vs 4%, p=0.04). Er was geen verschil in incidentie tussen beide groe-
pen voor gediagnosticeerde anastomoselekkage (16% vs 16%, p=0.96), naadischemie (26% vs 
17%, p=0.32) of reoperaties (16% vs 14%, p=0.69). Concluderend, is het perioperatief gebruik 
van bètablokkers in patiënten die een oesofagusresectie ondergaan geassocieerd met minder 
cardiale complicaties, zonder een toename van ischemische complicaties.
coNcLUSIe
Patiënten die grote operaties ondergaan hebben een verhoogd risico op perioperatieve en late 
cardiale complicaties. Preoperatieve cardiale risicostratificatie en een optimaal perioperatief 
beleid zijn daarom van uiterste belang. Een grote selectie patiënten zou baat bij statine- en 
bètablokkertherapie kunnen hebben, aangezien deze onafhankelijk geassocieerd zijn met 
een lagere incidentie van cardiale complicaties. Hoewel het aangetoond is dat medicamen-
teuze therapie de cardiale uitkomst kan verbeteren, blijft het een discussie welke patiënten 
behandeld dienen te worden en met welke medicijnen. Wij hopen dat wij door middel van dit 
onderzoek hebben bijgedragen aan het inzicht in cardiale risicostratificatie en perioperatieve 
medicamenteuze therapie.
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